WO2021023154A1 - 四并环类化合物及其制备方法和应用 - Google Patents

四并环类化合物及其制备方法和应用 Download PDF

Info

Publication number
WO2021023154A1
WO2021023154A1 PCT/CN2020/106573 CN2020106573W WO2021023154A1 WO 2021023154 A1 WO2021023154 A1 WO 2021023154A1 CN 2020106573 W CN2020106573 W CN 2020106573W WO 2021023154 A1 WO2021023154 A1 WO 2021023154A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
alkylamino
pharmacologically acceptable
membered heterocycloalkyl
Prior art date
Application number
PCT/CN2020/106573
Other languages
English (en)
French (fr)
Inventor
郭淑春
范珺
刘洋
彭建彪
郭海兵
Original Assignee
上海济煜医药科技有限公司
江西济民可信集团有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海济煜医药科技有限公司, 江西济民可信集团有限公司 filed Critical 上海济煜医药科技有限公司
Priority to MX2022001421A priority Critical patent/MX2022001421A/es
Priority to US17/632,167 priority patent/US20220298174A1/en
Priority to CA3149403A priority patent/CA3149403A1/en
Priority to JP2022506075A priority patent/JP2022543767A/ja
Priority to KR1020227006959A priority patent/KR20220079521A/ko
Priority to AU2020325477A priority patent/AU2020325477A1/en
Priority to EP20850862.2A priority patent/EP4011886A4/en
Publication of WO2021023154A1 publication Critical patent/WO2021023154A1/zh
Priority to IL290276A priority patent/IL290276A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Definitions

  • the present invention relates to a compound represented by formula (I), its optical isomers and pharmacologically acceptable salts, and the application of the compound as a KRAS inhibitor.
  • Cancer has been the top ten cause of death in China for 31 consecutive years. Among them, lung cancer is one of the tumors with the highest incidence. Non-small cell lung cancer accounts for more than 80%. At the same time, the incidence of lung cancer is high and there are many types of mutations. In order to enrich the company's R&D pipeline and focus on unmet medical needs, the development of innovative drugs for cancer treatment is very necessary for the company's long-term development, and has important economic and social significance.
  • RAS gene mutations About 30% of cancer patients have RAS gene mutations.
  • pancreatic cancer In the United States, the three cancers with the highest mortality rates (pancreatic cancer, colorectal cancer, and lung cancer) also happen to be the three cancers with the most common RAS mutations, accounting for 95%, 52%, and 31% of the three cancer patients, respectively.
  • KRAS mutations account for the absolute majority, while NRAS mutations are more common in melanoma and acute myeloid leukemia, and HRAS mutations are more common in bladder cancer and head and neck cancer.
  • KRAS The mutation rate of KRAS gene in Asian population is 10-15%.
  • KRAS is mutated in many cancers and is one of the main oncogenes.
  • KRAS mutant tumor is the most potentially targeted molecular subtype of non-small cell lung cancer (NSCLC), and its mutation rate is about 15%-25% in non-small cell lung cancer (NSCLC).
  • NSCLC non-small cell lung cancer
  • KRAS mutations mainly occur in codons 12 and 13. The most common codon variation accounts for about 39% of KRAS mutant NSCLCs, which is the KRAS-G12C mutation.
  • KRAS mutation is the most important tumor driver gene. This part of mutation cases account for a certain proportion of pancreatic cancer, lung cancer and rectal and gastric cancer. Currently, there is no specific targeted drug that acts on this target. Therefore, the project has important medical research value and clinical application value, and has greater medical value to Chinese people.
  • the molecular mechanism of the development of KRAS-G12C small molecule drugs has been basically clarified. The molecular structure and efficacy of the drug have been verified under the existing test conditions, and it has high activity characteristics and the possibility of being a drug.
  • the present invention provides a compound represented by formula (I), its optical isomers and pharmacologically acceptable salts,
  • R 1 , R 2 , and R 11 are each independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 alkoxy and C 1-6 alkylamino, said C 1 -6 alkyl, C 1-6 alkoxy or C 1-6 alkylamino is optionally substituted with 1, 2 or 3 R;
  • T 1 is selected from N and C(R 3 );
  • T 2 is selected from N and C(R 4 );
  • R 3 and R 4 are each independently selected from H, halogen, OH, NH 2 , CN, C 2-4 alkenyl, C 2-4 alkynyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C 2-4 alkenyl, C 2-4 alkynyl, C 1-6 alkyl, C 1- 6 alkoxy, C 1-6 alkylamino, C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R;
  • Ring A is selected from C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 aryl and 5-10 membered heteroaryl;
  • Ring B is selected from C 6-10 aryl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl, 5-6 membered heteroaryl and 5-6 membered heterocycloalkyl;
  • R 7 is selected from H, halogen, CN, C 1-6 alkyl, C 1-6 alkoxy and C 1-6 alkylamino, said C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkylamino is optionally substituted with 1, 2 or 3 R;
  • R 8 and R 9 are each independently selected from H, halogen, CN, C 1-6 alkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 1-6 alkylamino, C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R; representative And when for When, R 7 and R 9 do not exist;
  • n is selected from 1, 2, 3 and 4;
  • n is selected from 1, 2, 3 and 4;
  • R 10 is selected from H, C 1-6 alkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl, said C 1-6 alkyl, C 3-6 cycloalkyl or 3-6
  • the membered heterocycloalkyl group is optionally substituted with 1, 2 or 3 R;
  • R 12 is each independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me and CF 3 ;
  • the membered heterocycloalkyl is optionally substituted with 1, 2 or 3 R';
  • R' is selected from F, Cl, Br, I, OH, NH 2 and CH 3 ;
  • the above R is independently selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, C 1-3 alkylamino, and 5-6 membered heterocycloalkyl, wherein C 1-3 alkyl, C 1- 3 alkoxy, C 1-3 alkylthio, C 1-3 alkylamino or 5-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R', and other variables are as defined in the present invention.
  • the above-mentioned R is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, Where Me, Optionally substituted by 1, 2 or 3 R', other variables are as defined in the present invention.
  • the above-mentioned R is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, Other variables are as defined in the present invention.
  • the above-mentioned R 1 , R 2 , and R 11 are each independently selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy and C 1- 3 Alkylamino, the C 1-3 alkyl, C 1-3 alkoxy or C 1-3 alkylamino is optionally substituted with 1, 2 or 3 R, and other variables are as defined in the present invention.
  • R 1 , R 2 , and R 11 are each independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 , Other variables are as defined in the present invention.
  • R 3 and R 4 are independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 , Other variables are as defined in the present invention.
  • R 5 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 , Other variables are as defined in the present invention.
  • R 6 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 , N(CH 3 ) 2 , Other variables are as defined in the present invention.
  • the above-mentioned ring A is selected from C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, naphthyl, thienyl, pyrazolyl, thiazolyl, imidazolyl, pyridyl , Pyrimidinyl, indazolyl and indolyl, other variables are as defined in the present invention.
  • the above-mentioned ring B is selected from phenyl, naphthyl, thienyl, pyridyl, pyrimidinyl, indazolyl, indolyl, 1H-benzo[d][1,2,3] three Azolyl, 1,3-dihydro-2H-benzo[d]imidazol-2-onyl, benzo[d]oxazole-2(3H)-onyl, 1H-pyrazolo[3,4- b] Pyridyl, isoquinoline-1(2H)-keto and 1H-benzo[d]imidazolyl, other variables are as defined in the present invention.
  • R 7 is selected from H, F, Cl, Br, I, CN, Me, CF 3 , Other variables are as defined in the present invention.
  • R 8 and R 9 are independently selected from H, F, Cl, Br, I, CN, Me, CF 3 , Other variables are as defined in the present invention.
  • the above-mentioned compound, its optical isomer and its pharmacologically acceptable salt are selected from
  • R 1 , R 2 , L 1 , L 2 , T, T 2 , R 5 , R 6 , ring A, ring B, R 7 , R 8 , and R 9 are as defined above.
  • the above-mentioned compound, its optical isomer and its pharmacologically acceptable salt are selected from
  • R 1 , R 2 , L 1 , T, T 2 , R 5 , R 6 , ring A, ring B, R 7 , R 8 , and R 9 are as defined above.
  • the above-mentioned compound, its optical isomer and its pharmacologically acceptable salt are selected from
  • R 1 , R 2 , L 1 , T, T 2 , R 5 , R 6 , ring A, ring B, R 7 , R 8 , and R 9 are as defined above.
  • the present invention also provides a compound of the following formula, its optical isomers and pharmacologically acceptable salts thereof, which are selected from
  • the present invention also provides a pharmaceutical composition, which contains a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients Agent.
  • the present invention also provides the use of the above-mentioned compound or its pharmaceutically acceptable salt or the above-mentioned pharmaceutical composition in the preparation of a medicine for preventing and/or treating KRAS-G12C related diseases.
  • the aforementioned KRAS-G12C related diseases are selected from non-small cell lung cancer, colon cancer and pancreatic cancer.
  • pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms that are within the scope of reliable medical judgment and are suitable for use in contact with human and animal tissues , Without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salt refers to a salt of the compound of the present invention, which is prepared from a compound with specific substituents discovered in the present invention and a relatively non-toxic acid or base.
  • the base addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of base in a pure solution or a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salt or similar salts.
  • the acid addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of acid in a pure solution or a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogen carbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, the organic acid includes such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid; also include salts of amino acids (such as arginine, etc.) , And salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic
  • the pharmaceutically acceptable salt of the present invention can be synthesized from the parent compound containing acid or base by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of appropriate base or acid in water or an organic solvent or a mixture of both.
  • the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
  • the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers Isomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures, such as enantiomers or diastereomer-enriched mixtures, all of these mixtures belong to this Within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in substituents such as alkyl. All these isomers and their mixtures are included in the scope of the present invention.
  • enantiomer or “optical isomer” refers to stereoisomers that are mirror images of each other.
  • cis-trans isomer or “geometric isomer” is caused by the inability to rotate freely because of double bonds or single bonds of ring-forming carbon atoms.
  • diastereomer refers to a stereoisomer in which a molecule has two or more chiral centers and the relationship between the molecules is not mirror images.
  • wedge-shaped solid line keys and wedge-shaped dashed key Represents the absolute configuration of a three-dimensional center.
  • the compound of the present invention may be specific.
  • tautomer or “tautomeric form” means that at room temperature, the isomers of different functional groups are in dynamic equilibrium and can be transformed into each other quickly. If tautomers are possible (such as in solution), the chemical equilibrium of tautomers can be reached.
  • proton tautomers also called prototropic tautomers
  • proton migration such as keto-enol isomerization and imine-ene Amine isomerization.
  • Valence isomers include some recombination of bonding electrons to carry out mutual transformation.
  • keto-enol tautomerization is the tautomerism between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
  • the compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound.
  • compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I), or C-14 ( 14 C).
  • deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs have reduced toxic side effects and increased drug stability. , Enhance the efficacy, extend the biological half-life of drugs and other advantages.
  • substituted means that any one or more hydrogen atoms on a specific atom are replaced by substituents, and can include deuterium and hydrogen variants, as long as the valence of the specific atom is normal and the substituted compound is stable of.
  • oxygen it means that two hydrogen atoms are replaced. Oxygen substitution will not occur on aromatic groups.
  • optionally substituted means that it can be substituted or unsubstituted. Unless otherwise specified, the type and number of substituents can be arbitrary on the basis that they can be chemically realized.
  • any variable such as R
  • its definition in each case is independent.
  • the group may optionally be substituted with up to two Rs, and R has independent options in each case.
  • combinations of substituents and/or variants thereof are only permitted if such combinations result in stable compounds.
  • substituents When the listed substituents do not indicate which atom is connected to the substituted group, such substituents can be bonded via any atom.
  • a pyridyl group can pass through any one of the pyridine ring as a substituent. The carbon atom is attached to the substituted group.
  • the linking group L is at this time It can be formed by connecting benzene ring and cyclohexane in the same direction as the reading order from left to right It is also possible to connect the benzene ring and cyclohexane in the opposite direction to the reading order from left to right. Combinations of the linking groups, substituents, and/or variants thereof are only permitted if such combinations result in stable compounds.
  • the number of atoms in a ring is generally defined as the number of ring members.
  • “5-7 membered ring” refers to a “ring” in which 5-7 atoms are arranged around.
  • C 1-6 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 6 carbon atoms.
  • the C 1-6 alkyl group includes C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 and C 5 alkyl groups, etc.; it may Is monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine).
  • C 1-6 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl) , S-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl), hexyl, etc.
  • C 1-5 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 5 carbon atoms.
  • the C 1-5 alkyl group includes C 1-4 , C 1-3 , C 1-2 , C 2-5 , C 2-4 and C 5 alkyl groups, etc.; it may be monovalent (such as methyl) , Divalent (such as methylene) or multivalent (such as methine).
  • C 1-5 alkyl examples include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl) , S-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl) and so on.
  • C 1-4 alkyl is used to denote a linear or branched saturated hydrocarbon group composed of 1 to 4 carbon atoms.
  • the C 1-4 alkyl group includes C 1-2 , C 1-3 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent ( Such as methine).
  • Examples of C 1-4 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl) , S-butyl and t-butyl) and so on.
  • C 1-3 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 3 carbon atoms.
  • the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine) .
  • Example C 1- 3 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n- propyl and isopropyl) and the like.
  • C 2-8 alkenyl is used to mean a straight-chain or branched hydrocarbon group consisting of 2 to 8 carbon atoms containing at least one carbon-carbon double bond, and a carbon-carbon double bond It can be located at any position of the group.
  • the C 2-8 alkenyl group includes C 2-6 , C 2-4 , C 2-3 , C 4 , C 3 and C 2 alkenyl groups, etc.; it may be monovalent, divalent or multivalent.
  • Examples of C 2-8 alkenyl include, but are not limited to, vinyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, piperylene, hexadienyl, and the like.
  • C 2-4 alkenyl is used to mean a straight-chain or branched hydrocarbon group consisting of 2 to 4 carbon atoms containing at least one carbon-carbon double bond, and a carbon-carbon double bond It can be located at any position of the group.
  • the C 2-4 alkenyl group includes C 2-3 , C 4 , C 3 and C 2 alkenyl groups, etc.; the C 2-4 alkenyl group may be monovalent, divalent or multivalent.
  • Examples of C 2-4 alkenyl include, but are not limited to, vinyl, propenyl, butenyl, butadienyl and the like.
  • C 2-3 alkenyl is used to mean a linear or branched hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon double bond, and a carbon-carbon double bond It can be located at any position of the group.
  • the C 2-3 alkenyl group includes C 3 and C 2 alkenyl groups; the C 2-3 alkenyl group may be monovalent, divalent or multivalent. Examples of C 2-3 alkenyl include, but are not limited to, vinyl, propenyl and the like.
  • C 2-4 alkynyl is used to mean a linear or branched hydrocarbon group consisting of 2 to 4 carbon atoms containing at least one carbon-carbon triple bond, and a carbon-carbon triple bond It can be located at any position of the group.
  • the C 2-4 alkynyl includes C 2-3 , C 4 , C 3 and C 2 alkynyl and the like. It can be univalent, divalent or multivalent. Examples of C 2-4 alkynyl include, but are not limited to, ethynyl, propynyl, butynyl, and the like.
  • C 2-3 alkynyl is used to mean a linear or branched hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon triple bond, and a carbon-carbon triple bond It can be located at any position of the group. It can be univalent, divalent or multivalent.
  • the C 2-3 alkynyl group includes C 3 and C 2 alkynyl groups. Examples of C 2-3 alkynyl include, but are not limited to, ethynyl, propynyl, and the like.
  • heteroalkyl by itself or in combination with another term means a stable linear or branched alkyl group or a combination thereof composed of a certain number of carbon atoms and at least one heteroatom or heteroatom group.
  • the heteroatoms are selected from B, O, N, and S, where nitrogen and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized.
  • the heteroalkyl group is a C 1-6 heteroalkyl group; in other embodiments, the heteroalkyl group is a C 1-3 heteroalkyl group.
  • heteroatom or heteroatom group can be located in any internal position of the heteroalkyl group, including the position of attachment of the alkyl group to the rest of the molecule, but the terms "alkoxy”, “alkylamino” and “alkylthio” (or thioalkyl (Oxy) is a customary expression and refers to those alkyl groups that are connected to the rest of the molecule through an oxygen atom, amino or sulfur atom, respectively.
  • Up to two heteroatoms can
  • C 1-6 alkoxy refers to those alkyl groups containing 1 to 6 carbon atoms attached to the rest of the molecule through an oxygen atom.
  • the C 1-6 alkoxy group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 and C 3 alkoxy etc. .
  • C 1-6 alkoxy examples include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy) Oxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexoxy and the like.
  • C 1-3 alkoxy refers to those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an oxygen atom.
  • the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy groups and the like.
  • Examples of C 1-3 alkoxy include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy) and the like.
  • C 1-6 alkylamino refers to those alkyl groups containing 1 to 6 carbon atoms attached to the rest of the molecule through an amino group.
  • the C 1-6 alkylamino group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 , C 3 and C 2 alkylamino group Wait.
  • C 1-6 alkylamino examples include, but are not limited to -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -N(CH 2 CH 3 )( CH 2 CH 3 ), -NHCH 2 CH 2 CH 3 , -NHCH 2 (CH 3 ) 2 , -NHCH 2 CH 2 CH 2 CH 3 and so on.
  • C 1-3 alkylamino means those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an amino group.
  • the C 1-3 alkylamino group includes C 1-2 , C 3 and C 2 alkylamino groups and the like.
  • Examples of C 1-3 alkylamino groups include, but are not limited to, -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -NHCH 2 CH 2 CH 3 ,- NHCH 2 (CH 3 ) 2 and so on.
  • C 1-6 alkylthio refers to those alkyl groups containing 1 to 6 carbon atoms that are attached to the rest of the molecule through a sulfur atom.
  • the C 1-6 alkylthio group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 , C 3 and C 2 alkane Sulfur-based etc.
  • Examples of C 1-6 alkylthio include, but are not limited to, -SCH 3 , -SCH 2 CH 3 , -SCH 2 CH 2 CH 3 , -SCH 2 (CH 3 ) 2 and the like.
  • C 1-3 alkylthio refers to those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through a sulfur atom.
  • the C 1-3 alkylthio group includes C 1-3 , C 1-2 and C 3 alkylthio groups and the like. Examples of C 1-3 alkylthio include, but are not limited to, -SCH 3 , -SCH 2 CH 3 , -SCH 2 CH 2 CH 3 , -SCH 2 (CH 3 ) 2 etc.
  • C 3-6 cycloalkyl means a saturated cyclic hydrocarbon group composed of 3 to 6 carbon atoms, which is a monocyclic and bicyclic ring system.
  • the C 3-6 cycloalkyl includes C 3-5 , C 4-5 and C 5-6 cycloalkyl, etc.; it can be monovalent, divalent or multivalent.
  • Examples of C 3-6 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • 3-6 membered heterocycloalkyl by itself or in combination with other terms means a saturated cyclic group consisting of 3 to 6 ring atoms, with 1, 2, 3 or 4 ring atoms.
  • heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein nitrogen atoms are optionally quaternized, and nitrogen and sulfur heteroatoms can be optionally oxidized (ie, NO and S(O) p , p Is 1 or 2). It includes monocyclic and bicyclic ring systems, where the bicyclic ring system includes spiro, fused, and bridged rings.
  • a heteroatom may occupy the connection position of the heterocycloalkyl group with the rest of the molecule.
  • the 3-6 membered heterocycloalkyl group includes 4-6 membered, 5-6 membered, 4-membered, 5-membered and 6-membered heterocycloalkyl group.
  • Examples of 3-6 membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl ( Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2- Piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), Dioxanyl, dithiazinyl, isoxazolidinyl, isothiazolid
  • C 6-10 aromatic ring and “C 6-10 aryl” can be used interchangeably in the present invention.
  • C 6-10 aromatic ring or “C 6-10 aryl” means A cyclic hydrocarbon group composed of 6 to 10 carbon atoms with a conjugated ⁇ -electron system, which can be a monocyclic, fused bicyclic or fused tricyclic system, in which each ring is aromatic. It can be monovalent, divalent or multivalent, and C 6-10 aryl groups include C 6-9 , C 9 , C 10 and C 6 aryl groups and the like. Examples of C 6-10 aryl groups include, but are not limited to, phenyl, naphthyl (including 1-naphthyl, 2-naphthyl, etc.).
  • 5-10 membered heteroaryl ring and “5-10 membered heteroaryl group” can be used interchangeably in the present invention.
  • the term “5-10 membered heteroaryl group” means a ring consisting of 5 to 10 A cyclic group composed of atoms with a conjugated ⁇ -electron system, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. It can be a monocyclic, fused bicyclic or fused tricyclic system, where each ring is aromatic.
  • the nitrogen and sulfur heteroatoms can be optionally oxidized (ie NO and S(O) p , p is 1 or 2).
  • the 5-10 membered heteroaryl group can be attached to the rest of the molecule through a heteroatom or a carbon atom.
  • the 5-10 membered heteroaryl groups include 5-8 membered, 5-7 membered, 5-6 membered, 5 membered and 6 membered heteroaryl groups and the like.
  • Examples of the 5-10 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl, etc.) Azolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5- Oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1, 2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thi
  • 5-6 membered heteroaryl ring and “5-6 membered heteroaryl group” can be used interchangeably in the present invention.
  • the term “5-6 membered heteroaryl group” means a ring consisting of 5 to 6 ring atoms. It is composed of a monocyclic group with a conjugated ⁇ -electron system, in which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. Where the nitrogen atom is optionally quaternized, the nitrogen and sulfur heteroatoms can be optionally oxidized (ie NO and S(O) p , p is 1 or 2).
  • the 5-6 membered heteroaryl group can be attached to the rest of the molecule through a heteroatom or a carbon atom.
  • the 5-6 membered heteroaryl group includes 5-membered and 6-membered heteroaryl groups.
  • Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl, etc.) Azolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5- Oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1, 2,
  • benzo 5- to 6-membered heterocycloalkyl means a bi-cyclic structure formed by the combination of a phenyl group, a heterocyclic ring, and a 5- to 6-membered heterocycloalkyl group.
  • the substituent may be through a benzene ring or
  • the 5- to 6-membered heterocycloalkyl ring is connected to other structures. Examples of the benzo 5-6 membered heterocycloalkyl include but are not limited to Wait.
  • 5- to 6-membered heteroaryl and 5- to 6-membered heterocycloalkyl means a diplex formed by the combination of a 5- to 6-membered heteroaryl group and a heterocyclic ring and a 5- to 6-membered heterocycloalkyl group. Ring structure, the substituent can be connected to other structures through a 5- to 6-membered heteroaryl group or a 5- to 6-membered heterocycloalkyl ring. Examples of the benzo 5-6 membered heterocycloalkyl include but are not limited to Wait.
  • C n-n+m or C n -C n+m includes any specific case of n to n+m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4, C 5, C 6, C 7, C 8, C 9, C 10, C 11, and C 12, also including any one of n + m to n ranges, for example C 1- 3 comprises a C 1-12 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12, etc.; in the same way, from n to n +m means the number of atoms in the ring is n to n+m, for example, 3-12 membered ring includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membered ring, 9-membered ring , 10-membered ring, 11-member
  • the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those well known to those skilled in the art Equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
  • CDCl 3 stands for deuterated chloroform
  • CD 3 OD stands for deuterated methanol
  • DMSO-d 6 stands for deuterated dimethyl sulfoxide
  • TBS stands for tert-butyldimethylsilyl.
  • Diastereoisomer compound 1 (16mg, 27.89 ⁇ mol) was purified by SFC (Separation conditions: Column: DAICEL CHIRALCEL OJ-H (250mm*30mm, 5um); Mobile phase: [Neu-ethanol]; Ethanol%: 30 %-30%). After concentration, compound 1A (peak 1) and compound 1B (peak 2) were obtained.
  • Chromatographic column Waters Xbridge C18 3.5 ⁇ m, 150*4.6mm; column temperature: 40°C; mobile phase: water (0.05% ammonia solution)-acetonitrile; acetonitrile: 0%-95% 10min, 95% 5min; flow rate : 1.0mL/min.
  • Chromatographic column Waters Xbridge C18 3.5 ⁇ m, 150*4.6mm; column temperature: 40°C; mobile phase: water (0.05% ammonia solution)-acetonitrile; acetonitrile: 0%-95% 10min, 95% 5min; flow rate : 1.0mL/min.
  • the crude product is purified by high-efficiency preparative liquid phase (Separation conditions: column: YMC Triart C18 150*25mm*5 ⁇ m; mobile phase: [water (10mM ammonium bicarbonate solution)-acetonitrile]; acetonitrile%: 29%-59% 9.5min) , Get compound 2.
  • Diastereomer compound 2 was purified by SFC (Separation conditions: column DAICEL CHIRALPAK AD-H (250mm*30mm, 5um); mobile phase: [Neu-isopropanol (0.1% ammonia solution)]; isopropanol %: 35%). After concentration, compound 2A (peak 1) and compound 2B (peak 2) were obtained.
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Chiralpak AD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05% DEA)]; isopropanol%: 5-40%in 2min, 40% 1.2min, 5% 0.8min; flow rate: 4mL/min.
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Chiralpak AD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05% DEA)]; isopropanol%: 5-40%in 2min, 40% 1.2min, 5% 0.8min; flow rate: 4mL/min.
  • Diisopropylethylamine (861.66mg, 6.67mmol, 1.16mL) was dissolved in anhydrous tetrahydrofuran (40mL), after cooling to -78°C, n-butyllithium (2.5M, 26.67mL) was added dropwise to it After the addition is complete, the system is heated to -30°C and stirred for 10 min. The system was cooled to -78°C, compound 3-1 (7g, 33.33mmol) in tetrahydrofuran (40 mL) was added thereto, and the system was stirred at -78°C for 4h.
  • the reaction system was diluted with water (20 mL), extracted with ethyl acetate (3 x 20 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product is purified by high-efficiency preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; Mobile phase: [Water (10mM ammonium bicarbonate solution)-acetonitrile]; Acetonitrile%: 10%-80%, 9.5 min) to obtain compound 3 as a white solid.
  • the pH of the system was adjusted to neutral with 1N HCl, extracted with ethyl acetate (10 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product is purified by high-efficiency preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; mobile phase: [water (10mM ammonium bicarbonate solution)-acetonitrile]; acetonitrile%: 10%-80% 9.5min ; Flow rate 30 mL/min) to obtain compound 4.
  • Diastereomer compound 4 was purified by SFC (Separation conditions: Column: DAICEL CHIRALPAK AD (250mm*30mm, 10 ⁇ m); mobile phase: [Neu-isopropanol (0.1% ammonia solution)]; isopropanol% : 30%-30%; flow rate: 70mL/min). After concentration, compound 4A (peak 1) and compound 4B (peak 2) were obtained.
  • Chromatographic column Chiralpak AD-3 50*4.6mm ID, 3 ⁇ m; Column temperature: 35°C; Mobile phase: [Neu-isopropanol (0.05%DEA)]; Isopropanol%: 5%-40% 2min, 40% 1.2min, 5% 0.8min; flow rate: 4mL/min.
  • Chromatographic column Chiralpak AD-3 50*4.6mm ID, 3 ⁇ m; Column temperature: 35°C; Mobile phase: [Neu-isopropanol (0.05%DEA)]; Isopropanol%: 5%-40% 2min, 40% 1.2min, 5% 0.8min; flow rate: 4mL/min.
  • Diastereomer compound 4 was purified by SFC (Separation conditions: Column: Phenomenex Lux Cellulose-4 250*30mm*5 ⁇ m; Mobile phase: [Neu-ethanol (0.1% ammonia solution)]; Ethanol%: 40%- 40%; flow rate: 60 mL/min). After concentration, compound 5A (peak 1) and compound 5B (peak 2) were obtained.
  • chromatographic column Cellulose-4 100*4.6mm I.D., 3 ⁇ m; column temperature: 35°C; mobile phase: [Neu-ethanol (0.05% DEA)]; ethanol%: 40%; flow rate: 28mL/min.
  • chromatographic column Ultimate C18 3.0*50mm, 3 ⁇ m; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10%-80% 6min, 80% 2min; flow rate: 1.2mL/min.
  • chromatographic column Cellulose-4 100*4.6mm I.D., 3 ⁇ m; column temperature: 35°C; mobile phase: [Neu-ethanol (0.05% DEA)]; ethanol%: 40%; flow rate: 28mL/min.
  • the crude product is purified by high-performance preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; Mobile phase: [Water (10mM ammonium bicarbonate solution)-acetonitrile]; Acetonitrile%: 21%-51% 9.5min ; Flow rate 60 mL/min) to obtain compound 6.
  • Diastereomer compound 6 was purified by SFC (Separation conditions: Column: REGIS(s,s) WHELK-O1 (250mm*30mm, 5 ⁇ m); Mobile phase: [Neu-isopropanol (0.1% ammonia solution) ]; Isopropanol%: 50%-50%; Flow rate: 80mL/min). After concentration, compound 6A (peak 1) and compound 6B (peak 2) were obtained.
  • Chromatographic column Ultimate LP-C18 150*4.6mm 5 ⁇ m; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10%- 80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column (S,S)-Whelk-O1 100*4.6mm ID, 3 ⁇ m; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05%DEA)]; isopropanol%: 40%-40%; flow rate: 2.8 mL/min.
  • Chromatographic column Ultimate LP-C18 150*4.6mm 5 ⁇ m; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10%- 80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column (S,S)-Whelk-O1 100*4.6mm ID, 3 ⁇ m; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05%DEA)]; isopropanol%: 40%-40%; flow rate: 2.8 mL/min.
  • compound 7-6 35 mg, 0.064 mmol
  • compound 7-9 36.3 mg, 0.128 mmol
  • [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride 4.7mg, 0.0064mmol
  • potassium carbonate 26.0mg, 0.192mmol
  • the crude product is purified by high-performance preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; Mobile phase: [Water (10mM ammonium bicarbonate solution)-acetonitrile]; Acetonitrile%: 21%-51% 9.5min ; Flow rate 60 mL/min) to obtain compound 7.
  • Diastereoisomer compound 7 was purified by SFC (Separation conditions: Column: DAICEL CHIRALCEL OJ-H (250mm*30mm, 5um); Mobile phase: [Neu-isopropanol (0.1% ammonia solution)]; Isopropyl Alcohol %: 40%-40%). After concentration, compound 7A (peak 1) and compound 7B (peak B) are obtained
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: [water (0.06875% trifluoroacetic acid)-acetonitrile (0.0625% trifluoroacetic acid)]; acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Chiralcel OJ-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05%DEA)]; isopropanol%: 5%-40% 5min, 40% 2.5min, 5% 2.5min; flow rate: 2.5mL/min.
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: [water (0.06875% trifluoroacetic acid)-acetonitrile (0.0625% trifluoroacetic acid)]; acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Chiralcel OJ-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05%DEA)]; isopropanol%: 5%-40% 5min, 40% 2.5min, 5% 2.5min; flow rate: 2.5mL/min.
  • compound 8-1 (410 mg, 1.774 mmol) and sodium hydride (142 mg, 60%, 3.55 mmol) were dissolved in tetrahydrofuran (3.0 mL), and the system was stirred at room temperature (20° C.) for 5 min.
  • Compound 7-4 (750 mg, 1.774 mmol) was added thereto, and the system was stirred at room temperature (20° C.) for 1 h.
  • Water (5 mL) was added to the system to quench the reaction, extracted with ethyl acetate (5 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • compound 8-3 (100mg, 0.179mmol), compound 7-9 (100mg, 0.358mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride ( 13mg, 0.0179mmol) and potassium carbonate (50.0mg, 0.358mmol) were dissolved in a mixed solvent of tetrahydrofuran/water (2mL, v/v 10:1), and the system was heated to 80°C and stirred for 2h.
  • the crude product is purified by high-efficiency preparative liquid phase (Separation conditions: Column: Welch Xtimate ⁇ C18 21.2 ⁇ 250mm, 10 ⁇ m; column temperature: 25°C; mobile phase: water (10mM ammonium bicarbonate solution)-acetonitrile; mobile phase acetonitrile ratio 25% -45% in 12min; flow rate 30mL/min) to obtain compound 8.
  • Diastereomer compound 8 was purified by SFC (Separation conditions: chromatographic column ChiralPak AD, 300 ⁇ 50mm ID, 10 ⁇ m; column temperature: 38°C; mobile phase: [Neu-isopropanol (0.1% ammonia solution)]; % Isopropanol: 35%; flow rate: 80 mL/min). After concentration, compound 8A (peak 1) and compound 8B (peak 2) were obtained.
  • Chromatographic column Chiralpak AD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05% DEA)]; isopropanol%: 5-40%in 5min, 40% 2.5min; flow rate: 2.5mL/min.
  • Chromatographic column Chiralpak AD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05% DEA)]; isopropanol%: 5-40%in 5min, 40% 2.5min; flow rate: 2.5mL/min.
  • the pH of the system was adjusted to neutral with 1N HCl, extracted with ethyl acetate (10 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product is purified by high-performance preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; Mobile phase: [water (10mM ammonium bicarbonate solution)-acetonitrile]; Acetonitrile%: 36%-66% 9.5min ; Flow rate 30 mL/min) to obtain compound 9.
  • Diastereomer compound 10 was purified by SFC (Separation conditions: Column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); mobile phase: [Neu-isopropanol (0.1% ammonia solution)]; isopropanol% : 35%-35%; flow rate: 80mL/min). After concentration, compound 10A (peak 1) and compound 10B (peak 2) were obtained.
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Chiralpak AD-3 50*4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05%DEA)]; isopropanol%: 5%-40% in 2min, 40% 1.2min, 5% 0.8min; flow rate: 4mL/min.
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Chiralpak AD-3 50*4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-isopropanol (0.05%DEA)]; isopropanol%: 5%-40% in 2min, 40% 1.2min, 5% 0.8min; flow rate: 4mL/min.
  • the crude product is purified by high-performance preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; Mobile phase: [Water (10mM ammonium bicarbonate solution)-acetonitrile]; Acetonitrile%: 42%-72% 9.5min ), to give compound 11.
  • Diastereomer compound 11 was purified by SFC (Separation conditions: Column: DAICEL CHIRALCEL OD (250mm*30mm, 10um); Mobile phase: [Neu-ethanol (0.1% ammonia solution)]; Ethanol%: 45%- 45%). After concentration, compound 11A, compound 11B, compound 11C and compound 11D are obtained.
  • Chromatographic column Xbridge Shield RP-18, 5um, 2.1*50mm; column temperature: 50°C; mobile phase: water (0.02% ammonia solution)-acetonitrile; acetonitrile: 10%-80% 6min, 80% 2min; Flow rate: 0.8 mL/min.
  • Chromatographic column Chiralcel OD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-ethanol (0.05%DEA)]; ethanol%: 40%-40%; flow rate: 2.5 mL/min.
  • Chromatographic column Xbridge Shield RP-18, 5um, 2.1*50mm; column temperature: 50°C; mobile phase: water (0.02% ammonia solution)-acetonitrile; acetonitrile: 10%-80% 6min, 80% 2min; Flow rate: 0.8 mL/min.
  • Chromatographic column Chiralcel OD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-ethanol (0.05%DEA)]; ethanol%: 40%-40%; flow rate: 2.5 mL/min.
  • Chromatographic column Xbridge Shield RP-18, 5um, 2.1*50mm; column temperature: 50°C; mobile phase: water (0.02% ammonia solution)-acetonitrile; acetonitrile: 10%-80% 6min, 80% 2min; Flow rate: 0.8 mL/min.
  • Chromatographic column Chiralcel OD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-ethanol (0.05%DEA)]; ethanol%: 40%-40%; flow rate: 2.5 mL/min.
  • Chromatographic column Xbridge Shield RP-18, 5um, 2.1*50mm; column temperature: 50°C; mobile phase: water (0.02% ammonia solution)-acetonitrile; acetonitrile: 10%-80% 6min, 80% 2min; Flow rate: 0.8 mL/min.
  • Chromatographic column Chiralcel OD-3 150 ⁇ 4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-ethanol (0.05%DEA)]; ethanol%: 40%-40%; flow rate: 2.5 mL/min.
  • compound 12-2 (0.12 g, 193.96 ⁇ mol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (770 mg, 6.75 mmol, 0.5 mL) was added, and the reaction was stirred for 3 h. The reaction solution was concentrated under reduced pressure to obtain compound 12-3.
  • Diastereomer compound 12 was purified by SFC (Separation conditions: Column: Phenomenex-Cellulose-2 (250mm*50mm, 10um); Mobile phase: [Neu-methanol (0.1% ammonia solution)]; Methanol%: 50 %-50%). After concentration, compound 12A (peak 1) and compound 12B (peak 2) are obtained
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: [water (0.06875% trifluoroacetic acid)-acetonitrile (0.0625% trifluoroacetic acid)]; acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Cellulose 2 100*4.6mm I.D., 3um; column temperature: 35°C; mobile phase: [Neu-methanol(0.05%DEA)];
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5um; column temperature: 40°C; mobile phase: [water (0.06875% trifluoroacetic acid)-acetonitrile (0.0625% trifluoroacetic acid)]; acetonitrile: 10% -80% for 10 min, 80% for 5 min; flow rate: 1.5 mL/min.
  • Chromatographic column Cellulose 2 100*4.6mm ID, 3um; column temperature: 35°C; mobile phase: [Neu-methanol (0.05% DEA)]; methanol%: 40%-40%; flow rate: 2.8mL/ min.
  • the crude product is purified by high-efficiency preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; Mobile phase: [Water (10mM ammonium bicarbonate solution)-acetonitrile]; Acetonitrile%: 18%-48%, 9min ), to give compound 13.
  • the system was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product.
  • the crude product is purified by high-performance preparative liquid phase (Separation conditions: Column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; Mobile phase: [Water (10mM ammonium bicarbonate solution)-acetonitrile]; Acetonitrile%: 29%-59% 9.5min ) To obtain compounds 14A and 14B.
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5 ⁇ m; column temperature: 40°C; mobile phase: water (0.0688% trifluoroacetic acid solution)-acetonitrile (0.0625% trifluoroacetic acid solution); acetonitrile: 5% -95% 0.7min, 95% 0.4min; flow rate: 1.5mL/min
  • Chromatographic column WELCH Ultimate LP-C18 150*4.6mm 5 ⁇ m; column temperature: 40°C; mobile phase: water (0.0375% trifluoroacetic acid solution)-acetonitrile (0.01875% trifluoroacetic acid solution); acetonitrile: 5% -95% 0.7min, 95% 0.4min; flow rate: 1.5mL/min.
  • the aqueous phase was adjusted to pH 3 with 6M hydrochloric acid and extracted with ethyl acetate (50mL x 3).
  • the organic phases were combined, washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 15-3.
  • Diisopropylethylamine (1.23g, 9.50mmol, 1.65mL) was dissolved in anhydrous tetrahydrofuran (60mL), and n-butyllithium (2.5M, 57.00mL) was added dropwise at -78°C. After the dropwise addition, the system was stirred at -30°C for 10 min. The system was cooled to -78°C, and a solution of compound 15-4 (10 g, 47.50 mmol) in tetrahydrofuran (60 mL) was added thereto. After the addition, the system was stirred at -78°C for 4h.
  • the crude product was purified by high-performance preparative liquid phase (separation conditions: chromatographic column Xtimate C18 150*40mm*5 ⁇ m, mobile phase: water (10mM ammonium bicarbonate)-acetonitrile; acetonitrile 30%-50% 8min) to obtain compound 15-5.
  • Step 13 Preparation of compounds 15A, 15B, 15C and 15D
  • the crude product is purified by high-performance preparative liquid phase (separation conditions: chromatographic column: Phenomenex Gemini-NX 80*30mm*3 ⁇ m; mobile phase: [water (10mM ammonium bicarbonate solution)-acetonitrile]; acetonitrile%: 24%-54%) , And then purified by SFC twice (separation conditions: column: DAICEL CHIRALPAK AD (250mm*30mm, 10 ⁇ m); mobile phase: [CO 2 -isopropanol (0.1% ammonia)]; isopropanol%: 35%- 35%), (Separation conditions: Column: DAICEL CHIRALCEL OJ (250mm*30mm, 10 ⁇ m); mobile phase: [CO 2 -ethanol (0.1% ammonia)]; ethanol%: 25%-25%), to give compound 15A , 15B, 15C and 15D.
  • Chromatographic column Chiralcel OD-3 100x 4.6mm ID, 3um; column temperature: 35°C; mobile phase: CO 2 -ethanol (0.05% DEA); ethanol: 5%-40% 4min, 40% 2.5min, 5% 1.5min; Flow rate: 2.8mL/min.
  • Chromatographic column Chiralcel OD-3 100x 4.6mm ID, 3 ⁇ m; column temperature: 35°C; mobile phase: CO 2 -ethanol (0.05% DEA); ethanol: 5%-40% 4min, 40% 2.5min, 5% 1.5min; Flow rate: 2.8mL/min.
  • Chromatographic column Chiralcel OD-3 100x 4.6mm ID, 3 ⁇ m; column temperature: 35°C; mobile phase: CO 2 -ethanol (0.05% DEA); ethanol: 5%-40% 4min, 40% 2.5min, 5% 1.5min; Flow rate: 2.8mL/min.
  • Chromatographic column Chiralcel OD-3 100x 4.6mm ID, 3 ⁇ m; column temperature: 35°C; mobile phase: CO 2 -ethanol (0.05% DEA); ethanol: 5%-40% 4min, 40% 2.5min, 5% 1.5min; Flow rate: 2.8mL/min.
  • the ability of the compounds disclosed herein to inhibit RAS-mediated signal transduction was evaluated and demonstrated as follows.
  • the cell NCI-H358 (ATCC catalog number CRL-5807) expressing mutant RAS (G12C) was cultured in RPMI medium containing 10% fetal bovine serum, penicillin/streptomycin double antibody. Cells were plated in 96-well plates (Corning catalog number 3699) at 40,000 cells per well, and allowed to stand overnight to attach to the bottom of the plate. Treat the cells with or without the compound of the invention (dimethyl sulfoxide, DMSO), and ensure that the final concentration of DMSO is 0.5%.
  • DMSO dimethyl sulfoxide
  • the level of phosphorylated ERK was detected using an enzyme-linked immunosorbent (ELISA) method.
  • Phosphorylated ERK antibody (Cell Signal Technology catalog number 4370) was diluted 1:400 with 1X blocking solution containing 0.05% Tween 20, added to a 96-well plate and incubated overnight at 4°C. Wash the plate 5 times with PBS containing 0.05% Tween 20.
  • the HRP-conjugated secondary antibody (Thermo catalog number 31460) was diluted 1:10,000 with 1X blocking solution containing 0.05% Tween 20, added to a 96-well plate and incubated for 2 hours at room temperature.
  • the plate was washed 5 times with PBS containing 0.05% Tween, TMB (Thermo catalog number 4816) was added and incubated at room temperature for 15 minutes. Add 1mol/L H2SO4 to stop the reaction, use EnVision (PerkinElmer) to read the OD value at 450nm wavelength.
  • the total number of cells in each well was measured using the Jiana Green staining method. After detecting the level of phosphorylated ERK, the 96-well plate was washed with PBS until colorless, and 0.1% Gena Green (Abcam catalog number ab111622) was added and incubated for 10 minutes. After washing with double distilled water, add 0.1mol/L HCl and incubate for 10 minutes with shaking. Use EnVision (PerkinElmer) to read the OD value at 595nm wavelength.
  • the signal of pERK (Thr202/Tyr204) was normalized with the signal value of Jiana Green, and the percentage of inhibition relative to the DMSO reference after drug treatment was calculated. The percentage value is fitted by a four-parameter dose-response curve and the IC50 value is generated.
  • Table 1 The experimental results are shown in Table 1.
  • the compounds of the present invention exhibit excellent ability to inhibit RAS-mediated signal transduction.
  • the ability of the compounds of the present invention to inhibit the growth of KRAS-G12C cells was evaluated by measuring cell viability and calculating GI50 value.
  • the tumor cell line NCI-H358 expresses KRAS-G12C and is cultured in RPMI medium supplemented with 10% fetal bovine serum and penicillin/streptomycin ;
  • Tumor cell line MIA PaCa2 (ATCC CRL-1420) expressing KRAS-G12C, using 10% fetal bovine serum, 2.5% horse serum (horse serum) and penicillin/streptomycin (penicillin/ streptomycin) in DMEM medium.
  • the cells NCI-H358 and MIA-Paca2 were seeded in a black transparent bottom 384-well plate (PerkinElmer catalog number 6007460) at a cell density of 1000 and 800 cells, respectively, and the cells were allowed to adhere overnight (8-12 hours).
  • the experimental group was added with the compound of the present invention diluted 5 times the concentration of the working solution (final concentration containing 0.1% dimethyl sulfoxide, namely DMSO); the control group was added with the same dilution as the experimental group (final concentration Containing 0.1% DMSO).
  • the Cell Titer Glo reagent Promega catalog number G7572 was used to detect the ATP content according to the instructions to determine the amount of cell proliferation.
  • the brief operation steps are: take out the cell plate and equilibrate at room temperature for 30 minutes; add the same volume of CellTiter Glo reagent as the culture; place the culture plate on a shaker and shake for 2 minutes; leave the culture plate at room temperature for 10 minutes ; Use the microplate reader EnVision (PerkinElmer) to read the light signal value.
  • the compound of the present invention has excellent NCI-H358, and MIA-Paca2 cell proliferation inhibitory activity.

Abstract

式(Ⅰ)所示化合物、其光学异构体及其药效上可接受的盐，以及该化合物作为KRAS抑制剂的应用。

Description

四并环类化合物及其制备方法和应用
本发明主张如下优先权：
CN201910712388.0，申请日2019年8月2号；
CN201910899724.7，申请日2019年9月23号；
CN201911157922.2，申请日2019年11月22号；
CN202010054185.X，申请日2020年1月17号。
技术领域
本发明涉及式(Ⅰ)所示化合物、其光学异构体及其药效上可接受的盐，以及该化合物作为KRAS抑制剂的应用。
背景技术
癌症已蝉联31年中国十大死因之首，其中肺癌是发病率最高的肿瘤之一，其非小细胞肺癌占比超过80％，同时肺癌发病率高、突变种类多。为了丰富公司的研发管线，聚焦未被满足的医疗需求，创新药的研发布局癌症治疗，对公司的长远发展非常有必要，同时有重要的经济意义和社会意义。
约3成左右癌症患者有RAS基因突变。在癌症基因的研究中，科学家早在20多年前已发现，RAS基因是包括肺癌、大肠直肠癌与胰腺癌等癌症的关键基因。
在美国，死亡率最高的三种癌症(胰腺癌、结直肠癌和肺癌)也恰好是RAS突变最多见的三种癌症，分别占这三种癌症患者数的95％、52％和31％。在胰腺癌、结直肠癌和肺癌中，KRAS突变占绝对多数，而NRAS突变多见于黑色素瘤和急性骨髓性白血病，HRAS突变多见于膀胱癌和头颈癌。
KRAS基因在亚洲人群中突变率为10–15％，KRAS在许多癌症中会发生突变，是主要癌基因之一。KRAS突变型肿瘤是最具潜在靶向性的非小细胞肺癌分子亚型(NSCLC)，其突变率在非小细胞肺癌(NSCLC)中约为15％-25％。在NSCLC的病例中，KRAS突变主要发生在12和13号密码子。最常见的密码子变异约占KRAS突变型NSCLCs的39％，是KRAS-G12C突变。
在肺腺癌中，KRAS基因的阳性概率占到了1/5-1/4，仅次于EGFR的阳性突变的概率。靶向抑制剂的缺乏使得KRAS阳性的非小细胞肺癌患者无论是在治疗还是预后都十分困难。《2013年NCCN非小细胞肺癌临床实践指南》明确指出：肺癌患者在接受EGFR-TKI治疗之前，必须进行KRAS基因检测，根据检测结果来决定是否使用EGFR-TKI靶向药物作为临床治疗措施。如果KRAS基因发生了突变，则不建议病人使用EGFR-TKI进行分子靶向治疗。
据汤森路透竞争情报药物数据库(Cortellis For CI)，目前各种与RAS基因/蛋白直接相关的药物数共有162个(数据查询时间2016年8月18日)，其中KRAS小分子药物有18个，其中包括10个KRAS GTP酶抑制剂，4个KRAS基因抑制剂，2个KRAS GTP酶调节剂和2个KRAS基因调节剂；目前临床在研的该类药物有1个。另外，台湾企业研发的首个KRAS抑制剂安卓健已进入美国FDA二期临床试验，阿斯利康研发的针对KRAS下游通路MEK的抑制剂司美替尼也在进行二期临床试验。KRAS突变是最重要的肿瘤驱动基因。这一部分突变病例在胰腺癌、肺癌及直肠胃癌中均占有一定比例。目前尚无作用于该靶点的特异性靶向药物。因此，该项目具有重要的医学研究价值和临床应用价值，对国人的医疗价值更大。开发KRAS-G12C小分子药物，其分子机制已基本阐明，药物分子结构和药效作用在现有试验条件下得到验证，具备高活性特征和成药的可能性。
发明内容
本发明提供了式(Ⅰ)所示化合物、其光学异构体及其药效上可接受的盐，
Figure PCTCN2020106573-appb-000001
其中，
R 1、R 2、R 11分别独立地选自H、卤素、OH、NH 2、CN、C 1-6烷基、C 1-6烷氧基和C 1-6烷氨基，所述C 1-6烷基、C 1-6烷氧基或C 1-6烷氨基任选被1、2或3个R取代；
T 1选自N和C(R 3)；
T 2选自N和C(R 4)；
R 3、R 4分别独立地选自H、卤素、OH、NH 2、CN、C 2-4烯基、C 2-4炔基、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基和3～6元杂环烷基，所述C 2-4烯基、C 2-4炔基、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
R 5分别独立地选自H、卤素、OH、NH 2、CN、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基、3～6元杂环烷基、C 6-10芳基和5～10元杂芳基，所述C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基、3～6元杂环烷基、C 6-10芳基或5～10元杂芳基任选被1、2或3个R取代；
R 6分别独立地选自H、卤素、OH、NH 2、CN、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基和3～6元杂环烷基，所述C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
环A选自C 3-6环烷基、3～6元杂环烷基、C 6-10芳基和5～10元杂芳基；
环B选自C 6-10芳基、5～10元杂芳基、苯并5～6元杂环烷基和5～6元杂芳基并5～6元杂环烷基；
R 7选自H、卤素、CN、C 1-6烷基、C 1-6烷氧基和C 1-6烷氨基，所述C 1-6烷基、C 1-6烷氧基或C 1-6烷氨基任选被1、2或3个R取代；
R 8、R 9分别独立地选自H、卤素、CN、C 1-6烷基、C 3-6环烷基和3～6元杂环烷基，所述C 1-6烷基、C 1-6杂烷基、C 1-6烷氨基、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
Figure PCTCN2020106573-appb-000002
代表
Figure PCTCN2020106573-appb-000003
且当
Figure PCTCN2020106573-appb-000004
为
Figure PCTCN2020106573-appb-000005
时，R 7和R 9不存在；
L 1选自单键、CH 2、
Figure PCTCN2020106573-appb-000006
O、S、S(＝O)、C(＝O)、S(＝O) 2和N(R 10)；
L 2选自CH 2、O、S和C(＝O)；
L 3选自单键、C(R 12R 12)和C(＝O)；
L 4选自S(＝O)、S(＝O) 2和C(＝O)；
m选自1、2、3和4；
n选自1、2、3和4；
R 10选自H、C 1-6烷基、C 3-6环烷基和3～6元杂环烷基，所述C 1-6烷基、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
R 12分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me和CF 3；
R分别独立地选自H、卤素、OH、NH 2、CN、
Figure PCTCN2020106573-appb-000007
C 1-6烷基、C 1-6烷基-OC(＝O)-、C 1-6烷氧基、C 1-6 烷硫基、C 1-6烷氨基和5～6元杂环烷基，其中C 1-6烷基、C 1-6烷基-OC(＝O)-、C 1-6烷氧基、C 1-6烷硫基C 1-6烷氨基或5～6元杂环烷基任选被1、2或3个R’取代；
R’选自F、Cl、Br、I、OH、NH 2和CH 3；
所述3～6元杂环烷基、5～6元杂环烷基、5～10元杂芳基或C 1-6杂环烷基包含1、2或3个独立选自O、NH、S、C(＝O)、C(＝O)O、S(＝O)、S(＝O) 2和N的杂原子或杂原子团。
本发明的一些方案中，上述R分别独立地选自H、卤素、OH、NH 2、CN、
Figure PCTCN2020106573-appb-000008
C 1-3烷基、C 1-3烷氧基、C 1-3烷硫基、C 1-3烷氨基和5～6元杂环烷基，其中C 1-3烷基、C 1-3烷氧基、C 1-3烷硫基、C 1-3烷氨基或5～6元杂环烷基任选被1、2或3个R’取代，其它变量如本发明所定义。
本发明的一些方案中，上述R分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、
Figure PCTCN2020106573-appb-000009
Figure PCTCN2020106573-appb-000010
其中Me、
Figure PCTCN2020106573-appb-000011
Figure PCTCN2020106573-appb-000012
任选被1、2或3个R’取代，其它变量如本发明所定义。
本发明的一些方案中，上述R分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、
Figure PCTCN2020106573-appb-000013
Figure PCTCN2020106573-appb-000014
其它变量如本发明所定义。
本发明的一些方案中，上述R 1、R 2、R 11分别独立地选自H、卤素、OH、NH 2、CN、C 1-3烷基、C 1-3烷氧基和C 1-3烷氨基，所述C 1-3烷基、C 1-3烷氧基或C 1-3烷氨基任选被1、2或3个R取代，其它变量如本发明所定义。
本发明的一些方案中，上述R 1、R 2、R 11分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、
Figure PCTCN2020106573-appb-000015
其它变量如本发明所定义。
本发明的一些方案中，上述R 3、R 4分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、
Figure PCTCN2020106573-appb-000016
其它变量如本发明所定义。
本发明的一些方案中，上述R 5选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、
Figure PCTCN2020106573-appb-000017
Figure PCTCN2020106573-appb-000018
其它变量如本发明所定义。
本发明的一些方案中，上述R 6选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、N(CH 3) 2、
Figure PCTCN2020106573-appb-000019
Figure PCTCN2020106573-appb-000020
其它变量如本发明所定义。
本发明的一些方案中，上述环A选自C 3-6环烷基、3～6元杂环烷基、苯基、萘基、噻吩基、吡唑基、噻唑基、咪唑基、吡啶基、嘧啶基、吲唑基和吲哚基，其它变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2020106573-appb-000021
选自
Figure PCTCN2020106573-appb-000022
Figure PCTCN2020106573-appb-000023
Figure PCTCN2020106573-appb-000024
其它变量如本发明所定义。
本发明的一些方案中，上述环B选自苯基、萘基、噻吩基、吡啶基、嘧啶基、吲唑基、吲哚基、1H-苯并[d][1,2,3]***基、1,3-二氢-2H-苯并[d]咪唑-2-酮基、苯并[d]恶唑-2(3H)-酮基、1H-吡唑并[3,4-b]吡啶基、异喹啉-1(2H)-酮基和1H-苯并[d]咪唑基，其它变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2020106573-appb-000025
选自
Figure PCTCN2020106573-appb-000026
Figure PCTCN2020106573-appb-000027
Figure PCTCN2020106573-appb-000028
其它变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2020106573-appb-000029
选自：
Figure PCTCN2020106573-appb-000030
Figure PCTCN2020106573-appb-000031
Figure PCTCN2020106573-appb-000032
Figure PCTCN2020106573-appb-000033
其它变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2020106573-appb-000034
选自
Figure PCTCN2020106573-appb-000035
Figure PCTCN2020106573-appb-000036
Figure PCTCN2020106573-appb-000037
Figure PCTCN2020106573-appb-000038
Figure PCTCN2020106573-appb-000039
Figure PCTCN2020106573-appb-000040
Figure PCTCN2020106573-appb-000041
Figure PCTCN2020106573-appb-000042
其它变量如本发明所定义。
本发明的一些方案中，上述R 7选自H、F、Cl、Br、I、CN、Me、CF 3、
Figure PCTCN2020106573-appb-000043
Figure PCTCN2020106573-appb-000044
其它变量如本发明所定义。
本发明的一些方案中，上述R 8、R 9分别独立地选自H、F、Cl、Br、I、CN、Me、CF 3、
Figure PCTCN2020106573-appb-000045
Figure PCTCN2020106573-appb-000046
其它变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2020106573-appb-000047
选自
Figure PCTCN2020106573-appb-000048
Figure PCTCN2020106573-appb-000049
其它变量如本发明所定义。
本发明的一些方案中，上述化合物、其光学异构体及其药效上可接受的盐，其选自
Figure PCTCN2020106573-appb-000050
其中，
R 1、R 2、L 1、L 2、T、T 2、R 5、R 6、环A、环B、R 7、R 8、R 9如上述所定义。
本发明的一些方案中，上述化合物、其光学异构体及其药效上可接受的盐，其选自
Figure PCTCN2020106573-appb-000051
其中，
R 1、R 2、L 1、T、T 2、R 5、R 6、环A、环B、R 7、R 8、R 9如上述所定义。
本发明的一些方案中，上述化合物、其光学异构体及其药效上可接受的盐，其选自
Figure PCTCN2020106573-appb-000052
其中，
R 1、R 2、L 1、T、T 2、R 5、R 6、环A、环B、R 7、R 8、R 9如上述所定义。
本发明还提供了下式化合物、其光学异构体及其药效上可接受的盐，其选自
Figure PCTCN2020106573-appb-000053
Figure PCTCN2020106573-appb-000054
Figure PCTCN2020106573-appb-000055
Figure PCTCN2020106573-appb-000056
Figure PCTCN2020106573-appb-000057
Figure PCTCN2020106573-appb-000058
Figure PCTCN2020106573-appb-000059
Figure PCTCN2020106573-appb-000060
Figure PCTCN2020106573-appb-000061
Figure PCTCN2020106573-appb-000062
Figure PCTCN2020106573-appb-000063
Figure PCTCN2020106573-appb-000064
Figure PCTCN2020106573-appb-000065
Figure PCTCN2020106573-appb-000066
Figure PCTCN2020106573-appb-000067
Figure PCTCN2020106573-appb-000068
Figure PCTCN2020106573-appb-000069
Figure PCTCN2020106573-appb-000070
Figure PCTCN2020106573-appb-000071
Figure PCTCN2020106573-appb-000072
Figure PCTCN2020106573-appb-000073
Figure PCTCN2020106573-appb-000074
Figure PCTCN2020106573-appb-000075
Figure PCTCN2020106573-appb-000076
Figure PCTCN2020106573-appb-000077
Figure PCTCN2020106573-appb-000078
Figure PCTCN2020106573-appb-000079
Figure PCTCN2020106573-appb-000080
Figure PCTCN2020106573-appb-000081
Figure PCTCN2020106573-appb-000082
Figure PCTCN2020106573-appb-000083
Figure PCTCN2020106573-appb-000084
Figure PCTCN2020106573-appb-000085
Figure PCTCN2020106573-appb-000086
Figure PCTCN2020106573-appb-000087
本发明还提供了一种药物组合物，所述的药物组合物含有治疗有效量上述化合物或其药学上可药用盐，以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
本发明还提供了上述化合物或其可药用盐或上述药物组合物在制备预防和/或治疗用作KRAS-G12C相关疾病的药物中的用途。
本发明的一些方案中，上述的KRAS-G12C相关疾病选自非小细胞肺癌、结肠癌和胰腺癌。
定义和说明
除非另有说明，本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照普通的含义去理解。当本文中出现商品名时，意在指代其对应的商品或其活性成分。
这里所采用的术语“药学上可接受的”，是针对那些化合物、材料、组合物和/或剂型而言，它们在可靠的医学判断的范围之内，适用于与人类和动物的组织接触使用，而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症，与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐，由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机胺或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的中性形式接触的方式获得酸加成盐。药学上可接受的酸 加成盐的实例包括无机酸盐，所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸，碳酸氢根，磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸氢根、氢碘酸、亚磷酸等；以及有机酸盐，所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸；还包括氨基酸(如精氨酸等)的盐，以及如葡糖醛酸等有机酸的盐。本发明的某些特定的化合物含有碱性和酸性的官能团，从而可以被转换成任一碱或酸加成盐。
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下，这样的盐的制备方法是：在水或有机溶剂或两者的混合物中，经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物，包括顺式和反式异构体、(-)-和(+)-对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体，及其外消旋混合物和其他混合物，例如对映异构体或非对映体富集的混合物，所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物，均包括在本发明的范围之内。
除非另有说明，术语“对映异构体”或者“旋光异构体”是指互为镜像关系的立体异构体。
除非另有说明，术语“顺反异构体”或者“几何异构体”系由因双键或者成环碳原子单键不能自由旋转而引起。
除非另有说明，术语“非对映异构体”是指分子具有两个或多个手性中心，并且分子间为非镜像的关系的立体异构体。
除非另有说明，用楔形实线键
Figure PCTCN2020106573-appb-000088
和楔形虚线键
Figure PCTCN2020106573-appb-000089
表示一个立体中心的绝对构型。
本发明的化合物可以存在特定的。除非另有说明，术语“互变异构体”或“互变异构体形式”是指在室温下，不同官能团异构体处于动态平衡，并能很快的相互转化。若互变异构体是可能的(如在溶液中)，则可以达到互变异构体的化学平衡。例如，质子互变异构体(proton tautomer)(也称质子转移互变异构体(prototropic tautomer))包括通过质子迁移来进行的互相转化，如酮-烯醇异构化和亚胺-烯胺异构化。价键异构体(valence tautomer)包括一些成键电子的重组来进行的相互转化。其中酮-烯醇互变异构化的具体实例是戊烷-2,4-二酮与4-羟基戊-3-烯-2-酮两个互变异构体之间的互变。
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如，可用放射性同位素标记化合物，比如氚( 3H)，碘-125( 125I)或C-14( 14C)。又例如，可用重氢取代氢形成氘代药物，氘与碳构成的键比普通氢与碳构成的键更坚固，相比于未氘化药物，氘代药物有降低毒副作用、增加药物稳定性、增强疗效、延长药物生物半衰期等优势。本发明的化合物的所有同位素组成的变换，无论放射性与否，都包括在本发明的范围之内。“任选”或“任选地”指的是随后描述的事件或状况可能但不是必需出现的，并且该描述包括其中所述事件或状况发生的情况以及所述事件或状况不发生的情况。
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代，可以包括重氢和氢的变体，只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为氧(即＝O)时，意味着两个氢原子被取代。氧取代不会发生在芳香基上。术语“任选被取代的”是指可以被取代，也可以不被取代，除非另有规定，取代基的种类和数目在化学上可以实现的基础上可以是任意的。
当任何变量(例如R)在化合物的组成或结构中出现一次以上时，其在每一种情况下的定义都是独立的。因此，例如，如果一个基团被0-2个R所取代，则所述基团可以任选地至多被两个R所取代，并且每种情况下的R都有独立的选项。此外，取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当其中一个变量选自单键时，表示其连接的两个基团直接相连，比如
Figure PCTCN2020106573-appb-000090
中L 3代表单键时表示该结构实际上是
Figure PCTCN2020106573-appb-000091
当所列举的取代基中没有指明其通过哪一个原子连接到被取代的基团上时，这种取代基可以通过其任何原子相键合，例如，吡啶基作为取代基可以通过吡啶环上任意一个碳原子连接到被取代的基团上。
当所列举的连接基团没有指明其连接方向，其连接方向是任意的，例如，
Figure PCTCN2020106573-appb-000092
中连接基团L为
Figure PCTCN2020106573-appb-000093
此时
Figure PCTCN2020106573-appb-000094
既可以按与从左往右的读取顺序相同的方向连接苯环和环己烷构成
Figure PCTCN2020106573-appb-000095
也可以按照与从左往右的读取顺序相反的方向连接苯环和环己烷构成
Figure PCTCN2020106573-appb-000096
所述连接基团、取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
除非另有规定，环上原子的数目通常被定义为环的元数，例如，“5-7元环”是指环绕排列5-7个原子的“环”。
除非另有规定，术语“C 1-6烷基”用于表示直链或支链的由1至6个碳原子组成的饱和碳氢基团。所述C 1-6烷基包括C 1-5、C 1-4、C 1-3、C 1-2、C 2-6、C 2-4、C 6和C 5烷基等；其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C 1-6烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)、丁基(包括n-丁基，异丁基，s-丁基和t-丁基)、戊基(包括n-戊基，异戊基和新戊基)、己基等。
除非另有规定，术语“C 1-5烷基”用于表示直链或支链的由1至5个碳原子组成的饱和碳氢基团。所述C 1-5烷基包括C 1-4、C 1-3、C 1-2、C 2-5、C 2-4和C 5烷基等；其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C 1-5烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)、丁基(包括n-丁基，异丁基，s-丁基和t-丁基)、戊基(包括n-戊基，异戊基和新戊基)等。
除非另有规定，术语“C 1-4烷基”用于表示直链或支链的由1至4个碳原子组成的饱和碳氢基团。所述C 1-4烷基包括C 1-2、C 1-3和C 2-3烷基等；其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C 1-4烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)、丁基(包括n-丁基，异丁基，s-丁基和t-丁基)等。
除非另有规定，术语“C 1-3烷基”用于表示直链或支链的由1至3个碳原子组成的饱和碳氢基团。所述C 1-3烷基包括C 1-2和C 2-3烷基等；其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C 1- 3烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)等。除非另有规定，“C 2-8烯基”用于表示直链或支链的包含至少一个碳-碳双键的由2至8个碳原子组成的碳氢基团，碳-碳双键可以位于该基团的任何位置上。所述C 2-8烯基包括C 2-6、C 2-4、C 2-3、C 4、C 3和C 2烯基等；其可以是一价、二价或者多价。C 2-8烯基的实例包括但不限于乙烯基、丙烯基、丁烯基、戊烯基、己烯基、丁间二烯基、戊间二烯基、己间二烯基等。
除非另有规定，“C 2-4烯基”用于表示直链或支链的包含至少一个碳-碳双键的由2至4个碳原子组成的碳氢基团，碳-碳双键可以位于该基团的任何位置上。所述C 2-4烯基包括C 2-3、C 4、C 3和C 2烯基等；所述C 2-4烯基可以是一价、二价或者多价。C 2-4烯基的实例包括但不限于乙烯基、丙烯基、丁烯基、丁间二烯基等。除非另有规定，“C 2-3烯基”用于表示直链或支链的包含至少一个碳-碳双键的由2至3个碳原子组成的碳氢基团，碳-碳双键可以位于该基团的任何位置上。所述C 2-3烯基包括C 3和C 2烯基；所述C 2-3烯基可 以是一价、二价或者多价。C 2-3烯基的实例包括但不限于乙烯基、丙烯基等。
除非另有规定，“C 2-4炔基”用于表示直链或支链的包含至少一个碳-碳三键的由2至4个碳原子组成的碳氢基团，碳-碳三键可以位于该基团的任何位置上。所述C 2-4炔基包括C 2-3、C 4、C 3和C 2炔基等。其可以是一价、二价或者多价。C 2-4炔基的实例包括但不限于乙炔基、丙炔基、丁炔基等。
除非另有规定，“C 2-3炔基”用于表示直链或支链的包含至少一个碳-碳三键的由2至3个碳原子组成的碳氢基团，碳-碳三键可以位于该基团的任何位置上。其可以是一价、二价或者多价。所述C 2-3炔基包括C 3和C 2炔基。C 2-3炔基的实例包括但不限于乙炔基、丙炔基等。
术语“杂烷基”本身或者与另一术语联合，表示由一定数目碳原子和至少一个杂原子或杂原子团组成的，稳定的直链或支链的烷基原子团或其组合物。在一些实施方案中，杂原子选自B、O、N和S，其中氮和硫原子任选地被氧化，氮杂原子任选地被季铵化。在另一些实施方案中，杂原子团选自-C(＝O)O-、-C(＝O)-、-C(＝S)-、-S(＝O)、-S(＝O) 2-、-C(＝O)N(H)-、-N(H)-、-C(＝NH)-、-S(＝O) 2N(H)-和-S(＝O)N(H)-。在一些实施方案中，所述杂烷基为C 1-6杂烷基；在另一些实施方案中，所述杂烷基为C 1-3杂烷基。杂原子或杂原子团可以位于杂烷基的任何内部位置，包括该烷基与分子其余部分的连接位置，但术语“烷氧基”、“烷氨基”和“烷硫基”(或硫代烷氧基)属于惯用表达，是指分别通过一个氧原子、氨基或硫原子连接到分子的其余部分的那些烷基基团。杂烷基的实例包括但不限于-OCH 3、-OCH 2CH 3、-OCH 2CH 2CH 3、-OCH 2(CH 3) 2、-CH 2-CH 2-O-CH 3、-NHCH 3、-N(CH 3) 2、-NHCH 2CH 3、-N(CH 3)(CH 2CH 3)、-CH 2-CH 2-NH-CH 3、-CH 2-CH 2-N(CH 3)-CH 3、-SCH 3、-SCH 2CH 3、-SCH 2CH 2CH 3、-SCH 2(CH 3) 2、-CH 2-S-CH 2-CH 3、-CH 2-CH 2、-S(＝O)-CH 3、-CH 2-CH 2-S(＝O) 2-CH 3、和。至多两个杂原子可以是连续的，例如-CH 2-NH-OCH 3。
除非另有规定，术语“C 1-6烷氧基”表示通过一个氧原子连接到分子的其余部分的那些包含1至6个碳原子的烷基基团。所述C 1-6烷氧基包括C 1-4、C 1-3、C 1-2、C 2-6、C 2-4、C 6、C 5、C 4和C 3烷氧基等。C 1-6烷氧基的实例包括但不限于甲氧基、乙氧基、丙氧基(包括正丙氧基和异丙氧基)、丁氧基(包括n-丁氧基、异丁氧基、s-丁氧基和t-丁氧基)、戊氧基(包括n-戊氧基、异戊氧基和新戊氧基)、己氧基等。
除非另有规定，术语“C 1-3烷氧基”表示通过一个氧原子连接到分子的其余部分的那些包含1至3个碳原子的烷基基团。所述C 1-3烷氧基包括C 1-2、C 2-3、C 3和C 2烷氧基等。C 1-3烷氧基的实例包括但不限于甲氧基、乙氧基、丙氧基(包括正丙氧基和异丙氧基)等。
除非另有规定，术语“C 1-6烷氨基”表示通过氨基连接到分子的其余部分的那些包含1至6个碳原子的烷基基团。所述C 1-6烷氨基包括C 1-4、C 1-3、C 1-2、C 2-6、C 2-4、C 6、C 5、C 4、C 3和C 2烷氨基等。C 1-6烷氨基的实例包括但不限于-NHCH 3、-N(CH 3) 2、-NHCH 2CH 3、-N(CH 3)CH 2CH 3、-N(CH 2CH 3)(CH 2CH 3)、-NHCH 2CH 2CH 3、-NHCH 2(CH 3) 2、-NHCH 2CH 2CH 2CH 3等。
除非另有规定，术语“C 1-3烷氨基”表示通过氨基连接到分子的其余部分的那些包含1至3个碳原子的烷基基团。所述C 1-3烷氨基包括C 1-2、C 3和C 2烷氨基等。C 1-3烷氨基的实例包括但不限于-NHCH 3、-N(CH 3) 2、-NHCH 2CH 3、-N(CH 3)CH 2CH 3、-NHCH 2CH 2CH 3、-NHCH 2(CH 3) 2等。
除非另有规定，术语“C 1-6烷硫基”表示通过硫原子连接到分子的其余部分的那些包含1至6个碳原子的烷基基团。所述C 1-6烷硫基包括C 1-4、C 1-3、C 1-2、C 2-6、C 2-4、C 6、C 5、C 4、C 3和C 2烷硫基等。C 1-6烷硫基的实例包括但不限于-SCH 3、-SCH 2CH 3、-SCH 2CH 2CH 3、-SCH 2(CH 3) 2等等。
除非另有规定，术语“C 1-3烷硫基”表示通过硫原子连接到分子的其余部分的那些包含1至3个碳原子的烷基基团。所述C 1-3烷硫基包括C 1-3、C 1-2和C 3烷硫基等。C 1-3烷硫基的实例包括但不限于-SCH 3、-SCH 2CH 3、-SCH 2CH 2CH 3、-SCH 2(CH 3) 2等
除非另有规定，“C 3-6环烷基”表示由3至6个碳原子组成的饱和环状碳氢基团，其为单环和双环体系，所述C 3-6环烷基包括C 3-5、C 4-5和C 5-6环烷基等；其可以是一价、二价或者多价。C 3-6环烷基的实例包括，但不限于，环丙基、环丁基、环戊基、环己基等。
除非另有规定，术语“3-6元杂环烷基”本身或者与其他术语联合分别表示由3至6个环原子组成的饱 和环状基团，其1、2、3或4个环原子为独立选自O、S和N的杂原子，其余为碳原子，其中氮原子任选地被季铵化，氮和硫杂原子可任选被氧化(即NO和S(O) p，p是1或2)。其包括单环和双环体系，其中双环体系包括螺环、并环和桥环。此外，就该“3-6元杂环烷基”而言，杂原子可以占据杂环烷基与分子其余部分的连接位置。所述3-6元杂环烷基包括4-6元、5-6元、4元、5元和6元杂环烷基等。3-6元杂环烷基的实例包括但不限于氮杂环丁基、氧杂环丁基、硫杂环丁基、吡咯烷基、吡唑烷基、咪唑烷基、四氢噻吩基(包括四氢噻吩-2-基和四氢噻吩-3-基等)、四氢呋喃基(包括四氢呋喃-2-基等)、四氢吡喃基、哌啶基(包括1-哌啶基、2-哌啶基和3-哌啶基等)、哌嗪基(包括1-哌嗪基和2-哌嗪基等)、吗啉基(包括3-吗啉基和4-吗啉基等)、二噁烷基、二噻烷基、异噁唑烷基、异噻唑烷基、1,2-噁嗪基、1,2-噻嗪基、六氢哒嗪基、高哌嗪基或高哌啶基等。
除非另有规定，本发明术语“C 6-10芳环”和“C 6-10芳基”可以互换使用，术语“C 6-10芳环”或“C 6-10芳基”表示由6至10个碳原子组成的具有共轭π电子体系的环状碳氢基团，它可以是单环、稠合双环或稠合三环体系，其中各个环均为芳香性的。其可以是一价、二价或者多价，C 6-10芳基包括C 6-9、C 9、C 10和C 6芳基等。C 6-10芳基的实例包括但不限于苯基、萘基(包括1-萘基和2-萘基等)。
除非另有规定，本发明术语“5-10元杂芳环”和“5-10元杂芳基”可以互换使用，术语“5-10元杂芳基”是表示由5至10个环原子组成的具有共轭π电子体系的环状基团，其1、2、3或4个环原子为独立选自O、S和N的杂原子，其余为碳原子。其可以是单环、稠合双环或稠合三环体系，其中各个环均为芳香性的。其中氮原子任选地被季铵化，氮和硫杂原子可任选被氧化(即NO和S(O) p，p是1或2)。5-10元杂芳基可通过杂原子或碳原子连接到分子的其余部分。所述5-10元杂芳基包括5-8元、5-7元、5-6元、5元和6元杂芳基等。所述5-10元杂芳基的实例包括但不限于吡咯基(包括N-吡咯基、2-吡咯基和3-吡咯基等)、吡唑基(包括2-吡唑基和3-吡唑基等)、咪唑基(包括N-咪唑基、2-咪唑基、4-咪唑基和5-咪唑基等)、噁唑基(包括2-噁唑基、4-噁唑基和5-噁唑基等)、***基(1H-1,2,3-***基、2H-1,2,3-***基、1H-1,2,4-***基和4H-1,2,4-***基等)、四唑基、异噁唑基(3-异噁唑基、4-异噁唑基和5-异噁唑基等)、噻唑基(包括2-噻唑基、4-噻唑基和5-噻唑基等)、呋喃基(包括2-呋喃基和3-呋喃基等)、噻吩基(包括2-噻吩基和3-噻吩基等)、吡啶基(包括2-吡啶基、3-吡啶基和4-吡啶基等)、吡嗪基、嘧啶基(包括2-嘧啶基和4-嘧啶基等)、苯并噻唑基(包括5-苯并噻唑基等)、嘌呤基、苯并咪唑基(包括2-苯并咪唑基等)、苯并噁唑基、吲哚基(包括5-吲哚基等)、异喹啉基(包括1-异喹啉基和5-异喹啉基等)、喹喔啉基(包括2-喹喔啉基和5-喹喔啉基等)或喹啉基(包括3-喹啉基和6-喹啉基等)。
除非另有规定，本发明术语“5-6元杂芳环”和“5-6元杂芳基”可以互换使用，术语“5-6元杂芳基”表示由5至6个环原子组成的具有共轭π电子体系的单环基团，其1、2、3或4个环原子为独立选自O、S和N的杂原子，其余为碳原子。其中氮原子任选地被季铵化，氮和硫杂原子可任选被氧化(即NO和S(O) p，p是1或2)。5-6元杂芳基可通过杂原子或碳原子连接到分子的其余部分。所述5-6元杂芳基包括5元和6元杂芳基。所述5-6元杂芳基的实例包括但不限于吡咯基(包括N-吡咯基、2-吡咯基和3-吡咯基等)、吡唑基(包括2-吡唑基和3-吡唑基等)、咪唑基(包括N-咪唑基、2-咪唑基、4-咪唑基和5-咪唑基等)、噁唑基(包括2-噁唑基、4-噁唑基和5-噁唑基等)、***基(1H-1,2,3-***基、2H-1,2,3-***基、1H-1,2,4-***基和4H-1,2,4-***基等)、四唑基、异噁唑基(3-异噁唑基、4-异噁唑基和5-异噁唑基等)、噻唑基(包括2-噻唑基、4-噻唑基和5-噻唑基等)、呋喃基(包括2-呋喃基和3-呋喃基等)、噻吩基(包括2-噻吩基和3-噻吩基等)、吡啶基(包括2-吡啶基、3-吡啶基和4-吡啶基等)、吡嗪基或嘧啶基(包括2-嘧啶基和4-嘧啶基等)。
除非另有规定，“苯并5～6元杂环烷基”表示由苯基和杂环和5～6元杂环烷基并合形成的双并环结构，该取代基可通过苯环或5～6元杂环烷基环与其它结构相连接。所述苯并5～6元杂环烷基的实施例包括并不限于
Figure PCTCN2020106573-appb-000097
等。
除非另有规定，“5～6元杂芳基并5～6元杂环烷基”表示由5～6元杂芳基和杂环和5～6元杂环烷基并合形成的双并环结构，该取代基可通过5～6元杂芳基或5～6元杂环烷基环与其它结构相连接。所述苯并5～6元杂环烷基的实施例包括并不限于
Figure PCTCN2020106573-appb-000098
等。
除非另有规定，C n-n+m或C n-C n+m包括n至n+m个碳的任何一种具体情况，例如C 1-12包括C 1、C 2、C 3、C 4、C 5、C 6、C 7、C 8、C 9、C 10、C 11、和C 12，也包括n至n+m中的任何一个范围，例如C 1-12包括C 1- 3、C 1-6、C 1-9、C 3-6、C 3-9、C 3-12、C 6-9、C 6-12、和C 9-12等；同理，n元至n+m元表示环上原子数为n至n+m个，例如3-12元环包括3元环、4元环、5元环、6元环、7元环、8元环、9元环、10元环、11元环、和12元环，也包括n至n+m中的任何一个范围，例如3-12元环包括3-6元环、3-9元环、5-6元环、5-7元环、6-7元环、6-8元环、和6-10元环等。
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。
本发明所使用的溶剂可经市售获得。本发明采用下述缩略词：CDCl 3代表氘代氯仿；CD 3OD代表氘代甲醇；DMSO-d 6代表氘代二甲亚砜；TBS代表叔丁基二甲基硅基。
化合物依据本领域常规命名原则或者使用
Figure PCTCN2020106573-appb-000099
软件命名，市售化合物采用供应商目录名称。
具体实施方式
下面通过实施例对本申请进行详细描述，但并不意味着存在对本申请而言任何不利的限制。本文已经详细地描述了本申请，其中也公开了其具体实施例方式，对本领域的技术人员而言，在不脱离本申请精神和范围的情况下针对本申请具体实施方式进行各种变化和改进将是显而易见的。
实施例1：化合物1的制备
步骤1：化合物1-2的制备
Figure PCTCN2020106573-appb-000100
将二异丙基乙基胺(1.34g,10.33mmol,1.80mL)溶于无水四氢呋喃(50mL)中，冷却至-78℃后，向其中滴加正丁基锂(2.5M,47.78mL)，滴加完毕后，将体系升温至-30℃搅拌10min。将体系冷却至-78℃，向其中加入化合物1-1(10g,51.94mmol)的四氢呋喃(50mL)溶液，体系在-78℃搅拌4h。向体系加入1,2-二溴四氯乙烷(33.82g,103.87mmol)的四氢呋喃(50mL)溶液，体系在-78℃搅拌2h后，升温至室温(20℃)搅拌16h。体系加水(500mL)淬灭后，静置分层，水相用甲基叔丁基醚(3 x 30mL)洗涤，将水相用2N盐酸水溶液酸化至pH＝2(出现沉淀)，乙酸乙酯(3 x 200mL)萃取体系，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(乙醇/乙酸乙酯(v/v)＝0～10％)得浅黄色粘稠物1-2。
步骤2：化合物1-3的制备
Figure PCTCN2020106573-appb-000101
将化合物1-2(12g,44.21mmol)溶于无水二氯甲烷(150mL)中，0℃条件下，向其中依次滴加草酰氯(8.42g,66.31mmol,5.80mL)及1滴N,N-二甲基甲酰胺。滴加完毕后，将体系在0℃搅拌15min，然后升至室温(20℃)搅拌2h。体系减压浓缩，得粗品1-3，不经进一步纯化直接用于下一步反应。
步骤3：化合物1-4的制备
Figure PCTCN2020106573-appb-000102
将化合物1-3(12.8g,44.15mmol)溶于无水二氧六环(100mL)，0℃条件下，向其中滴加氨的甲醇溶液(7M,31.54mL)。滴加完毕后，将体系在室温(20℃)搅拌2h。体系减压浓缩，加水(200mL)稀释，乙酸乙酯(3 x 50mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～30％)得浅黄色固体1-4。
MS(ESI)m/z(M+H) +＝269.9.
1H NMR(400MHz,DMSO-d 6)8.14(s,1H),7.96(s,1H),7.83-7.80(m,1H).
步骤4：化合物1-6的制备
Figure PCTCN2020106573-appb-000103
将化合物1-4(6g,22.18mmol)溶于无水1,2-二氯乙烷(60mL)，室温(20℃)条件下，向其中滴加草酰氯(3.94g,31.06mmol)。滴加完毕后，将体系升温至80℃搅拌1h。将反应液浓缩至一半体积，降温至0℃，向其中滴加化合物1-5(3.50g,23.29mmol)的1,2-二氯乙烷(30mL)溶液。滴加完毕后，将体系在室温(20℃)搅拌1h。体系减压浓缩，粗品经真空干燥后得白色固体1-6，不经进一步纯化直接用于下一步反应。
步骤5：化合物1-7的制备
Figure PCTCN2020106573-appb-000104
将化合物1-6(9g,20.15mmol)溶于无水四氢呋喃(150mL)，0℃条件，氮气氛围下，向其中加入双(三甲基硅基)氨基钠(1M,40.30mL)。加毕，将体系升温至室温(20℃)搅拌1h。将体系倒入水(500mL)中，乙酸乙酯(3 x 150mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～30％)得浅白色固体1-7。
1H NMR(400MHz,DMSO-d 6)8.58(d,J＝5.2Hz,1H),7.34(d,J＝4.8Hz,1H),6.40(d,J＝6Hz,1H),2.86-2.80(m,1H),2.07(s,3H),1.05-0.98(m,6H)
步骤6：化合物1-8的制备
Figure PCTCN2020106573-appb-000105
将化合物1-7(6g,14.06mmol)溶于乙腈(150mL)，向其中依次加入二异丙基乙基胺(7.27g,56.25mmol)及三氯氧磷(8.62g,56.25mmol)。加毕，体系升温至80℃搅拌4h。将体系倒入冰水(250mL)淬灭，乙酸乙酯萃取(3 x 100mL)，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得棕褐色粗品。粗品不经进一步纯化直接用于下一步反应。
步骤7：化合物1-10的制备
Figure PCTCN2020106573-appb-000106
将化合物1-9(3g,13.87mmol)溶于二氯甲烷(40mL)，0℃条件下，向其中依次加入咪唑(1.42g,20.81mmol)及叔丁基二甲基氯硅烷(2.30g,15.26mmol)。加毕，体系升温至室温(20℃)搅拌16h。体系加水(10mL)淬灭，二氯甲烷(2 x 10mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～100％)，得无色油状化合物1-10。
步骤8：化合物1-11的制备
Figure PCTCN2020106573-appb-000107
将化合物1-8(5g,11.23mmol)溶于无水1,2-二氯乙烷(50mL)，0℃条件下，向其中依次加入二异丙基乙基胺(1.89g,14.60mmol,2.54mL)，化合物1-10(3.71g,11.23mmol)的1,2-二氯乙烷(5mL)溶液。加毕，体系升温至室温(20℃)搅拌2h。反应体系加水(100mL)稀释，二氯甲烷(3 x 50mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(石油醚/乙酸乙酯(v/v)＝0～75％)得浅黄色粘稠物1-11。
步骤9：化合物1-12的制备
Figure PCTCN2020106573-appb-000108
将化合物1-11(6.5g,8.79mmol)溶于无水四氢呋喃(100mL)，0℃条件下，向其中加入四丁基氟化铵(1M,10.55mL)。加毕，体系升温至室温(20℃)搅拌1h。体系浓缩得粗品，粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝30～90％)得浅黄色固体1-12。
1H NMR(400MHz,DMSO-d 6)8.84(s,1H),8.57-8.55(m,1H),7.25-7.33(m,1H),6.14-6.10(m,1H),4.24-4.21(m,2H),3.99-3.94(m,2H),2.76-2.71(m,5H),2.26-2.23(m,1H),2.04-2.01(m,3H),1.42(s,9H),1.11-1.04(m,6H)
步骤10：化合物1-13的制备
Figure PCTCN2020106573-appb-000109
将化合物1-12(400mg,640.07μmol)溶于甲苯(10mL)，向其中依次加入三(二亚苄基丙酮)二钯(36.80mg,64.01μmol)，4,5-双二苯基膦-9,9-二甲基氧杂蒽(74.07mg,128.01μmol)及磷酸钾(271.73mg,1.28mmol)。加毕，氩气氛围下，体系升温至100℃搅拌16h。体系过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(石油醚/乙酸乙酯(v/v)＝75～100％)及高效制备液相分离(分离条件:色谱柱:YMC Triart C18 150*25mm*5μm；流动相:[水(10mM的碳酸氢铵溶液)-乙腈]；乙腈％:52％-82％)，得化合物1-13(HPLC保留时间9.5min)，浓缩后冻干得白色固体1-13。
MS(ESI)m/z(M+H) +＝544.3.
步骤11：化合物1-14的制备
Figure PCTCN2020106573-appb-000110
将化合物1-14A(2g,11.77mmol)溶于甲醇(3mL)，向其中加入二氟氢化钾(4.5M的水溶液,8mL)，体系出现白色沉淀。加毕，将该浑浊体系室温(20℃)搅拌2h。体系过滤，滤饼依次用水(2 x 5mL)洗，乙腈(5mL)洗。所得粗品经真空干燥得白色固体1-14。
步骤12：化合物1-15的制备
Figure PCTCN2020106573-appb-000111
将化合物1-13(30mg,55.15μmol)溶于二氧六环(2mL)及水(0.4mL)，向其中依次加入化合物1-14(51.18mg,220.58μmol)，2-二环己基磷-2,4,6-三异丙基联苯(5.26mg,11.03μmol)，三(二亚苄基丙酮)二钯(3.17mg,5.51μmol)及碳酸钾(30.49mg,220.58μmol)。加毕，Ar氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～100％)得浅黄色固体1-15。
MS(ESI)m/z(M+H) +＝634.3.
步骤13：化合物1-16的制备
Figure PCTCN2020106573-appb-000112
将化合物1-15(20mg,31.56μmol)溶于无水二氯甲烷(1mL)，0℃条件下，向其中加入三溴化硼(0.5M的二氯甲烷溶液,378.74μL)。加毕，体系升温至室温(20℃)搅拌4h。向体系加入甲醇(2mL)并搅拌10min。体系浓缩后冻干得淡黄色固体1-16(氢溴酸盐)。
MS(ESI)m/z(M+H) +＝520.3
步骤14：化合物1的制备
Figure PCTCN2020106573-appb-000113
将化合物1-16(8mg,13.32μmol,氢溴酸盐)溶于四氢呋喃(1mL)及饱和NaHCO 3水溶液(1mL)，室温(20℃)条件下，向其中加入丙烯酸酐(0.2M,99.92μL)。加毕，体系于室温(20℃)搅拌1h。向体系中加入甲醇(1mL)及氢氧化锂(0.2M,0.1mL)，继续室温(20℃)搅拌2h。体系浓缩，加甲醇(2mL)稀释，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:YMC Triart C18 150*25mm*5um；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:29％-59％)，得化合物1(HPLC保留时间9.5min)。
MS(ESI)m/z(M+H) +＝574.4.
1H NMR(400MHz,DMSO-d 6)8.51(d,J＝5.2Hz,1H),7.34(d,J＝4.8Hz,1H),7.24-7.20(m,1H),6.88-6.80(m,1H),6.68-6.60(m,2H),6.35-6.30(m,1H),6.06-6.01(m,1H),5.87-5.83(m,1H),5.08-5.02(m,1H),4.73-4.61(m,3H),4.49-4.35(m,1H),4.25-4.15(m,2H),3.68-3.46(m,2H),2.88-2.78(m,1H),2.11-2.07(m,3H),1.23-1.21(m,3H),1.21-1.07(m,3H).
19F NMR(376MHz,DMSO-d6)-115.93,-139.68.
步骤15：化合物1异构体的拆分
Figure PCTCN2020106573-appb-000114
非对映异构体化合物1(16mg,27.89μmol)经SFC纯化(分离条件：色谱柱：DAICEL CHIRALCEL OJ-H(250mm*30mm,5um)；流动相:[Neu-乙醇]；乙醇％:30％-30％)。浓缩后，得化合物1A(峰1)及化合物1B(峰2)。
化合物1A
1H NMR(400MHz,DMSO-d 6)8.51(d,J＝5.2Hz,1H),7.34(d,J＝4.8Hz,1H),7.24-7.20(m,1H),6.88-6.80(m,1H),6.68-6.60(m,2H),6.35-6.30(m,1H),6.06-6.01(m,1H),5.87-5.83(m,1H),5.08-5.02(m,1H),4.73-4.61(m,3H),4.49-4.35(m,1H),4.25-4.15(m,2H),3.68-3.46(m,2H),2.88-2.78(m,1H),2.11-2.07(m,3H),1.23-1.21(m,3H),1.21-1.07(m,3H)
19F NMR(376MHz,DMSO-d6)-115.93,-139.68
HPLC保留时间6.443min
分离条件：色谱柱：Waters Xbridge C18 3.5μm,150*4.6mm；柱温：40℃；流动相:水(0.05％氨水溶液)-乙腈；乙腈:0％-95％10min，95％5min；流速：1.0mL/min。
SFC保留时间3.436min
分离条件：色谱柱：Chiralcel OJ-3 100×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5-40％in 4min,40％2.5min,5％1.5min；流速：2.8mL/min。MS(ESI)m/z(M+H) +＝574.4
化合物1B
1H NMR(400MHz,DMSO-d6)8.51(d,J＝5.2Hz,1H),7.34(d,J＝4.8Hz,1H),7.24-7.20(m,1H),6.88-6.80(m,1H),6.68-6.60(m,2H),6.35-6.30(m,1H),6.06-6.01(m,1H),5.87-5.83(m,1H),5.08-5.02(m,1H),4.73-4.61(m, 3H),4.49-4.35(m,1H),4.25-4.15(m,2H),3.68-3.46(m,2H),2.88-2.78(m,1H),2.11-2.07(m,3H),1.23-1.21(m,3H),1.21-1.07(m,3H)
HPLC保留时间6.498min
分离条件：色谱柱：Waters Xbridge C18 3.5μm,150*4.6mm；柱温：40℃；流动相:水(0.05％氨水溶液)-乙腈；乙腈:0％-95％10min，95％5min；流速：1.0mL/min。
SFC保留时间3.780min
分离条件：色谱柱：Chiralcel OJ-3 100×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5-40％in 4min,40％2.5min,5％1.5min；流速：2.8mL/min。MS(ESI)m/z(M+H) +＝574.4
实施例2：化合物2的制备
步骤1：化合物2-2的制备
Figure PCTCN2020106573-appb-000115
将化合物2-1(2.4g,11.1mmol)溶于二氯甲烷(30mL)，0℃条件下，向其中依次加入咪唑(1.13g,16.65mmol)及叔丁基二甲基氯硅烷(2.17g,14.43mmol)。加毕，体系升温至室温(20℃)搅拌16h。体系加水(10mL)淬灭，二氯甲烷(2 x 10mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～100％)，得无色油状化合物2-2。
1H NMR(400MHz,CDCl3)4.02-3.85(m,2H),3.65-3.55(m,1H),3.49-3.42(m,1H),3.03-2.97(m,1H),2.82-2.75(m,1H),2.75-2.68(m,2H),2.55-2.45(m,1H),1.46(s,9H),0.90(s,9H),0.06(s,6H).
步骤2：化合物2-3的制备
Figure PCTCN2020106573-appb-000116
将化合物1-8(2g,4.49mmol)溶于无水乙腈(20mL)，0℃条件下，向其中依次加入二异丙基乙基胺(4.65g,35.92mmol,6.26mL)，化合物2-2(1.48g,4.49mmol)的乙腈(10mL)溶液。加毕，体系升温至室温(20℃)搅拌2h。反应体系加水(100mL)稀释，乙酸乙酯(3 x 50mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(石油醚/乙酸乙酯(v/v)＝0～75％)得浅黄色粘稠物化合物2-3。
步骤3：化合物2-4的制备
Figure PCTCN2020106573-appb-000117
将化合物2-3(3.00g,4.06mmol)溶于无水四氢呋喃(100mL)，0℃条件下，向其中加入四丁基氟化铵 (1.17g,4.46mmol)。加毕，体系升温至室温(20℃)搅拌1h。体系浓缩得粗品，粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝30～90％)得浅黄色固体化合物2-4。
1H NMR(400MHz,DMSO-d 6)8.84(s,1H),8.57-8.55(m,1H),7.25-7.33(m,1H),6.14-6.10(m,1H),4.24-4.21(m,2H),3.99-3.94(m,2H),2.76-2.71(m,4H),2.26-2.23(m,1H),2.04-2.01(m,3H),1.42(s,9H),1.11-1.04(m,6H)
步骤4：化合物2-5的制备
Figure PCTCN2020106573-appb-000118
将化合物2-4(400mg,640.07μmol)溶于甲苯(10mL)，向其中依次加入三(二亚苄基丙酮)二钯(36.80mg,64.01μmol)，4,5-双二苯基膦-9,9-二甲基氧杂蒽(74.07mg,128.01μmol)及磷酸钾(271.73mg,1.28mmol)。加毕，氩气氛围下，体系升温至100℃搅拌16h。体系过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(石油醚/乙酸乙酯(v/v)＝75～100％)及高效制备液相分离(分离条件:色谱柱:YMC Triart C18 150*25mm*5μm；流动相:[水(10mM的碳酸氢铵溶液)-乙腈]；乙腈％:52％-82％)，得化合物1-13(HPLC保留时间9.5min)，浓缩后冻干得白色固体化合物2-5。
MS(ESI)m/z(M+H) +＝544.3.
步骤5：化合物2-6的制备
Figure PCTCN2020106573-appb-000119
将化合物2-5(15mg,27.57umol)溶于二氧六环(0.5mL)及水(0.1mL)，向其中依次加入化合物1-14(19.19mg,82.72umol)，2-二环己基磷-2,4,6-三异丙基联苯(2.63mg,5.51umol)，三(二亚苄基丙酮)二钯(1.59mg,2.76umol)及碳酸钾(11.43mg,82.73umol)。加毕，Ar氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～100％)得浅黄色固体化合物2-6。
步骤6：化合物2-7的制备
Figure PCTCN2020106573-appb-000120
将化合物2-6(15mg,23.67umol)溶于无水二氯甲烷(1mL)，0℃条件下，向其中加入三溴化硼(0.5M的二氯甲烷溶液,236.71μL)。加毕，体系升温至室温(20℃)搅拌4h。向体系加入甲醇(2mL)并搅拌10min。体系浓缩后冻干得淡黄色固体2-7(氢溴酸盐)。
步骤7：化合物2的制备
Figure PCTCN2020106573-appb-000121
将化合物2-7(14mg,26.95umol,氢溴酸盐)溶于四氢呋喃(1mL)及饱和碳酸氢钠水溶液(1mL)，室温(20℃)条件下，向其中加入丙烯酸酐(0.2M,161.68uL)。加毕，体系于室温(20℃)搅拌1h。向体系中加入甲醇(1mL)及氢氧化锂(0.2M,0.1mL)，继续室温(20℃)搅拌2h。体系浓缩，加甲醇(2mL)稀释，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:YMC Triart C18 150*25mm*5μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:29％-59％9.5min)，得化合物2。
1H NMR(400MHz,DMSO-d 6)8.51(d,J＝5.2Hz,1H),7.34(d,J＝4.8Hz,1H),7.24-7.20(m,1H),6.88-6.80(m,1H),6.68-6.60(m,2H),6.35-6.30(m,1H),6.06-6.01(m,1H),5.87-5.83(m,1H),5.08-5.02(m,1H),4.73-4.61(m,3H),4.49-4.35(m,1H),4.25-4.15(m,2H),3.68-3.46(m,2H),2.88-2.78(m,1H),2.11-2.07(m,3H),1.23-1.21(m,3H),1.21-1.07(m,3H)
MS(ESI)m/z(M+H) +＝574.4
步骤8：化合物2A及2B的制备
Figure PCTCN2020106573-appb-000122
非对映异构体化合物2经SFC纯化(分离条件：色谱柱DAICEL CHIRALPAK AD-H(250mm*30mm,5um)；流动相:[Neu-异丙醇(0.1％氨水溶液)]；异丙醇％:35％)。浓缩后，得化合物2A(峰1)及化合物2B(峰2)。
化合物2A：
1H NMR(400MHz,DMSO-d6)8.51(d,J＝5.2Hz,1H),7.34(d,J＝5.2Hz,1H),7.24-7.20(m,1H),6.88-6.80(m,1H),6.68-6.60(m,2H),6.35-6.30(m,1H),6.06-6.01(m,1H),5.87-5.83(m,1H),5.08-5.02(m,1H),4.73-4.31(m,4H),4.25-4.15(m,2H),3.68-3.46(m,2H),2.88-2.78(m,1H),2.11-2.07(m,3H),1.23-1.05(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-115.6(s,1F),-139.6(s,1F)
MS(ESI)m/z(M+H) +＝574.4
HPLC保留时间6.91min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间：1.657min.
分离条件：色谱柱：Chiralpak AD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5-40％in 2min,40％1.2min,5％0.8min；流速：4mL/min。
化合物2B：
1H NMR(400MHz,DMSO-d6)8.40(d,J＝5.2Hz,1H),7.22(d,J＝5.2Hz,1H),7.14-7.07(m,1H),6.80-6.75(m,1H),6.58-6.45(m,2H),6.25-6.15(m,1H),6.01-5.91(m,1H),5.75-5.70(m,1H),4.98-4.92(m,1H),4.63-4.21(m,4H),4.15-4.05(m,2H),3.60-3.37(m,2H),2.78-2.68(m,1H),2.01-1.95(m,3H),1.13-0.95(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-115.7(s,1F),-139.6(s,1F)
MS(ESI)m/z(M+H) +＝574.4
HPLC保留时间6.91min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间：1.844min.
分离条件：色谱柱：Chiralpak AD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5-40％in 2min,40％1.2min,5％0.8min；流速：4mL/min。
实施例3：化合物3的制备
步骤1：化合物3-2的制备
Figure PCTCN2020106573-appb-000123
将二异丙基乙基胺(861.66mg,6.67mmol,1.16mL)溶于无水四氢呋喃(40mL)中，冷却至-78℃后，向其中滴加正丁基锂(2.5M,26.67mL)，滴加完毕后，将体系升温至-30℃搅拌10min。将体系冷却至-78℃，向其中加入化合物3-1(7g,33.33mmol)的四氢呋喃(40mL)溶液，体系在-78℃搅拌4h。向体系加入1,2-二溴四氯乙烷(21.71g,66.67mmol)的四氢呋喃(40mL)溶液，体系在-78℃搅拌2h后，升温至室温(20℃)搅拌16h。体系加水(200mL)淬灭后，静置分层，水相用甲基叔丁基醚(3 x 30mL)洗涤，将水相用2N盐酸水溶液酸化至pH＝2(出现沉淀)，乙酸乙酯(3 x 50mL)萃取体系，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品用石油醚(20mL)打浆得化合物3-2。
步骤2：化合物3-3的制备
Figure PCTCN2020106573-appb-000124
将化合物3-2(9g,31.15mmol)溶于无水二氯甲烷(80mL)中，0℃条件下，向其中依次滴加草酰氯(5.93g,46.73mmol,4.09mL)及1滴N,N-二甲基甲酰胺。滴加完毕后，将体系在0℃搅拌15min，然后升至室温(20℃)搅拌2h。体系减压浓缩，得化合物3-3，不经进一步纯化直接用于下一步反应。
步骤3：化合物3-4的制备
Figure PCTCN2020106573-appb-000125
将化合物3-3(9g,29.28mmol)溶于无水二氧六环(80mL),0℃条件下，向其中滴加氨的甲醇溶液(7M,20mL)。滴加完毕后，将体系在室温(20℃)搅拌2h。体系浓缩，加水(200mL)稀释，过滤，滤饼用水(2 x 10mL)洗涤后，真空干燥得化合物3-4。
1H NMR(400MHz,DMSO-d 6)δ＝8.20(s,1H),8.14(s,1H)
步骤4：化合物3-5的制备
Figure PCTCN2020106573-appb-000126
将化合物3-4(7.5g,26.05mmol)溶于无水1,2-二氯乙烷(80mL)，室温(20℃)条件下，向其中滴加草酰氯(4.63g,36.47mmol)。滴加完毕后，将体系升温至80℃搅拌1h。将反应液浓缩至一半体积，降温至0℃，向其中滴加化合物1-5(4.11g,27.35mmol)的1,2-二氯乙烷(20mL)溶液。滴加完毕后，将体系在室温(20℃)搅拌1h。体系减压浓缩，粗品经真空干燥后得化合物3-5，不经进一步纯化直接用于下一步反应。
MS(ESI)m/z(M+H) +＝465.0
步骤5：化合物3-6的制备
Figure PCTCN2020106573-appb-000127
将化合物3-5(12g,20.68mmol)溶于无水四氢呋喃(100mL)，0℃条件，氮气氛围下，向其中加入双(三甲基硅基)氨基钾(1M,45.51mL)。加毕，将体系升温至室温(20℃)搅拌1h。将体系倒入水(300mL)中，乙酸乙酯(3 x 150mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～70％)得化合物3-6。
1H NMR(400MHz,DMSO-d 6)δ＝12.42(br,1H),8.53(d,J＝4.8,1H),7.27(d,J＝4.8,1H),3.11-3.04(m,1H),2.13(s,3H),1.09-1.03(m,6H)
MS(ESI)m/z(M+H) +＝383.0
步骤6：化合物3-7的制备
Figure PCTCN2020106573-appb-000128
将化合物3-6(1.5g,3.91mmol)溶于甲醇(35mL)中，室温(20℃)条件下，向其中加入甲醇钠(465.23mg,8.61mmol)。加毕，将体系升温至60℃搅拌16h。体系减压浓缩得粗品3-7，不经进一步纯化直接用于下一步反应。
MS(ESI)m/z(M+H) +＝379.0
步骤7：化合物3-9的制备
Figure PCTCN2020106573-appb-000129
将化合物3-7(2.33g,10.77mmol)溶于四氢呋喃(80mL)中，0℃条件下，向其中加入氢化钠(718.02mg,17.95mmol,60％purity)。加毕，将体系升温至室温(20℃)搅拌20min,向其中加入化合物3-8(3.4g, 8.98mmol)。加毕，将体系升温至60℃搅拌2h。体系用饱和氯化铵水溶液(2mL)淬灭，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物3-9。
MS(ESI)m/z(M+H) +＝559.2
步骤8：化合物3-10的制备
Figure PCTCN2020106573-appb-000130
将化合物3-9(0.9g,1.61mmol)及1H-苯并***-1-基氧三吡咯烷基六氟磷酸盐(1.68g,3.22mmol)溶于乙腈(10mL)，0℃条件下，向其中滴加1,8-二氮杂双环[5.4.0]十一碳-7-烯(1.23g,8.06mmol,1.21mL)。滴加完毕，氮气氛围下，将体系升温至室温(20℃)搅拌16h。反应体系加水(20mL)稀释，乙酸乙酯(3 x 20mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(石油醚/乙酸乙酯(v/v)＝0～100％)得化合物3-10。
1H NMR(400MHz,DMSO-d6)δ＝8.44(d,J＝4.8Hz,1H),7.28-7.13(m,1H),4.72-4.53(m,3H),4.04(br s,2H),3.88(s,4H),3.18(br s,3H),2.92-2.81(m,1H),2.02(d,J＝4.9Hz,3H),1.45(s,9H),1.16-0.99(m,6H)
MS(ESI)m/z(M+H) +＝541.3
步骤9：化合物3-11的制备
Figure PCTCN2020106573-appb-000131
将化合物3-10(350mg,647.45μmol)溶于无水二氯甲烷(2mL)，0℃条件下，向其中加入三溴化硼(1.62g,6.47mmol)。加毕，体系升温至室温(20℃)搅拌16h。向体系加入甲醇(10mL)并搅拌10min。体系浓缩后冻干得化合物3-11。
步骤10：化合物3-12的制备
Figure PCTCN2020106573-appb-000132
将化合物3-11(270mg,506.52μmol)溶于四氢呋喃(1mL)及饱和碳酸氢钠(2mL)的混合溶剂，室温(20℃)条件下，向其中滴加CbzCl(0.5M,1.52mL)。滴加完毕，将体系在室温(20℃)搅拌4h。向体系加入甲醇(2mL)及氢氧化锂的水溶液(2N,0.2mL)，加毕，将体系在室温条件下搅拌1h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物3-12。
1H NMR(400MHz,DMSO-d 6)δ＝8.38(d,J＝4.6Hz,1H),7.44-7.27(m,5H),7.20-7.12(m,1H),5.21-5.09(m,2H),4.70-4.46(m,3H),4.09-3.85(m,3H),3.57-3.54(m,3H),2.91-2.81(m,1H),2.02(d,J＝6.4Hz,3H),1.11-1.01(m,6H).
步骤11：化合物3-13的制备
Figure PCTCN2020106573-appb-000133
将化合物3-12(250mg,445.97μmol)溶于乙腈(5mL)，向其中依次加入二异丙基乙基胺(230.55mg,1.78mmol)及三氯氧磷(2.05g,13.38mmol)。加毕，体系升温至80℃搅拌2h。将体系冷却至室温后浓缩，残余物倒入冰水(10mL)淬灭，用饱和碳酸氢钠调节pH至中性，用乙酸乙酯萃取(3 x 10mL)，合并有机相，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物3-13。
MS(ESI)m/z(M+H) +＝579.3
步骤12：化合物3-14的制备
Figure PCTCN2020106573-appb-000134
将化合物3-13(60mg,103.62μmol)溶于二氧六环(0.8mL)及水(0.2mL)，向其中依次加入化合物1-14(72.13mg,310.87μmol)，2-二环己基磷-2,4,6-三异丙基联苯(9.88mg,20.72μmol)，三(二亚苄基丙酮)二钯(9.49mg,10.36μmol)及碳酸钾(42.97mg,310.87μmol)。加毕，Ar氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物3-14。
MS(ESI)m/z(M+H) +＝669.2
步骤13：化合物3-15的制备
Figure PCTCN2020106573-appb-000135
将化合物3-14(18mg,26.92μmol)溶于无水二氯甲烷(1mL)，0℃条件下，向其中加入三溴化硼(1M的二氯甲烷溶液,269.18μL)。加毕，体系升温至室温(20℃)搅拌4h。向体系加入甲醇(2mL)并搅拌10min。体系浓缩后冻干得化合物3-15(HBr盐)。
MS(ESI)m/z(M+H) +＝521.1
步骤14：化合物3的制备
Figure PCTCN2020106573-appb-000136
将化合物1-16(13.85mg,21.28μmol,HBr盐)溶于四氢呋喃(1mL)及饱和碳酸氢钠水溶液(1mL)，室温(20℃)条件下，向其中加入丙烯酸酐(0.2M,161.68μL)。加毕，体系于室温(20℃)搅拌1h。向体系中加入甲醇(1mL)及氢氧化锂(0.2M,0.1mL)，继续室温(20℃)搅拌2h。体系浓缩，加甲醇(2mL)稀释，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:10％-80％，9.5min)，得白色固体化合物3。
1H NMR(400MHz,METHANOL-d 4)δ＝8.44(d,J＝5.0Hz,1H),7.32-7.21(m,2H),6.95-6.79(m,1H),6.73-6.61(m,2H),6.32(dd,J＝1.7,16.7Hz,1H),5.85(dd,J＝1.7,10.7Hz,1H),4.86-4.66(m,3H),4.60-4.14(m,3H),3.79-3.37(m,3H),2.99(qd,J＝6.5,13.1Hz,1H),2.19(s,3H),1.26-1.13(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-116.81(s,1F),-137.44--140.32(m,1F)
MS(ESI)m/z(M+H) +＝575.5
实施例4：化合物4的制备
步骤1：化合物4-1的制备
Figure PCTCN2020106573-appb-000137
将化合物2-4(750mg,1.20mmol)溶于乙腈(20mL)，向其中依次加入甲磺酸(2-二叔丁基膦基-3,6-二甲氧基-2',4',6'-三异丙基-1,1'-联苯)(2-氨基-1,1'-联苯-2-基)钯(150mg,175.56μmol)，2-二叔丁基膦-2′,4′,6′-三异丙基-3,6-二甲氧基-1,1′-联苯(75.00mg,154.74μmol)及碳酸铯(825mg,2.53mmol)。加毕，氩气氛围下，体系升温至80℃搅拌16h。体系过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(石油醚/乙酸乙酯(v/v)＝70％～甲醇/二氯甲烷(v/v)＝30％)得化合物4-1。
1H NMR(400MHz,Methanol-d 4)δ8.57(d,J＝4.9Hz,1H),7.38(d,J＝5.1Hz,1H),6.12(d,J＝6.0Hz,1H),4.97(br d,J＝10.8Hz,1H),4.78-4.55(m,2H),4.22-3.96(m,3H),3.48-3.35(m,3H),2.88-2.64(m,1H),2.08(d,J＝4.4Hz,3H),1.51(s,9H),1.18(dd,J＝4.1,6.7Hz,3H),1.10(d,J＝6.8Hz,3H).
MS(ESI)m/z(M+H) +＝544.2.
步骤2：化合物4-3的制备
Figure PCTCN2020106573-appb-000138
将化合物4-1(60mg,110.29μmol)溶于二氧六环(2.5mL)及水(0.5mL)，向其中依次加入化合物4-2(60.00mg,319.26μmol)，2-二环己基磷-2,4,6-三异丙基联苯(12mg,25.17μmol)，甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(12mg,14.18μmol)及碳酸钾(60mg,434.12μmol)。加毕，氩气氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～7％)得化合物4-3。
1H NMR(400MHz,Methanol-d 4)δ8.59-8.46(m,1H),7.44-7.20(m,2H),6.83(d,J＝8.6Hz,1H),6.10-5.90(m,1H),5.03(br d,J＝12.8Hz,1H),4.75-4.58(m,2H),4.25-4.02(m,3H),3.78-3.61(m,3H),3.54-3.33(m,3H),2.91-2.72(m,1H),2.11-2.02(m,3H),1.52(s,9H),1.25-1.18(m,3H),1.13-1.00(m,3H).
MS(ESI)m/z(M+H) +＝652.4.
步骤3：化合物4-4的制备
Figure PCTCN2020106573-appb-000139
将化合物4-3(65mg,99.74μmol)溶于无水二氯甲烷(1.5mL)，0℃条件下，向其中加入三溴化硼(1M,598.46μL)。加毕，体系升温至室温(20℃)搅拌2h。向体系加入甲醇(2mL)并搅拌10min。体系浓缩后冻干得化合物4-4(氢溴酸盐)。
MS(ESI)m/z(M+H) +＝538.3.
步骤4：化合物4的制备
Figure PCTCN2020106573-appb-000140
将化合物4-4(80mg,129.36μmol,氢溴酸盐)溶于四氢呋喃(5mL)及饱和碳酸氢钠水溶液(3mL)，室温(20℃)条件下，向其中加入丙烯酸酐(20mg,158.59μmol)。加毕，体系于室温(20℃)搅拌2h。向体系中加入甲醇(3mL)及氢氧化锂(20mg,476.60μmol)，继续室温(20℃)搅拌2h。体系用1N HCl调节pH至中性，用乙酸乙酯萃取(10mL x 2)，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:10％-80％9.5min；流速30mL/min)，得化合物4。
1H NMR(400MHz,Methanol-d 4)δ8.51(d,J＝5.0Hz,1H),7.33(d,J＝5.3Hz,1H),7.16-7.09(m,1H),6.94-6.82(br s,1H),6.62(br s,1H),6.31(d,J＝15.3Hz,1H),6.09-6.03(br s,1H),5.84(d,J＝12.3Hz,1H),5.08-4.99(m,1H),4.76-4.68(m,2H),4.61(s,1H),4.51-4.31(m,1H),4.27-4.18(m,1H),3.80-3.40(m,3H),2.90-2.80(m,1H),2.14-1.99(m,3H),1.27-1.00(m,6H).
MS(ESI)m/z(M+H) +＝592.3.
步骤5：化合物4A及4B的制备
Figure PCTCN2020106573-appb-000141
非对映异构体化合物4经SFC纯化(分离条件：色谱柱：DAICEL CHIRALPAK AD(250mm*30mm,10μm)；流动相:[Neu-异丙醇(0.1％氨水溶液)]；异丙醇％:30％-30％；流速：70mL/min)。浓缩后，得化合物4A(峰1)及化合物4B(峰2)。
化合物4A
1H NMR(400MHz,Methanol-d 4)δ8.48(d,J＝4.9Hz,1H),7.30(d,J＝4.9Hz,1H),7.13-7.16(m,1H),6.94-6.77(m,1H),6.59(br s,1H),6.28(dd,J＝1.8,16.8Hz,1H),6.03(br s,1H),5.81(dd,J＝1.8,10.6Hz,1H),4.99(br s,1H),4.74-4.66(m,2H),4.58(s,1H),4.45-4.28(m,1H),4.23-4.15(m,1H),3.74-3.37(m,3H),2.88-2.78(m,1H),2.05(br d,J＝8.8Hz,3H),1.18-1.01(m,6H).
MS(ESI)m/z(M+H) +＝592.2.
HPLC保留时间3.26min
分离条件：色谱柱：Ultimate C18 3.0*50mm,3μm；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％6min，80％2min；流速：1.2mL/min。
SFC保留时间1.577min
分离条件：色谱柱：Chiralpak AD-3 50*4.6mm I.D.,3μm；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5％-40％2min,40％1.2min,5％0.8min；流速：4mL/min。
化合物4B
1H NMR(400MHz,Methanol-d 4)δ8.50(d,J＝4.9Hz,1H),7.45-7.26(m,1H),7.21-7.04(m,1H),6.91-6.81(m,1H),6.60(br s,1H),6.30(dd,J＝1.9,16.6Hz,1H),6.05(br s,1H),5.91-5.74(m,1H),5.07-4.99(m,1H),4.80-4.66(m,2H),4.60(s,1H),4.51-4.31(m,1H),4.23(br s,1H),3.70-3.62(m,1H),3.58-3.44(m,1H),3.42-3.35(m,1H),2.87-2.77(m,1H),2.19-2.01(m,3H),1.25-1.00(m,6H).
MS(ESI)m/z(M+H) +＝592.3.
HPLC保留时间3.26min
分离条件：色谱柱：Ultimate C18 3.0*50mm,3μm；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％6min，80％2min；流速：1.2mL/min。
SFC保留时间1.761min
分离条件：色谱柱：Chiralpak AD-3 50*4.6mm I.D.,3μm；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5％-40％2min,40％1.2min,5％0.8min；流速：4mL/min。
实施例5：化合物5的制备
步骤1：化合物5的制备
Figure PCTCN2020106573-appb-000142
将化合物2-7(100mg,157.84μmol)及2-氟丙烯酸(50mg,555.23μmol)溶于N,N-二甲基甲酰胺(4mL)，室温(20℃)条件下，向其中加入O-(7-氮杂苯并***-1-基)-N,N,N',N'-四甲基脲六氟磷酸盐(240mg,631.20μmol)及N,N-二异丙基乙基胺(222.60mg,1.72mmol,0.3mL)。加毕，体系于室温(20℃)搅拌1h。向体系中加入水(30mL),用乙酸乙酯萃取(30mL x 2)，有机相用饱和食盐水洗涤后(30mL)，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品溶于甲醇(5mL)，向其中加入碳酸钾(2M,1mL)。加毕，体系于室温(20℃)搅拌30min。向体系加水(30mL)，用1N HCl调节PH至中性，用乙酸乙酯萃取(30mL x 2)，有机相用饱和食盐水洗涤后(30mL)，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:38％-68％9.5min；流速30mL/min)，得化合物5。
1H NMR(400MHz,Methanol-d 4)δ8.50(d,J＝5.1Hz,1H),7.33(br d,J＝3.5Hz,1H),7.20(br d,J＝7.5Hz,1H),6.70-6.56(m,2H),6.04(br s,1H),5.42-5.26(m,2H),5.06(br d,J＝13.5Hz,1H),4.80-4.61(m,2H),4.58-4.35(m,1H),4.31-4.13(m,2H),3.87-3.60(m,1H),3.60-3.42(m,2H),2.83(br s,1H),2.09(br d,J＝11.9Hz,3H),1.28-1.00(m,6H).
MS(ESI)m/z(M+H) +＝592.4.
步骤2：化合物5A及5B的制备
Figure PCTCN2020106573-appb-000143
非对映异构体化合物4经SFC纯化(分离条件：色谱柱：Phenomenex Lux Cellulose-4 250*30mm*5μm；流动相:[Neu-乙醇(0.1％氨水溶液)]；乙醇％:40％-40％；流速：60mL/min)。浓缩后，得化合物5A(峰1)及化合物5B(峰2)。
化合物5A
1H NMR(400MHz,Methanol-d 4)δ8.48(d,J＝4.9Hz,1H),7.31(d,J＝4.9Hz,1H),7.21-7.15(m,1H),6.71-6.52(m,2H),6.11-5.92(m,1H),5.44-5.22(m,2H),5.05(br d,J＝12.1Hz,1H),4.75-4.62(m,2H),4.58-4.11(m,3H),3.71-3.37(m,3H),3.03-2.70(m,1H),2.07(br d,J＝13.7Hz,3H),1.24-0.96(m,6H).
MS(ESI)m/z(M+H) +＝592.2.
HPLC保留时间3.26min
分离条件：色谱柱：Ultimate C18 3.0*50mm,3μm；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％6min，80％2min；流速：1.2mL/min。
SFC保留时间1.449min
分离条件：色谱柱：Cellulose-4 100*4.6mm I.D.,3μm；柱温：35℃；流动相:[Neu-乙醇(0.05％DEA)]；乙醇％:40％；流速：28mL/min。
化合物5B
1H NMR(400MHz,Methanol-d 4)δ8.50(d,J＝5.1Hz,1H),7.32(d,J＝4.9Hz,1H),7.26-7.13(m,1H),6.75-6.55(m,2H),6.12-5.95(m,1H),5.51-5.21(m,2H),5.06(br d,J＝11.5Hz,1H),4.78-4.65(m,2H),4.55-4.13(m,3H),3.78-3.39(m,3H),2.92-2.73(m,1H),2.09(br d,J＝12.8Hz,3H),1.24-1.01(m,6H).
MS(ESI)m/z(M+H) +＝592.2.
HPLC 96.11％纯度；保留时间3.25min
分离条件：色谱柱：Ultimate C18 3.0*50mm,3μm；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％6min,80％2min；流速：1.2mL/min。
SFC 99.10％ee.保留时间1.912min
分离条件：色谱柱：Cellulose-4 100*4.6mm I.D.,3μm；柱温：35℃；流动相:[Neu-乙醇(0.05％DEA)]；乙醇％:40％；流速：28mL/min。
实施例6：化合物6的制备
步骤1：化合物6-2的制备
Figure PCTCN2020106573-appb-000144
将化合物4-1(80mg,147.05μmol)溶于二氧六环(4mL)及水(0.8mL)，向其中依次加入化合物6-1(74.79mg,424.99μmol)，2-二环己基磷-2,4,6-三异丙基联苯(15.98mg,33.53μmol)，甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(16.06mg,18.97μmol)及碳酸钾(80.08mg,579.39μmol)。加毕，Ar氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～7％)得化合物6-2。
1H NMR(400MHz,Methanol-d 4)δ8.42(d,J＝5.0Hz,1H),7.49-7.41(m,2H),7.32-7.26(m,2H),5.94(d,J＝5.5Hz,1H),5.06(br d,J＝9.8Hz,1H),4.79-4.64(m,2H),4.29-4.01(m,3H),3.53-3.32(m,3H),2.98-2.75(m,1H),2.20-2.10(m,6H),1.52(m,9H),1.29-1.13(m,6H).MS(ESI)m/z(M+H) +＝640.1.
步骤2：化合物6-3的制备
Figure PCTCN2020106573-appb-000145
将化合物6-2(70mg,109.42μmol)溶于无水二氯甲烷(2.5mL)，0℃条件下，向其中加入三氟乙酸(770mg,6.75mmol,0.5mL)。加毕，体系升温至室温(20℃)搅拌3h。体系浓缩后得化合物6-3(三氟乙酸盐)，不经进一步纯化直接用于下一步反应。
MS(ESI)m/z(M+H) +＝540.3.
步骤3：化合物6的制备
Figure PCTCN2020106573-appb-000146
将化合物6-3(71mg,108.62μmol,三氟乙酸盐)溶于四氢呋喃(2mL)及饱和碳酸氢钠水溶液(2mL)的混合溶剂，室温(20℃)条件下，向其中加入丙烯酸酐(13.70mg,108.62μmol)。加毕，体系于室温(20℃)搅拌30min。向体系加水(10mL)稀释，用乙酸乙酯萃取(10mL x 2)，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:21％-51％9.5min；流速60mL/min)，得化合物6。
1H NMR(400MHz,Methanol-d 4)δ8.43(d,J＝5.1Hz,1H),7.54-7.41(m,2H),7.37-7.26(m,2H),6.95-6.79(m,1H),6.31(br d,J＝16.5Hz,1H),5.95(d,J＝5.7Hz,1H),5.84(br d,J＝10.8Hz,1H),5.05(br s,1H),4.77(br s,1H),4.60(br s,2H),4.51-4.15(m,2H),3.85-3.42(m,3H),3.00-2.77(m,1H),2.20-2.05(m,6H),1.23-1.16(m,3H),1.12-0.97(m,3H).
MS(ESI)m/z(M+H) +＝594.4.
步骤4：化合物6A及6B的制备
Figure PCTCN2020106573-appb-000147
非对映异构体化合物6经SFC纯化(分离条件：色谱柱：REGIS(s,s)WHELK-O1(250mm*30mm,5μm)；流动相:[Neu-异丙醇(0.1％氨水溶液)]；异丙醇％:50％-50％；流速：80mL/min)。浓缩后，得化合物6A(峰1)及化合物6B(峰2)。
化合物6A
1H NMR(400MHz,Methanol-d 4)δ8.42(d,J＝4.9Hz,1H),7.53-7.39(m,2H),7.35-7.22(m,2H),6.85(dd,J＝10.1,16.8Hz,1H),6.31(br d,J＝15.2Hz,1H),5.95(br d,J＝5.3Hz,1H),5.84(br d,J＝11.2Hz,1H),5.03(br d,J＝10.4Hz,1H),4.77(br s,1H),4.65-4.56(m,1H),4.50-4.16(m,3H),3.81-3.45(m,3H),3.00-2.82(m,1H),2.35-1.95(m,6H),1.19(br t,J＝7.4Hz,3H),1.14-0.97(m,3H).
MS(ESI)m/z(M+H) +＝594.3.
HPLC保留时间6.73min
分离条件：色谱柱：Ultimate LP-C18 150*4.6mm 5μm；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间5.039min
分离条件：色谱柱：(S,S)-Whelk-O1 100*4.6mm I.D.,3μm；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:40％-40％；流速：2.8mL/min。
化合物6B
1H NMR(400MHz,Methanol-d 4)δ8.42(br d,J＝2.2Hz,1H),7.47(br dd,J＝8.9,16.2Hz,2H),7.36-7.23(m, 2H),6.95-6.80(m,1H),6.31(br d,J＝16.3Hz,1H),5.94(br d,J＝5.3Hz,1H),5.84(br d,J＝10.1Hz,1H),5.06(br d,J＝12.6Hz,1H),4.77(br s,1H),4.61(br s,1H),4.55-4.16(m,3H),3.76-3.37(m,3H),2.97-2.75(m,1H),2.25-2.04(m,6H),1.20(t,J＝7.3Hz,3H),1.12-0.97(m,3H).
MS(ESI)m/z(M+H) +＝594.3.
HPLC保留时间6.75min
分离条件：色谱柱：Ultimate LP-C18 150*4.6mm 5μm；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间7.271min
分离条件：色谱柱：(S,S)-Whelk-O1 100*4.6mm I.D.,3μm；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:40％-40％；流速：2.8mL/min。
实施例7：化合物7的制备
步骤1：化合物7-1的制备
Figure PCTCN2020106573-appb-000148
将化合物3-4(1.60g,5.55mmol)溶于二氧六环(1.20mL)中，室温(20℃)条件下，向其中滴加甲硫醇钠的N,N二甲基甲酰胺溶液(20％,2.30g)。滴加完毕后，将体系在室温(20℃)搅拌2h。向体系加入水(8mL)淬灭反应，用乙酸乙酯(6mL x 2)萃取。合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得化合物7-1，不经进一步纯化直接用于下一步反应。
MS(ESI)m/z(M+H) +＝255.0
步骤2：化合物7-2的制备
Figure PCTCN2020106573-appb-000149
将化合物7-1(1.00g,0.39mmol)溶于1,2-二氯乙烷(10mL)中，室温(20℃)条件下，向其中滴加草酰氯(1.00g,0.78mmol)。滴加完毕后，将体系升温至80℃搅拌1h。体系浓缩，将剩余物溶于四氢呋喃(10mL)，0℃条件下，向其中滴加化合物1-5(0.75g，5mmol)。滴加完毕后，将体系在室温(20℃)下搅拌1h。体系过滤，乙酸乙酯洗涤滤饼，滤液浓缩得粗品。粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～30％)得化合物7-2。
MS(ESI)m/z(M+H) +＝431.0
步骤3：化合物7-3的制备
Figure PCTCN2020106573-appb-000150
氮气氛围下，将化合物7-2(500mg,1.16mmol)溶于无水四氢呋喃(5mL)，0℃条件下，向其中滴加双(三甲基硅基)氨基钠的四氢呋喃溶液(2N,1.2mL)。滴加完毕后，将体系降温至0℃搅拌1h。向体系加水(10mL)淬灭反应，用稀盐酸(3N)调节pH值到5.0后，用乙酸乙酯(5mL x 2)萃取。合并有机相， 经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～30％)得化合物7-3。
MS(ESI)m/z(M+H) +＝395.0.
步骤4：化合物7-4的制备
Figure PCTCN2020106573-appb-000151
将化合物7-3(260mg,0.66mmol),间氯过氧苯甲酸(300mg，1.74mmol)溶于二氯甲烷(4mL)，将体系在室温(20℃)搅拌15min后，将体系升温至50℃搅拌15min。体系冷却至室温后，浓缩得粗品。粗品经中压柱层析纯化(二氯甲烷/甲醇(v/v)＝0～10％)得化合物7-4。
MS(ESI)m/z(M+H) +＝427.0.
步骤5：化合物7-5的制备
Figure PCTCN2020106573-appb-000152
氮气氛围下，将化合物2-1(137mg，0.64mmol)，氢化钠(51.2mg,60％,1.28mmol)溶于四氢呋喃(3.0mL)，将体系在室温(20℃)搅拌5min。向其中加入化合物7-4(210mg,0.49mmol)，将体系在室温(20℃)搅拌1h。向体系加水(5mL)淬灭反应，用乙酸乙酯(5mL x 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物7-5。
MS(ESI)m/z(M+H) +＝563.0.
步骤6：化合物7-6的制备
Figure PCTCN2020106573-appb-000153
将化合物7-5(75mg,0.133mmol)，三吡咯烷基溴化鏻六氟磷酸盐(124mg，0.267mmol)溶于乙腈(2mL)，室温(20℃)条件下，向其中滴加入1,8-二氮杂二环十一碳-7-烯(81.0mg,0.534mmol)，将体系在室温(20℃)搅拌18h。向体系加入水(2mL)淬灭反应，用乙酸乙酯(2ml x 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物7-6。
MS(ESI)m/z(M+H) +＝545.0
步骤7：化合物7-8的制备
Figure PCTCN2020106573-appb-000154
将化合物7-7(2.87g,15mmol)溶于无水N,N-二甲基乙酰胺(10mL)中，0℃条件下，向其中分批加入氢化钠(60％，660mg,16.5mol)，加毕，将体系升温至室温搅拌10min，向体系滴加氯甲基甲基醚(2.4g,30mmol),滴加完毕，将体系室温搅拌10min。将体系倒入冰水(50mL)中淬灭，用甲基叔丁基醚(3 x 50mL)萃取体系，合并有机相，用饱和氯化钠水溶液洗一次，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～10％)得化合物7-8。
1H NMR(400MHz,CDCl 3-d 1)7.24-7.18(m,1H),6.95-6.93(m,1H),6.83-6.79(m,1H),5.26(s,2H),3.52(s,3H).
步骤8：化合物7-9的制备
Figure PCTCN2020106573-appb-000155
将化合物7-8(650mg,2.77mmol)溶于无水四氢呋喃(5mL)中，-78℃条件下，向体系滴加正丁基锂(2.5N，1.22mL，3.05mmol)，将体系在-78℃搅拌30min，再向体系滴加频哪醇硼酸异丙酯(567mg，3.05mmol)，将体系在-78℃搅拌30min。将体系升至室温，用水淬灭反应，乙酸乙酯(10mL)萃取，合并有机相，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压层析柱纯化(乙酸乙酯/石油醚(v/v)＝0～20％)得化合物7-9。
步骤9：化合物7-10的制备
Figure PCTCN2020106573-appb-000156
氮气氛围下，将化合物7-6(35mg,0.064mmol),化合物7-9(36.3mg，0.128mmol)，[1,1'-双(二苯基膦基)二茂铁]二氯化钯(4.7mg，0.0064mmol)及碳酸钾(26.0mg，0.192mmol)，溶于四氢呋喃/水(2mL，v/v 10:1)的混合溶剂中，将体系升温至80℃搅拌2h。将体系冷却至室温，向其中加水(1mL)淬灭反应，用乙酸乙酯(1mL x 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品用中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物7-10。
MS(ESI)m/z(M+H) +＝665.0.
步骤10：化合物7-11的制备
Figure PCTCN2020106573-appb-000157
将化合物7-10(20mg,0.03mmol)溶于甲醇，盐酸(6N)的混合溶剂中(2mL，v/v＝1:1)，将体系升温至55℃搅拌反应15min。将体系冷却至室温后，浓缩得粗品化合物7-11，不经进一步纯化直接用于下一步反应。
MS(ESI)m/z(M+H) +＝521.0.
步骤9：化合物7的制备
Figure PCTCN2020106573-appb-000158
将化合物7-11溶于二氯甲烷(1mL)，0℃条件下，向其中依次加入三乙胺(9.0mg)，丙烯酰氯(4.0mg)。将反应体系0℃搅拌30min。向其中加水(1mL)淬灭反应，用二氯甲烷(1mLx 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:21％-51％9.5min；流速60mL/min)，得化合物7。
MS(ESI)m/z(M+H) +＝575.0.
步骤10：化合物7A及7B的制备
Figure PCTCN2020106573-appb-000159
非对映异构体化合物7经SFC纯化(分离条件：色谱柱：DAICEL CHIRALCEL OJ-H(250mm*30mm,5um)；流动相:[Neu-异丙醇(0.1％氨水溶液)]；异丙醇％:40％-40％)。浓缩后，得化合物7A(峰1)及化合物7B(峰B)
化合物7A:
1H NMR(400MHz,METHANOL-d 4)δ＝8.44(d,J＝5.0Hz,1H),7.34-7.20(m,2H),6.88-6.82(m,1H),6.72-6.60(m,2H),6.32(dd,J＝1.9,16.7Hz,1H),5.85(dd,J＝1.9,10.7Hz,1H),4.86-4.64(m,3H),4.62-4.11(m,3H),3.74-3.37(m,3H),3.02-2.95(m,1H),2.19(s,3H),1.29-1.14(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-116.80(s,1F),-137.87--139.98(m,1F)
MS(ESI)m/z(M+H) +＝575.3
HPLC保留时间:6.30min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:[水(0.06875％三氟乙酸)-乙腈(0.0625％三氟乙酸)]；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间5.488min
分离条件：色谱柱：Chiralcel OJ-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5％-40％5min,40％2.5min,5％2.5min；流速：2.5mL/min。
化合物7B:
1H NMR(400MHz,METHANOL-d 4)δ＝8.44(d,J＝5.0Hz,1H),7.31-7.21(m,2H),6.96-6.80(m,1H),6.73-6.60(m,2H),6.32(dd,J＝1.8,16.8Hz,1H),5.85(dd,J＝1.8,10.5Hz,1H),4.86-4.64(m,3H),4.56-4.14(m,3H),3.87-3.42(m,3H),3.04-2.93(m,1H),2.19(s,3H),1.24-1.15(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-116.81(s,1F),-139.04--139.11(m,1F)
MS(ESI)m/z(M+H) +＝575.3
HPLC保留时间:6.32min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:[水(0.06875％三氟乙酸)-乙腈(0.0625％三氟乙酸)]；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间5.970min
分离条件：色谱柱：Chiralcel OJ-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5％-40％5min,40％2.5min,5％2.5min；流速：2.5mL/min。
实施例8：化合物8的制备
步骤1：化合物8-2的制备
Figure PCTCN2020106573-appb-000160
氮气氛围下，将化合物8-1(410mg，1.774mmol)，氢化钠(142mg,60％,3.55mmol)溶于四氢呋喃(3.0mL)，将体系在室温(20℃)搅拌5min。向其中加入化合物7-4(750mg,1.774mmol)，将体系在室温(20℃)搅拌1h。向体系加水(5mL)淬灭反应，用乙酸乙酯(5mL x 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物8-2。
MS(ESI)m/z(M+H) +＝577.2.
步骤2：化合物8-3的制备
Figure PCTCN2020106573-appb-000161
将化合物8-2(300mg,0.52mmol)，三吡咯烷基溴化鏻六氟磷酸盐(485mg，1.04mmol)溶于N,N二 甲基甲酰胺(4mL)，室温(20℃)条件下，向其中滴加入1,8-二氮杂二环十一碳-7-烯(316m g，2.08mmol)，将体系在室温(20℃)搅拌8h。向体系加入水(10mL)淬灭反应，用乙酸乙酯(4mL x 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物8-3。
MS(ESI)m/z(M+H) +＝559.2
步骤3：化合物8-4的制备
Figure PCTCN2020106573-appb-000162
氮气氛围下，将化合物8-3(100mg,0.179mmol),化合物7-9(100mg，0.358mmol)，[1,1'-双(二苯基膦基)二茂铁]二氯化钯(13mg，0.0179mmol)及碳酸钾(50.0mg，0.358mmol)，溶于四氢呋喃/水(2mL，v/v 10:1)的混合溶剂中，将体系升温至80℃搅拌2h。将体系冷却至室温，向其中加水(1mL)淬灭反应，用乙酸乙酯(1mL x 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品用中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～5％)得化合物8-4。
MS(ESI)m/z(M+H) +＝679.2.
步骤4：化合物8-5的制备
Figure PCTCN2020106573-appb-000163
将化合物8-4(18mg,0.0265mmol)溶于甲醇，盐酸(6N)的混合溶剂中(2mL，v/v＝1:1)，将体系升温至55℃搅拌反应15min。将体系冷却至室温后，浓缩得化合物8-5。
MS(ESI)m/z(M+H) +＝535.2.
步骤5：化合物8的制备
Figure PCTCN2020106573-appb-000164
将化合物8-5溶于二氯甲烷(1mL)，0℃条件下，向其中依次加入三乙胺(8.1mg)，丙烯酰氯(2.1mg)。将反应体系0℃搅拌30min。向其中加水(1mL)淬灭反应，用二氯甲烷(1mL x 2)萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱：Welch Xtimate□C18 21.2×250mm,10μm；柱温：25℃；流动相：水(10mM碳酸氢铵溶液)-乙腈；流动相乙腈比 例25％-45％in 12min；流速30mL/min)，得化合物8。
MS(ESI)m/z(M+H) +＝589.3.
步骤6：化合物8A及8B的制备
Figure PCTCN2020106573-appb-000165
非对映异构体化合物8经SFC纯化(分离条件：色谱柱ChiralPak AD,300×50mm I.D.,10μm；柱温:38℃；流动相:[Neu-异丙醇(0.1％氨水溶液)]；异丙醇％:35％；流速：80mL/min)。浓缩后，得化合物8A(峰1)及化合物8B(峰2)。
化合物8A：
1H NMR(400MHz,DMSO-d 6):10.10(s,1H),8.38-8.32(m,1H),7.25-7.05(m,2H),6.95-6.75(m,1H),6.67-6.55(m,2H),6.19-6.10(m,1H),5.75-5.65(m,1H),5.00-4.83(m,1H),4.73-4.57(m,2H),4.45-4.13(m,2H),4.13-4.00(m,1H),3.93-3.80(m,1H),2.90-2.78(m,1H),2.05-1.85(m,4H),1.20-1.12(s,3H),1.08-0.93(m,6H).
SFC保留时间：5.339min.
分离条件：色谱柱：Chiralpak AD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5-40％in 5min,40％2.5min；流速：2.5mL/min。
化合物8B：
1H NMR(400MHz,DMSO-d 6) :10.10(s,1H),8.40-8.28(d,J＝8.0Hz,1H),7.25-7.05(m,2H),6.95-6.75(m,1H),6.70-6.55(m,2H),6.20-6.10(m,1H),5.75-5.68(m,1H),5.30-5.20(m,1H),5.05-4.80(m,1H),4.45-4.00(m,4H),3.95-3.83(m,1H),,2.85-2.75(m,1H),2.03-1.93(m,4H),1.28-1.21(s,3H),1.10-0.90(m,6H).
SFC保留时间:5.681min
分离条件：色谱柱：Chiralpak AD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5-40％in 5min,40％2.5min；流速：2.5mL/min。
MS(ESI)m/z(M+H) +＝589.3.
实施例9：化合物9的制备
步骤1：化合物9-2的制备
Figure PCTCN2020106573-appb-000166
将化合物4-1(120mg,220.58μmol)溶于二氧六环(5mL)及水(1mL)，向其中依次加入化合物9-1(118.83mg,637.48μmol)，2-二环己基磷-2,4,6-三异丙基联苯(23.98mg,50.29μmol)，甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(24.09mg,28.46μmol)及碳酸钾(120.11mg,869.09μmol)。加毕，氩气氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～7％)得化合物9-2。
MS(ESI)m/z(M+H) +＝650.3.
步骤2：化合物9-3的制备
Figure PCTCN2020106573-appb-000167
将化合物9-2(100mg,153.81μmol)溶于无水二氯甲烷(1mL)，0℃条件下，向其中加入三溴化硼(260.00mg,1.04mmol,0.1mL)。加毕，体系升温至室温(20℃)搅拌2h。向体系加入甲醇(2mL)并搅拌30min。体系浓缩后冻干得化合物9-3(氢溴酸盐)。
MS(ESI)m/z(M+H) +＝536.2.
步骤3：化合物9的制备
Figure PCTCN2020106573-appb-000168
将化合物9-3(100mg,162.10μmol,氢溴酸盐)溶于四氢呋喃(3mL)及饱和碳酸氢钠水溶液(1.7mL)，室温(20℃)条件下，向其中加入丙烯酸酐(20.44mg,162.10μmol)。加毕，体系于室温(20℃)搅拌30min。向体系中加入异丙醇(5mL)及碳酸钾水溶液(2M,2mL)，继续室温(20℃)搅拌3h。体系用1N HCl调节pH至中性，用乙酸乙酯萃取(10mL x 2)，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:36％-66％9.5min；流速30mL/min)，得化合物9。
1H NMR(400MHz,Acetonitrile-d 3)δ8.47(d,J＝4.9Hz,1H),7.24-7.17(m,2H),7.00-6.93(m,1H),6.88-6.82(m,1H),6.74(br s,1H),6.25(dd,J＝2.0,16.8Hz,1H),5.93-5.86(m,1H),5.75(dd,J＝2.2,10.6Hz,1H),4.79(br s,1H),4.67-4.33(m,3H),4.27-3.99(m,2H),3.66-3.11(m,3H),2.92-2.77(m,1H),2.04-1.99(m,3H),1.13-1.03(m,6H).
MS(ESI)m/z(M+H) +＝590.1.
实施例10：化合物10的制备
步骤1：化合物10-2的制备
Figure PCTCN2020106573-appb-000169
将化合物10-1(2.06g,9.50mmol)溶于四氢呋喃(70mL)中，0℃条件下，向其中加入氢化钠(763.54mg,15.84mmol,60％purity)。加毕，将体系升温至室温(20℃)搅拌20min,向其中加入化合物3-7(3g,7.92mmol)。加毕，将体系升温至20℃搅拌20min。体系用饱和氯化铵水溶液(2mL)淬灭，过滤，滤液 浓缩得粗品。粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物10-2。
MS(ESI)m/z(M+H) +＝559.2
步骤2：化合物10-3的制备
Figure PCTCN2020106573-appb-000170
将化合物10-2(1.6g,2.86mmol)及PyBOP(2.98g,5.73mmol)溶于乙腈(22mL)，0℃条件下，向其中滴加1，8-二氮杂二环十一碳-7-烯(2.18g,14.32mmol,2.16mL)。滴加完毕，氮气氛围下，将体系升温至室温(20℃)搅拌16h。反应体系加水(40mL)稀释，乙酸乙酯(3 x 20mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(石油醚/乙酸乙酯(v/v)＝0～100％)得化合物10-3。
MS(ESI)m/z(M+H) +＝541.3
步骤3：化合物10-4的制备
Figure PCTCN2020106573-appb-000171
将化合物10-3(754mg,1.39mmol)溶于无水二氯甲烷(4mL)，0℃条件下，向其中加入三溴化硼(3.49g,13.95mmol,1.34mL)。加毕，体系升温至室温(20℃)搅拌16h。向体系加入甲醇(10mL)并搅拌10min。体系浓缩后冻干得化合物10-4。
步骤4：化合物10-5的制备
Figure PCTCN2020106573-appb-000172
将化合物10-4(594mg,1.11mmol)溶于四氢呋喃(10mL)及饱和碳酸氢钠(5.5mL)的混合溶剂，室温(20℃)条件下，向其中滴加氯甲酸苄酯(380.20mg,2.23mmol,316.83uL)。滴加完毕，将体系在室温(20℃)搅拌4h。向体系加入甲醇(2mL)及氢氧化锂的水溶液(2N,0.2mL)，加毕，将体系在室温条件下搅拌1h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物10-5。
MS(ESI)m/z(M+H) +＝561.2.
步骤5：化合物10-6的制备
Figure PCTCN2020106573-appb-000173
将化合物10-5(750mg,1.34mmol)溶于乙腈(10mL)，向其中依次加入三氯氧磷(8.21g,53.52mmol,4.97mL)。加毕，体系升温至80℃搅拌2h。将体系冷却至室温后浓缩，残余物倒入冰水(10mL)淬灭，用饱和碳酸氢钠调节pH至中性，用乙酸乙酯萃取(3 x 10mL)，合并有机相，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物10-6。
MS(ESI)m/z(M+H) +＝579.2
步骤6：化合物10-7的制备
Figure PCTCN2020106573-appb-000174
将化合物10-6(350mg,604.47μmol)溶于二氧六环(8mL)及水(1mL)，向其中依次加入化合物1-14(280.50mg,1.21mmol)，2-二环己基磷-2,4,6-三异丙基联苯(57.63mg,120.89μmol)，三(二亚苄基丙酮)二钯(34.76mg,60.45μmol)及碳酸钾(250.63mg,1.81mmol)。加毕，氩气氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～5％)得化合物10-7。
MS(ESI)m/z(M+H) +＝669.3
步骤7：化合物10-8的制备
Figure PCTCN2020106573-appb-000175
将化合物10-7(90mg,134.59μmol)溶于无水二氯甲烷(0.5mL)，0℃条件下，向其中加入三溴化硼(1M的二氯甲烷溶液,807.55uL)。加毕，体系升温至室温(20℃)搅拌6h。向体系加入甲醇(5mL)并搅拌10min。体系浓缩后冻干得化合物10-8(氢溴酸盐)。
MS(ESI)m/z(M+H) +＝521.2
步骤8：化合物10的制备
Figure PCTCN2020106573-appb-000176
将化合物10-8(81mg,107.74μmol,氢溴酸盐)溶于四氢呋喃(5mL)及饱和NaHCO 3水溶液(5mL)，室温(20℃)条件下，向其中加入丙烯酸酐(0.2M,646.45μL)。加毕，体系于室温(20℃)搅拌1h。向体系中加入甲醇(1mL)及氢氧化锂(0.2M,0.1mL)，继续室温(20℃)搅拌2h。体系浓缩，加甲醇(5mL)稀释，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:24％-54％，9.5min)，得化合物10。
步骤9：化合物10A及10B的制备
Figure PCTCN2020106573-appb-000177
非对映异构体化合物10经SFC纯化(分离条件：色谱柱：DAICEL CHIRALPAK AD(250mm*30mm,10um)；流动相:[Neu-异丙醇(0.1％氨水溶液)]；异丙醇％:35％-35％；流速：80mL/min)。浓缩后，得化合物10A(峰1)及化合物10B(峰2)。
化合物10A:
1H NMR(400MHz,METHANOL-d 4)δ＝8.32(d,J＝5.0Hz,1H),7.20-7.07(m,2H),6.80-6.67(m,1H),6.61-6.49(m,2H),6.20(d,J＝16.8Hz,1H),5.73(dd,J＝1.4,10.7Hz,1H),4.72-4.49(m,3H),4.48-4.02(m,3H),3.74-3.27(m,3H),2.87(m,1H),2.07(s,3H),1.14-1.00(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-116.83(s,1F),-139.10(s,1F)
MS(ESI)m/z(M+H) +＝575.3
HPLC保留时间:6.31min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间1.853min
分离条件：色谱柱：Chiralpak AD-3 50*4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5％-40％in 2min,40％1.2min,5％0.8min；流速：4mL/min。
化合物10B:
1H NMR(400MHz,METHANOL-d 4)δ＝8.31(d,J＝5.0Hz,1H),7.19-7.10(m,2H),6.83-6.67(m,1H),6.61-6.48(m,2H),6.20(dd,J＝1.5,16.8Hz,1H),5.73(dd,J＝1.5,10.6Hz,1H),4.75-4.50(m,3H),4.50-3.98(m,3H),3.60-3.23(m,3H),2.86(m,1H),1.15-1.01(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-116.81(s,1F),-138.96(s,1F)
MS(ESI)m/z(M+H) +＝575.3
HPLC保留时间:6.31min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间2.071min
分离条件：色谱柱：Chiralpak AD-3 50*4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-异丙醇(0.05％DEA)]；异丙醇％:5％-40％in 2min,40％1.2min,5％0.8min；流速：4mL/min。
实施例11：化合物11的制备
步骤1：化合物11-1的制备
Figure PCTCN2020106573-appb-000178
将化合物4-1(270mg,496.31μmol)溶于二氧六环(10mL)，向其中依次加入化合物频那醇联硼酸酯(270.00mg,1.06mmol)，三环己基膦四氟硼酸盐(54.00mg,146.64μmol)，三(二亚苄基丙酮)二钯(54.00mg,58.97μmol)及醋酸钾(270mg,2.75mmol)。加毕，Ar氛围下，体系升温至100℃搅拌3h。体系浓缩得粗品。粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～50％)得化合物11-1。
1H NMR(400MHz,MeOD)δ8.52(d,J＝5.1Hz,1H),7.35(d,J＝4.9Hz,1H),6.09(br s,1H),4.99(br d,J＝14.3Hz,1H),4.73-4.46(m,2H),4.29-3.88(m,3H),3.43-3.31(m,3H),2.87-2.58(m,1H),2.05(d,J＝3.5Hz,3H),1.50(s,9H),1.33-0.76(m,6H).
MS(ESI)m/z(M+H) +＝554.3.
步骤2：化合物11-3的制备
Figure PCTCN2020106573-appb-000179
将化合物11-1(100.00mg,126.49μmol)溶于二氧六环(3mL)及水(0.3mL)，向其中依次加入化合物11-2(70.08mg,270.70μmol)，2-二环己基磷-2,4,6-三异丙基联苯(5mg,10.49μmol)，甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(5mg,5.91μmol)及碳酸钾(70mg,506.49μmol)。加毕，氩气氛围下，体系升温至100℃搅拌2h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～7％)得化合物11-3。MS(ESI)m/z(M+H) +＝687.0.
步骤3：化合物11-4的制备
Figure PCTCN2020106573-appb-000180
将化合物11-3(100mg,145.44μmol)溶于二氯甲烷(2.5mL)，向其中加入三氟乙酸(154.00mg,1.35mmol,100uL),将体系在室温(20℃)反应3h。将体系浓缩得化合物11-4(三氟乙酸盐)。
MS(ESI)m/z(M+H) +＝587.2.
步骤4：化合物11的制备
Figure PCTCN2020106573-appb-000181
将化合物11-4(100mg,142.56μmol,三氟乙酸盐)溶于四氢呋喃(3mL)及饱和碳酸氢钠水溶液(2mL)，室温(20℃)条件下，向其中加入丙烯酸酐(17.98mg,142.56μmol)。加毕，体系于室温(20℃)搅拌30min。向体系中加入水(10mL)，用乙酸乙酯萃取(10mL x 2)，有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:42％-72％9.5min)，得化合物11。
1H NMR(400MHz,Acetonitrile-d 3)δ8.56-8.42(m,1H),7.40(br d,J＝7.3Hz,1H),7.21(br d,J＝4.0Hz,1H),6.75(br s,1H),6.32-6.18(m,1H),5.99(br t,J＝5.2Hz,1H),5.75(br dd,J＝2.1,10.7Hz,1H),4.89-4.36(m,5H),4.17-4.05(m,1H),3.63-3.38(m,2H),2.92-2.74(m,1H),2.73-2.72(m,1H),2.02(br dd,J＝4.7,18.4Hz,3H),1.42-0.78(m,6H).
MS(ESI)m/z(M+H) +＝641.1
步骤5：化合物11A、11B、11C及11D的制备
Figure PCTCN2020106573-appb-000182
非对映异构体化合物11经SFC纯化(分离条件：色谱柱：DAICEL CHIRALCEL OD(250mm*30mm,10um)；流动相:[Neu-乙醇(0.1％氨水溶液)]；乙醇％:45％-45％)。浓缩后，得化合物11A、化合物11B、化合物11C及化合物11D。
化合物11A:
1H NMR(400MHz,MeOD)δ8.50(br d,J＝5.1Hz,1H),7.39(br d,J＝7.5Hz,1H),7.32(br d,J＝3.3Hz,1H),6.84(br s,1H),6.31(br d,J＝18.7Hz,1H),5.97(br dd,J＝5.4,8.5Hz,1H),5.84(br d,J＝12.3Hz,1H),5.00-4.94(m,1H),4.74(br d,J＝10.6Hz,2H),4.59-4.23(m,3H),3.63-3.40(m,3H),2.90-2.79(m,1H),2.18-1.98(m,3H),1.19(br dd,J＝2.5,6.7Hz,3H),1.14-1.01(m,3H).
MS(ESI)m/z(M+H) +＝641.1.
HPLC保留时间:4.142min
分离条件：色谱柱：Xbridge Shield RP-18,5um,2.1*50mm；柱温：50℃；流动相:水(0.02％氨水溶液)-乙腈；乙腈:10％-80％6min，80％2min；流速：0.8mL/min。
SFC保留时间2.975min+7.090min
分离条件：色谱柱：Chiralcel OD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-乙醇(0.05％DEA)]；乙醇％:40％-40％；流速：2.5mL/min。
化合物11B:
1H NMR(400MHz,MeOD)δ8.58-8.40(m,1H),7.39(br d,J＝7.3Hz,1H),7.32(br d,J＝4.6Hz,1H),6.85(br dd,J＝9.0,16.3Hz,1H),6.31(br d,J＝15.9Hz,1H),5.96(br dd,J＝5.5,8.6Hz,1H),5.84(br d,J＝11.9Hz,1H),5.00(br d,J＝14.8Hz,1H),4.84-4.66(m,2H),4.66-4.55(m,1H),4.50-4.33(m,1H),4.23(br s,1H),3.71-3.45(m,3H),2.91-2.74(m,1H),2.23-1.97(m,3H),1.20(br dd,J＝3.1,6.4Hz,3H),1.19-1.00(m,3H).
MS(ESI)m/z(M+H) +＝641.1.
HPLC保留时间:4.133min
分离条件：色谱柱：Xbridge Shield RP-18,5um,2.1*50mm；柱温：50℃；流动相:水(0.02％氨水溶液)-乙腈；乙腈:10％-80％6min，80％2min；流速：0.8mL/min。
SFC保留时间2.999min+4.228min+7.114min+9.409min
分离条件：色谱柱：Chiralcel OD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-乙醇(0.05％DEA)]；乙醇％:40％-40％；流速：2.5mL/min。
化合物11C:
1H NMR(400MHz,MeOD)δ8.50(d,J＝5.1Hz,1H),7.39(br d,J＝7.5Hz,1H),7.32(br d,J＝4.2Hz,1H),6.85(br dd,J＝8.6,16.5Hz,1H),6.31(br d,J＝16.8Hz,1H),5.97(br dd,J＝5.4,8.3Hz,1H),5.84(br dd,J＝1.8,10.6Hz,1H),5.00(br d,J＝13.2Hz,1H),4.80-4.68(m,2H),4.60-4.23(m,3H),3.63-3.39(m,3H),2.91-2.77(m,1H),2.17-2.00(m,3H),1.25-0.96(m,6H).
MS(ESI)m/z(M+H) +＝641.1.
HPLC保留时间:4.136min
分离条件：色谱柱：Xbridge Shield RP-18,5um,2.1*50mm；柱温：50℃；流动相:水(0.02％氨水溶液)-乙腈；乙腈:10％-80％6min，80％2min；流速：0.8mL/min。
SFC保留时间2.999min+4.234min+7.118min+9.426min
分离条件：色谱柱：Chiralcel OD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-乙醇(0.05％DEA)]；乙醇％:40％-40％；流速：2.5mL/min。
化合物11D:
1H NMR(400MHz,MeOD)δ8.49(br d,J＝4.9Hz,1H),7.39(br d,J＝7.5Hz,1H),7.32(br d,J＝4.9Hz,1H),6.91-6.79(m,1H),6.31(br d,J＝16.8Hz,1H),5.96(br dd,J＝5.4,8.7Hz,1H),5.84(br d,J＝10.6Hz,1H),5.02-4.68(m,3H),4.60-4.23(m,3H),3.65-3.48(m,3H),2.87-2.74(m,1H),2.15-2.01(m,3H),1.26-0.99(m,6H).
MS(ESI)m/z(M+H) +＝641.1.
HPLC保留时间:4.140min
分离条件：色谱柱：Xbridge Shield RP-18,5um,2.1*50mm；柱温：50℃；流动相:水(0.02％氨水溶液)-乙腈；乙腈:10％-80％6min，80％2min；流速：0.8mL/min。
SFC保留时间4.210min+9.403min
分离条件：色谱柱：Chiralcel OD-3 150×4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-乙醇(0.05％DEA)]；乙醇％:40％-40％；流速：2.5mL/min。
实施例12：化合物12的制备
步骤1：化合物12-2的制备
Figure PCTCN2020106573-appb-000183
氮气保护条件下，化合物4-1(100mg,183.82μmol)、化合物12-1(80mg,292.46μmol)溶于二氧六环(2mL)和水(0.4mL)中，依次加入甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(20mg,23.63μmol)、2-二环己基磷-2,4,6-三异丙基联苯(20mg,41.95μmol)和碳酸钾(100mg,723.54μmol)，反应于100℃搅拌16h。反应液减压浓缩，粗品经制备薄层色谱(甲醇/二氯甲烷(v/v)＝0～7％)分离纯化，得化合物12-2.
MS(ESI)m/z(M+H) +＝619.3.
步骤2：化合物12-3的制备
Figure PCTCN2020106573-appb-000184
25℃条件下，化合物12-2(0.12g,193.96μmol)溶于二氯甲烷(5mL)中，加入三氟乙酸(770mg,6.75mmol,0.5mL)，反应于搅拌3h。反应液减压浓缩得化合物12-3。
MS(ESI)m/z(M+H) +＝519.3.
步骤3：化合物12的制备
Figure PCTCN2020106573-appb-000185
化合物12-3(0.1g,192.84μmol)溶于四氢呋喃(4mL)中，依次加入饱和碳酸氢钠溶液(6.05g,71.99mmol,2.8mL)、丙烯酸酐(21.89mg,173.56μmol)，反应于25℃搅拌2h。加入甲醇(3mL)和氢氧化锂(32.37mg,771.37μmol)，继续搅拌2h。反应液中加入1M盐酸溶液调节pH至7.0，乙酸乙酯(10mL x 2)萃取，无水硫酸钠干燥，过滤，滤液浓缩，粗品经高效制备液相分离(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3um；流动相:[水(10mM碳酸氢铵)-乙腈]；乙腈％:29％-59％,9.5min)，得化合物12。
MS(ESI)m/z(M+H) +＝573.3.
步骤4：化合物12A及12B的制备
Figure PCTCN2020106573-appb-000186
非对映异构体化合物12经SFC纯化(分离条件：色谱柱：Phenomenex-Cellulose-2(250mm*50mm,10um)；流动相:[Neu-甲醇(0.1％氨水溶液)]；甲醇％:50％-50％)。浓缩后，得化合物12A(峰1)及化合物12B(峰2)
化合物12A
1H NMR(400MHz,Methanol-d 4)δ8.49(d,J＝5.1Hz,1H),7.31(d,J＝4.9Hz,1H),7.14-7.03(m,1H),6.92-6.80(m,J＝10.9,16.4Hz,1H),6.53(t,J＝8.5Hz,1H),6.42-6.26(m,2H),5.97(dd,J＝5.4,9.8Hz,1H),5.83(dd,J＝1.8,10.6Hz,1H),5.02(s,1H),4.74-4.32(m,5H),4.22(s,1H),3.81-3.38(m,2H),2.97-2.77(m,1H),2.14-2.01(m,3H),1.19(dd,J＝3.5,6.6Hz,3H),1.14-1.03(m,3H).
MS(ESI)m/z(M+H) +＝573.3.
HPLC保留时间:7.15min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:[水(0.06875％三氟乙酸)-乙腈(0.0625％三氟乙酸)]；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间8.176min
分离条件：色谱柱：Cellulose 2 100*4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-甲醇(0.05％DEA)]；
甲醇％:40％-40％；流速：2.8mL/min。
化合物12B
1H NMR(400MHz,Methanol-d 4)8.49(d,J＝5.0Hz,1H),7.32(d,J＝4.8Hz,1H),7.13-7.03(m,1H),6.94-6.80(m,1H),6.57-6.49(m,1H),6.41-6.26(m,2H),5.96(dd,J＝5.5,9.3Hz,1H),5.83(dd,J＝1.6,10.7Hz,1H),5.05(br d,J＝8.0Hz,1H),4.80-4.16(m,5H),3.76-3.35(m,3H),2.90-2.72(m,1H),2.14-2.04(m,3H),1.19(dd,J＝4.4,6.9Hz,3H),1.14-1.02(m,3H).
MS(ESI)m/z(M+H) +＝573.3.
HPLC保留时间:7.12min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5um；柱温：40℃；流动相:[水(0.06875％三氟乙酸)-乙腈(0.0625％三氟乙酸)]；乙腈:10％-80％10min，80％5min；流速：1.5mL/min。
SFC保留时间10.832min
分离条件：色谱柱：Cellulose 2 100*4.6mm I.D.,3um；柱温：35℃；流动相:[Neu-甲醇(0.05％DEA)]；甲醇％:40％-40％；流速：2.8mL/min。
实施例13：化合物13的制备
步骤1：化合物13-1的制备
Figure PCTCN2020106573-appb-000187
将化合物3-7(2g,5.28mmol)，三乙胺(801.42mg,7.92mmol)及钯/碳(666mg,10％in carbon)溶于甲醇(100mL),氢气氛围(50psi)下，将体系升温至30℃反应20h。将体系过滤，滤液浓缩得化合物13-1。MS(ESI)m/z(M+H) +＝344.9
步骤2：化合物13-2的制备
Figure PCTCN2020106573-appb-000188
将化合物13-1(1.8g,5.23mmol及N,N-二异丙基乙胺(2.03g,15.68mmol,2.73mL)溶于乙腈(30mL)，室温条件(20℃)下，向其中加入三氯氧磷(1.60g,10.45mmol)。加毕，将体系升温至70℃搅拌1h。将体系浓缩得化合物13-2。
步骤3：化合物13-4的制备
Figure PCTCN2020106573-appb-000189
将化合物13-2(2.6g,4.30mmol)，13-3(1.03g,5.16mmol)，N,N-二异丙基乙胺(2.22g,17.20mmol)溶于四氢呋喃(20mL)中。氮气氛围下，将体系在室温(20℃)搅拌1h。体系浓缩得粗品。粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～70％)得化合物13-4。
MS(ESI)m/z(M+H) +＝527.1
步骤4：化合物13-5的制备
Figure PCTCN2020106573-appb-000190
化合物13-4(1.8g,3.42mmol)溶于二氯甲烷(5mL)中，加入三溴化硼(8.56g,34.18mmol,3.29mL)，反应于20℃搅拌16h。反应液用甲醇(20mL)淬灭，搅拌10min，减压浓缩得化合物13-5。
步骤5：化合物13-6的制备
Figure PCTCN2020106573-appb-000191
将化合物13-5(1.2g,2.43mmol)溶于四氢呋喃(10mL)，向其中加入碳酸氢钠的水溶液(1.02g,12.16mmol in 5mL H 2O 5mL)及氯甲酸苄酯(622.39mg,3.65mmol,518.65uL)。加毕，将体系在室温(20℃)反应16h。向体系加入乙酸乙酯(50mL)，分液萃取，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩的粗品，粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物13-6。
MS(ESI)m/z(M+H) +＝547.1
步骤6：化合物13-7的制备
Figure PCTCN2020106573-appb-000192
将化合物13-6(80mg,146.36μmol)溶于乙腈(5mL)，室温条件(20℃)下，向其中加入三氯氧磷(448.83mg,2.93mmol)。加毕，将体系升温至80℃搅拌4h。将体系浓缩得粗品，粗品经中压柱层析纯化(甲醇/二氯甲烷(v/v)＝0～10％)得化合物13-7。
MS(ESI)m/z(M+H) +＝565.1
步骤7：化合物13-8的制备
Figure PCTCN2020106573-appb-000193
将化合物13-7(70mg,123.89μmol)溶于二氧六环(1mL)及水(0.1mL)，向其中依次加入化合物1-14(43.12mg,185.83μmol)，2-二环己基磷-2,4,6-三异丙基联苯(11.81mg,24.78μmol)，三(二苄又丙酮)二钯(11.34mg,12.39μmol)及碳酸钠(26.26mg,247.77μmol)。加毕，Ar氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～5％)得化合物13-8。
MS(ESI)m/z(M+H) +＝655.2
步骤8：化合物13-9的制备
Figure PCTCN2020106573-appb-000194
将化合物13-8(16mg,24.44μmol)溶于无水二氯甲烷(1mL)，0℃条件下，向其中加入三溴化硼(1M的二氯甲烷溶液,807.55uL)。加毕，体系升温至室温(20℃)搅拌2h。向体系加入甲醇(5mL)并搅拌10min。体系浓缩后冻干得化合物13-9(氢溴酸盐)。
MS(ESI)m/z(M+H) +＝507.2
步骤9：化合物13的制备
Figure PCTCN2020106573-appb-000195
将化合物13-9(14mg,23.83μmol,氢溴酸盐)溶于四氢呋喃(2mL)及饱和碳酸氢钠水溶液(2mL)，室温(20℃)条件下，向其中加入丙烯酸酐(0.2M,178.74uL)。加毕，体系于室温(20℃)搅拌1h。向体系中加入甲醇(1mL)淬灭后，加入乙酸乙酯(5mL)，体系分层，有机相经无水硫酸钠干燥后，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动 相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:18％-48％，9min)，得化合物13。
1H NMR(400MHz,METHANOL-d 4)δ＝9.01(s,1H),8.45(d,J＝5.0Hz,1H),7.34-7.24(m,2H),6.96-6.78(m,1H),6.74-6.61(m,2H),6.33(br d,J＝16.3Hz,1H),5.89-5.82(m,1H),5.16-5.04(m,1H),4.62-4.41(m,2H),4.29-4.07(m,1H),3.97-3.51(m,2H),3.41-3.34(m,1H),3.05-2.88(m,1H),2.18-2.15(m,3H),1.56-1.45(m,3H),1.24-1.13(m,6H)
19F NMR(376MHz,METHANOL-d 4)δ＝-116.75(s,1F)
MS(ESI)m/z(M+Na) +＝583.0
实施例14：化合物14的制备
步骤1：化合物14-3的制备
Figure PCTCN2020106573-appb-000196
将化合物14-1(8.5g,41.87mmol)溶于甲苯(20mL)中，搅拌条件下，向其中加入化合物14-2(5.56g,41.75mmol,6.07mL)。加毕，氮气氛围下，将体系升温至100℃搅拌18h。将体系冷却至室温后浓缩，残余物溶于二氯甲烷(30mL)。将体系降温至0℃，向其中分批加入氯化铝(18.38g,137.84mmol,7.53mL)，加毕，将体系在0℃继续搅拌30min。将体系缓慢升至室温(25℃)后，继续室温(25℃)反应16h。将体系倒入冰水中，向其中加入二氯甲烷(100mL)，用2M氢氧化钠水溶液碱化后体系分层，有机相经无水硫酸钠干燥后，过滤，滤液浓缩得粗品，粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～100％)得化合物14-3。
1H NMR(400MHz,Chloroform-d)δ9.63(s,1H),8.63(d,J＝5.7Hz,1H),7.83(dd,J＝5.0,8.9Hz,1H),7.65(d,J＝5.5Hz,1H),7.53(t,J＝8.6Hz,1H).
步骤2：化合物14-4的制备
Figure PCTCN2020106573-appb-000197
将化合物14-3(2g,8.85mmol)溶于二氯甲烷(30mL)中，向其中加入间氯过氧苯甲酸(2.80g,13.78mmol,85％纯度)。加毕，将体系于室温(25℃)反应2h。向体系加入二氯甲烷(100mL)，用饱和碳酸氢钠水溶液(100mL x 2)洗涤后，有机相经无水硫酸钠干燥，过滤，滤液浓缩得化合物14-4，不经进一步纯化直接用于下一步反应。
1H NMR(400MHz,Chloroform-d)δ9.15(s,1H),8.17(dd,J＝1.3,7.1Hz,1H),7.77(dd,J＝5.0,8.9Hz,1H),7.68(d,J＝7.1Hz,1H),7.44-7.37(m,1H).
MS(ESI)m/z(M+H) +＝243.8.
步骤3：化合物14-5的制备
Figure PCTCN2020106573-appb-000198
0℃条件下，将化合物14-4(500mg,2.07mmol)及氯甲酸甲酯(253.77mg,2.69mmol,208.01μL)溶于甲醇(10mL)中，0℃条件下，向其中加入三乙胺(420.15mg,4.15mmol,577.92μL)。加毕，将体系升温至室温(25℃)搅拌16h。将体系浓缩，残余物溶于二氯甲烷(10mL)，依次用水(20mL)及饱和食盐水(20mL)洗涤。有机相经无水硫酸钠干燥后，过滤，滤液浓缩得粗品，粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～20％)得化合物14-5。
1H NMR(400MHz,Chloroform-d)δ8.00(d,J＝5.7Hz,1H),7.69(dd,J＝5.3,9.0Hz,1H),7.44(t,J＝8.5Hz,1H),7.22(d,J＝5.7Hz,1H),4.12(s,3H).
MS(ESI)m/z(M+H) +＝257.7.
步骤4：化合物14-6的制备
Figure PCTCN2020106573-appb-000199
将化合物11-1(130mg,234.92μmol)及化合物14-5(120.31mg,469.83μmol)溶于二氧六环(2mL)及水(0.4mL)中，向其中加入2-二环己基磷-2,4,6-三异丙基联苯(13.00mg,27.27μmol)，甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(19.50mg,23.04μmol)及碳酸钾(97.40mg,704.75μmol)。加毕，Ar氛围下，体系升温至100℃搅拌16h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～7％)得化合物14-6。
MS(ESI)m/z(M+H) +＝685.3.
步骤5：化合物14-7的制备
Figure PCTCN2020106573-appb-000200
将化合物14-6(50mg,73.02umol),氯化锂(12.38mg,292.09μmol,5.98uL),对甲基苯磺酸(55.56mg,292.09μmol)溶于N,N-二甲基甲酰胺(2mL)。将体系升温至120℃微波反应2h。将体系浓缩得化合物14-7，不经进一步纯化直接用于下一步反应。
MS(ESI)m/z(M+H) +＝571.1.
步骤6：化合物14A及14B的制备
Figure PCTCN2020106573-appb-000201
将化合物14-7(50mg,87.63μmol)溶于四氢呋喃(2mL)及饱和碳酸氢钠水溶液(2.16g,25.71mmol,1mL)，室温(25℃)条件下，向其中加入丙烯酸酐(11.05mg,87.63μmol)。加毕，体系于室温(25℃)搅拌30min。向体系中加入甲醇(2mL)及碳酸钾水溶液(2mL)，继续室温(25℃)搅拌1h。向体系加水(10mL)稀释后，用乙酸乙酯萃取(10mL x 2),有机相经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品 经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:29％-59％9.5min)，得化合物14A及14B。
化合物14A:
1H NMR(400MHz,Methanol-d 4)δ8.53-8.38(m,1H),7.89-7.75(m,1H),7.56(br t,J＝9.2Hz,1H),7.36-7.21(m,1H),7.19-7.07(m,1H),7.03-6.88(m,1H),6.73-6.61(m,1H),6.44-6.29(m,1H),5.93-5.83(m,1H),5.81(br d,J＝4.4Hz,1H),4.78(br s,1H),4.77-4.72(m,1H),4.63(br s,1H),4.58(br s,1H),4.42(br d,J＝10.8Hz,1H),3.88(br s,1H),3.61(br s,1H),3.49(br s,1H),3.01-2.88(m,1H),2.77(td,J＝6.9,13.6Hz,1H),2.26-1.98(m,3H),1.88-1.60(m,3H),1.38-0.96(m,6H).
MS(ESI)m/z(M+H) +＝625.2.
LCMS保留时间2.341&2.427&2.558min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5μm；柱温：40℃；流动相:水(0.0688％三氟乙酸溶液)-乙腈(0.0625％三氟乙酸溶液)；乙腈:5％-95％0.7min，95％0.4min；流速：1.5mL/min
化合物14B:
1H NMR(400MHz,Methanol-d 4)δ8.54-8.39(m,1H),7.85-7.74(m,1H),7.64-7.48(m,1H),7.33-7.22(m,1H),7.18-7.08(m,1H),7.01-6.88(m,1H),6.73-6.61(m,1H),6.41-6.30(m,1H),5.97-5.75(m,2H),5.06-4.95(m,1H),4.88-4.41(m,5H),3.70-3.34(m,3H),2.99-2.75(m,1H),2.14-2.04(m,3H),1.22-1.00(m,6H).
MS(ESI)m/z(M+H) +＝625.3.
LCMS保留时间3.026min
分离条件：色谱柱：WELCH Ultimate LP-C18 150*4.6mm 5μm；柱温：40℃；流动相:水(0.0375％三氟乙酸溶液)-乙腈(0.01875％三氟乙酸溶液)；乙腈:5％-95％0.7min，95％0.4min；流速：1.5mL/min.
实施例15：化合物15的制备
步骤1：化合物15-2的制备
Figure PCTCN2020106573-appb-000202
将化合物15-1(50g,240.26mmol)溶于乙腈(100mL)，向其中加入叔丁基胺(98.40g,1.35mol,141.38mL)。加毕，将体系升温至40℃搅拌16h。将体系浓缩，残余物经水稀释(50mL)后，用二氯甲烷萃取(50mL x 3)，合并有机相用饱和食盐水洗涤(50mLx 3)，经无水硫酸钠干燥后，过滤，滤液浓缩得化合物15-2，不经进一步纯化直接用于下一步反应。
步骤2：化合物15-3的制备
Figure PCTCN2020106573-appb-000203
将化合物15-2(57.5g,220.10mmol)溶于浓盐酸(12M,24.64mL)。加毕，将体系升温至80℃搅拌6h。将体系浓缩，残余物经水稀释(50mL)后，用二氯甲烷萃取(50mL x 3)，合并有机相用饱和食盐水洗涤(50mL x 3)，经无水硫酸钠干燥后，过滤，滤液浓缩得粗品。将粗品溶解于四氢呋喃(50mL)及水(50mL)的混合溶剂中，用1N氢氧化钠调节pH～10,分液萃取后，水相用6M盐酸调节pH～3，用乙酸乙酯萃取(50mL x 3)。合并有机相，经饱和食盐水洗涤(50mL x 3)后，无水硫酸钠干燥，过滤，滤液浓缩得化合物15-3。
1H NMR(400MHz,DMSO-d 6)δ7.02(br s,2H),7.90(ddd,J＝11.58,6.28,1.76Hz,1H).
MS(ESI)m/z(M+H) +＝192.1.
步骤3：化合物15-4的制备
Figure PCTCN2020106573-appb-000204
将氯化亚铜(13.52g,136.57mmol,3.27mL)及亚硝酸叔丁酯(12.80g,124.13mmol,14.76mL)溶于乙腈(150mL)，60℃条件下，向其中加入化合物15-3(16g,83.72mmol)。氮气氛围下，将体系于60℃搅拌20min。将体系降至室温(25℃)，向其中加入盐酸((4.32mol,273mL,15％纯度)，将体系于室温(25℃)搅拌1h。向体系加入硫代硫酸钠(10％,5mL)淬灭，用乙酸乙酯萃取(50mL x 3)，合并有机相经饱和食盐水洗涤(50mL x 3)后，用无水硫酸钠干燥，过滤，滤液浓缩得粗品，粗品经中压柱层析纯化(乙酸乙酯/石油醚(v/v)＝0～20％)得粗品，粗品经石油醚(30mL)室温(25℃)打浆1h得化合物15-4。
1H NMR(400MHz,Methanol-d 4)δ7.60-7.81(m,1H).
步骤4：化合物15-5的制备
Figure PCTCN2020106573-appb-000205
将二异丙基乙基胺(1.23g,9.50mmol,1.65mL)溶于无水四氢呋喃(60mL)，-78℃条件下，向其中滴加正丁基锂(2.5M,57.00mL)。滴加完毕后，将体系于-30℃搅拌10min。将体系降温至-78℃，向其中加入化合物15-4(10g,47.50mmol)的四氢呋喃(60mL)溶液。加毕，将体系与-78℃搅拌4h。向体系加入1,2-二溴四氯乙烷(30.93g,94.99mmol,11.41mL)的四氢呋喃(60mL)溶液，加毕，将体系于-78℃搅拌2h后，升温至室温(25℃)搅拌16h。向体系加水(5mL)淬灭，用乙酸乙酯洗涤(50mL x 3)。水相用2N盐酸调节pH～2，用乙酸乙酯萃取(50mL x 3)。合并有机相经用无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件：色谱柱Xtimate C18 150*40mm*5μm，流动相:水(10mM碳酸氢铵)-乙腈；乙腈30％-50％8min)得化合物15-5。
步骤5：化合物15-6的制备
Figure PCTCN2020106573-appb-000206
将化合物15-5(3g,10.37mmol)溶于无水二氯甲烷(10mL)，0℃条件下，向其中滴加草酰氯(1.97g,15.55mmol,1.36mL)，滴加完毕后，向其中滴加1滴N,N-二甲基甲酰胺。将体系于0℃搅拌15min后，升温至25℃搅拌1h。将体系浓缩得粗品，用二氧六环(5mL)溶解，0℃条件下，向其中滴加氨水(885.05mg,51.97mmol,867.69μL)。滴加完毕后，将体系于室温(25℃)搅拌1h。将体系浓缩，残余物用水(20mL)及乙酸乙酯分液萃取(50mL x 3)。合并有机相经用无水硫酸钠干燥，过滤，滤液浓缩得化合物15-6。
MS(ESI)m/z(M+H) +＝289.7.
步骤6：化合物15-7的制备
Figure PCTCN2020106573-appb-000207
将化合物15-6(2.8g,9.71mmol)溶于无水1,2-二氯乙烷(20mL)，室温(20℃)条件下，向其中滴加草酰氯(1.72g,13.59mmol,1.19mL)。滴加完毕后，将体系升温至80℃搅拌1h。将反应液浓缩至一半体积，降温至0℃，向其中滴加化合物1-5(1.46g,9.71mmol)的1,2-二氯乙烷(20mL)溶液。滴加完毕后，将体系在室温(20℃)搅拌1h。体系减压浓缩，粗品经真空干燥后得白色固体15-7，不经进一步纯化直接用于下一步反应。
MS(ESI)m/z(M+H) +＝465.9.
步骤7：化合物15-8的制备
Figure PCTCN2020106573-appb-000208
将化合物15-7(2.2g,4.73mmol)溶于无水四氢呋喃(20mL)，0℃条件，氮气氛围下，向其中加入双(三甲基硅基)氨基钠(1M,10.42mL)。加毕，将体系升温至室温(20℃)搅拌0.5h。将体系倒入水(50mL)中，用乙酸乙酯(3 x 150mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经甲基叔丁基醚及石油醚的混合溶剂(甲基叔丁基醚:石油醚＝1:5)打浆得化合物15-8。
MS(ESI)m/z(M+H) +＝445.9.
步骤8：化合物15-9的制备
Figure PCTCN2020106573-appb-000209
将化合物15-8(1.4g,3.15mmol)溶于乙腈(20mL)，向其中依次加入N,N二异丙基乙基胺(2.03g,15.74mmol,2.74mL)及三氯氧磷(2.41g,15.74mmol,1.46mL)。加毕，体系升温至80℃搅拌0.5h。将体系倒入冰水(50mL)淬灭，用1M氢氧化钠水溶液调节pH～7,用乙酸乙酯萃取(3 x 10mL)，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得化合物15-9，不经进一步纯化直接用于下一步反应。
(ESI)m/z(M+H) +＝459.9.
步骤9：化合物15-10的制备
Figure PCTCN2020106573-appb-000210
将化合物15-9((1.45g,3.13mmol)溶于无水乙腈(10mL)，向其中依次加入二异丙基乙基胺(2.02g,15.66mmol,2.73mL)及化合物3-8(812.61mg,3.76mmol)。加毕，体系升温至室温(20℃)搅拌16h。反应体系加水(10mL)稀释，二氯甲烷(3 x 50mL)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(乙酸乙酯/石油醚(v/v)＝60～80％)得化合物15-10。
(ESI)m/z(M+H) +＝644.0.
步骤10：化合物15-11的制备
Figure PCTCN2020106573-appb-000211
将化合物15-10(400mg,622.16μmol)溶于乙腈(10mL)，向其中依次加入甲磺酸-2-(二叔丁基膦基)-3,6-二甲氧基-2',4',6'-三异丙基-1,1'-联苯(2-氨基-1,1'-联苯-2-基)钯(100mg,117.04umol)，2-(二叔丁基膦基)-3,6-二甲氧基-2',4',6'-三异丙基-1,1'-联苯(60mg,123.79μmol)及碳酸铯(405.42mg,1.24mmol)。加毕，Ar氛围下，体系升温至80℃搅拌16h。体系过滤，滤液浓缩得粗品。粗品经硅胶柱层析纯化(乙酸乙酯/二氯甲烷(v/v)＝40～40％)得化合物15-11。
(ESI)m/z(M+H) +＝562.2.
步骤11：化合物15-12的制备
Figure PCTCN2020106573-appb-000212
将化合物15-11(100mg,177.93μmol)及化合物1-14A(90.72mg,533.80umol)溶于二氧六环(2.5mL)及水(0.5mL)，向其中依次加入甲烷磺酸(2-二环己基膦基-2',4',6'-三-异丙基-1,1'-联苯基)(2'-氨基-1,1'-联苯-2-基)钯(19.43mg,22.95μmol)，碳酸钾(72.55mg,524.90μmol)及2-二环己基磷-2,4,6-三异丙基联苯(19.34mg,40.57μmol)。加毕，Ar氛围下，体系升温至100℃搅拌12h。体系浓缩得粗品。粗品经硅胶柱层析纯化(甲醇/二氯甲烷(v/v)＝0～5％)得化合物15-12。
(ESI)m/z(M+H) +＝652.3.
步骤12：化合物15-13的制备
Figure PCTCN2020106573-appb-000213
将化合物15-12(40mg,61.38umol)溶于无水二氯甲烷(0.5mL)，0℃条件下，向其中加入三溴化硼 (76.89mg,306.90umol,29.57μL)。加毕，体系升温至室温(20℃)搅拌1h。向体系加入甲醇(1mL)并搅拌10min。体系浓缩后冻干得化合物15-13，不经进一步纯化直接用于下一步反应。
(ESI)m/z(M+H) +＝538.1.
步骤13：化合物15A、15B、15C及15D的制备
Figure PCTCN2020106573-appb-000214
将化合物15-13(37mg,59.83umol,氢溴酸盐)溶于四氢呋喃(1mL)及饱和碳酸氢钠水溶液(6.15g,73.18mmol,2.85mL)，室温(20℃)条件下，向其中加入丙烯酸酐(9.05mg,71.79μmol)。加毕，体系于室温(20℃)搅拌10min。向体系中加入甲醇(1mL)及氢氧化锂(7mg,476.60umol)，继续室温(20℃)搅拌2h。将体系用1N盐酸调节pH～7,用乙酸乙酯萃取(10mL x 2)，合并有机相，经无水硫酸钠干燥，过滤，滤液浓缩得粗品。粗品经高效制备液相纯化(分离条件:色谱柱:Phenomenex Gemini-NX 80*30mm*3μm；流动相:[水(10mM碳酸氢铵溶液)-乙腈]；乙腈％:24％-54％)后，再经两次SFC纯化(分离条件:色谱柱:DAICEL CHIRALPAK AD(250mm*30mm,10μm)；流动相:[CO 2-异丙醇(0.1％氨水)]；异丙醇％:35％-35％)，(分离条件:色谱柱:DAICEL CHIRALCEL OJ(250mm*30mm,10μm)；流动相:[CO 2-乙醇(0.1％氨水)]；乙醇％:25％-25％)，得化合物15A、15B、15C及15D。
化合物15A:
1H NMR(400MHz,Methanol-d 4)δ8.39(br d,J＝4.9Hz,1H),7.34-7.13(m,2H),6.84(br dd,J＝10.9,16.3Hz,1H),6.67(td,J＝8.3,16.9Hz,2H),6.31(br d,J＝16.1Hz,1H),5.84(br d,J＝10.0Hz,1H),4.79-4.54(m,3H),4.46(br d,J＝11.0Hz,1H),4.22(br s,2H),3.81-3.67(m,1H),3.66-3.43(m,2H),3.01-2.88(m,1H),2.14(s,3H),1.46-0.97(m,6H).
MS(ESI)m/z(M+H) +＝592.3.
SFC保留时间4.229min
分离条件：色谱柱：Chiralcel OD-3 100x 4.6mm I.D.,3um；柱温：35℃；流动相:CO 2-乙醇(0.05％DEA)；乙醇:5％-40％4min,40％2.5min,5％1.5min；流速：2.8mL/min。
化合物15B:
1H NMR(400MHz,METHANOL-d 4)δ8.37(br d,J＝4.9Hz,1H),7.33-7.14(m,2H),6.83(br dd,J＝11.1,16.0Hz,1H),6.72-6.54(m,2H),6.30(br d,J＝17.4Hz,1H),5.83(br d,J＝9.3Hz,1H),4.71-4.54(m,4H),4.31-4.15(m,2H),3.67(br d,J＝12.7Hz,1H),3.48(br d,J＝1.7Hz,2H),2.89(br d,J＝7.1Hz,1H),2.14(s,3H),1.37-1.04(m,6H).
MS(ESI)m/z(M+H) +＝592.3.
SFC保留时间4.375min
分离条件：色谱柱：Chiralcel OD-3 100x 4.6mm I.D.,3μm；柱温：35℃；流动相:CO 2-乙醇(0.05％DEA)；乙醇:5％-40％4min,40％2.5min,5％1.5min；流速：2.8mL/min。
化合物15C:
1H NMR(400MHz,METHANOL-d 4)δ8.40(d,J＝4.9Hz,1H),7.29-7.19(m,2H),6.85(br dd,J＝10.8,16.4Hz,1H),6.73-6.61(m,2H),6.32(br d,J＝16.9Hz,1H),5.85(br d,J＝10.8Hz,1H),4.62(br s,3H),4.45(br d,J＝13.0Hz,1H),4.22(br s,2H),3.82-3.68(m,1H),3.65-3.49(m,2H),3.04-2.92(m,1H),2.15(s,3H),1.23-1.04(m,6H).
MS(ESI)m/z(M+H) +＝592.3.
SFC保留时间4.688min
分离条件：色谱柱：Chiralcel OD-3 100x 4.6mm I.D.,3μm；柱温：35℃；流动相:CO 2-乙醇(0.05％DEA)；乙醇:5％-40％4min,40％2.5min,5％1.5min；流速：2.8mL/min。
化合物15D:
1H NMR(400MHz,METHANOL-d 4)δ8.39(d,J＝4.8Hz,1H),7.30-7.20(m,2H),6.85(br dd,J＝10.3,16.6Hz,1H),6.71-6.61(m,2H),6.31(br d,J＝16.8Hz,1H),5.84(br d,J＝10.5Hz,1H),4.71-4.59(m,3H),4.58-4.43(m,1H),4.23(br s,2H),3.75-3.64(m,1H),3.64-3.37(m,2H),2.96-2.86(m,1H),2.15(s,3H),1.21(d,J＝6.8Hz,3H),1.14(d,J＝6.8Hz,3H).
MS(ESI)m/z(M+H) +＝592.3.
SFC保留时间4.891min
分离条件：色谱柱：Chiralcel OD-3 100x 4.6mm I.D.,3μm；柱温：35℃；流动相:CO 2-乙醇(0.05％DEA)；乙醇:5％-40％4min,40％2.5min,5％1.5min；流速：2.8mL/min。
实验例1：RAS介导的信号转导的抑制
如下评定并证明本文所公开的化合物抑制RAS介导的信号传导的能力。表达突变型RAS(G12C)的细胞NCI-H358(ATCC目录号CRL-5807)利用含10％的胎牛血清，盘尼西林/链霉素双抗的RPMI培养基培养。细胞按每孔40,000个细胞铺于96孔板(Corning目录号3699)中，静置过夜使其附着于板底上。用本发明化合物或不用本发明化合物(二甲基亚砜，DMSO)对细胞进行处理，并保证DMSO的终浓度为0.5％。2小时处理后，去除培养基，加入4％多聚甲醛(Beyotime目录号E672002-0100)，静置20分钟。细胞固定后使用PBS清洗，用预冷的甲醇孵育10分钟以通透细胞膜。加入1X封闭缓冲液(Thermo目录号37520)孵育1小时阻断非特异性抗体的结合。
磷酸化ERK水平的检测使用酶联免疫吸附(ELISA)方法。磷酸化ERK抗体(Cell Signal Technology目录号4370)用含0.05％吐温20的1X封闭液按1：400稀释，加入96孔板并在4℃孵育过夜。用含0.05％吐温20的PBS将板子洗5遍。偶联HRP的二抗(Thermo目录号31460)用含0.05％吐温20的1X封闭液按1：10,000稀释，加入96孔板并在室温孵育2小时。用含0.05％吐温的PBS将板子洗5遍，加入TMB(Thermo目录号4816)并在室温孵育15分钟。加入1mol/L H2SO4中止反应，使用EnVision(PerkinElmer)在450nm波长处读OD值。
每孔细胞总数的检测使用健那绿染色法。检测完磷酸化ERK水平的96孔板用PBS清洗至无色，加入0.1％健那绿(Abcam目录号ab111622)孵育10分钟。用双蒸水清洗后加入0.1mol/L HCl振荡孵育10分钟。使用EnVision(PerkinElmer)在595nm波长处读OD值。
pERK(Thr202/Tyr204)的信号使用健那绿的信号值进行归一，并计算药物处理后相对于DMSO参照的抑制百分比。百分比数值通过四参数的剂量反应曲线拟合并生成IC50值。实验结果如表1所示。
表1
化合物编号 p-ERK IC50(NCI H358,μM)
ARS-1620 0.325
化合物1 0.288
化合物1A 0.610
化合物1B 0.044
化合物2 0.100
化合物2A 0.053
化合物2B 0.618
化合物3 0.647
化合物4A 0.038
化合物4B 0.564
化合物5A 0.637
化合物5B 3.81
化合物6A 1.774
化合物6B 0.088
化合物7A 0.196
化合物7B 0.073
化合物8A 0.260
化合物8B 0.919
化合物10A 0.065
化合物10B 0.105
化合物11A 0.052
化合物11D 0.772
化合物12A 0.032
化合物12B 0.327
化合物13 0.159
化合物14A >10
化合物14B >10
化合物15A 6.362
化合物15B >10
化合物15C 0.063
化合物15D 0.114
本发明化合物表现出优异的抑制RAS介导的信号传导的能力。
实验例2：细胞增殖实验
如下评定证明本发明化合物抑制表达KRAS-G12C肿瘤细胞系的生长能力。
通过测定细胞活率并计算GI50值来评价本发明化合物对表达KRAS-G12C细胞的生长抑制能力。
肿瘤细胞系NCI-H358(ATCC目录号CRL-5807)表达KRAS-G12C，使用添加有10％胎牛血清(fetal bovine serum)和盘尼西林/链霉素双抗(penicillin/streptomycin)的RPMI培养基培养；肿瘤细胞系MIA PaCa2(ATCC CRL-1420)表达KRAS-G12C，使用添加有10％胎牛血清(fetal bovine serum)、2.5％马血清(horse serum)和盘尼西林/链霉素双抗(penicillin/streptomycin)的DMEM培养基培养。
将细胞NCI-H358、MIA-Paca2分别以1000、800个的细胞密度接种于黑色透明底384孔板(PerkinElmer目录号6007460)中，并允许细胞贴壁过夜(8-12小时)。细胞贴壁后，实验组加入稀释后的5倍于工作液浓度的本发明化合物(终浓度含0.1％二甲基亚砜，即DMSO)；对照组加入与实验组相同的稀释液(终浓度含0.1％DMSO)。72小时后，使用Cell Titer Glo试剂(Promega目录号G7572)按说明书方法检测ATP含量来测定细胞增殖量。简要操作步骤为：将细胞板取出并置于常温平衡30分钟；加入与培养物等体积的Cell Titer Glo试剂；将培养板置于摇床上震荡裂解2分钟；将培养板在常温静置10分钟；利用酶标仪EnVision(PerkinElmer)读取光信号值。
所有实验组数据利用DMSO组计算各自抑制百分率，利用数据处理软件GraphPad分析9个按1/3倍比稀释的化合物剂量浓度产生的抑制率计算出GI50，实验结果如表2所示。
表2
化合物编号 GI 50(NCI-H358,μM) GI 50(MIA-Paca2,μM)
ARS-1620 0.510 1.209
化合物1B 0.084 0.296
化合物2A 0.029 0.048
化合物2B 1.116 15.993
化合物4A 0.034 0.324
化合物6B 0.066 0.297
化合物7A 0.133 0.629
化合物7B 0.080 0.200
化合物8A 0.350 0.304
化合物10A 0.111 0.333
化合物10B 0.155 0.403
化合物11A 0.070 0.685
化合物12A 0.010 0.054
化合物13 0.320 1.273
化合物15A 3.428 4.522
化合物15C 0.060 0.087
化合物15D 0.959 1.099
本发明化合物具有优异的NCI-H358,和MIA-Paca2细胞增殖抑制活性。

Claims (24)

  1. 式(Ⅰ)所示化合物、其光学异构体及其药效上可接受的盐，
    Figure PCTCN2020106573-appb-100001
    其中，
    R 1、R 2、R 11分别独立地选自H、卤素、OH、NH 2、CN、C 1-6烷基、C 1-6烷氧基和C 1-6烷氨基，所述C 1-6烷基、C 1-6烷氧基或C 1-6烷氨基任选被1、2或3个R取代；
    T 1选自N和C(R 3)；
    T 2选自N和C(R 4)；
    R 3、R 4分别独立地选自H、卤素、OH、NH 2、CN、C 2-4烯基、C 2-4炔基、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基和3～6元杂环烷基，所述C 2-4烯基、C 2-4炔基、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
    R 5分别独立地选自H、卤素、OH、NH 2、CN、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基、3～6元杂环烷基、C 6-10芳基和5～10元杂芳基，所述C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基、3～6元杂环烷基、C 6-10芳基或5～10元杂芳基任选被1、2或3个R取代；
    R 6分别独立地选自H、卤素、OH、NH 2、CN、C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基和3～6元杂环烷基，所述C 1-6烷基、C 1-6烷氧基、C 1-6烷氨基、C 1-6烷基-OC(＝O)-、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
    环A选自C 3-6环烷基、3～6元杂环烷基、C 6-10芳基和5～10元杂芳基；
    环B选自C 6-10芳基、5～10元杂芳基、苯并5～6元杂环烷基和5～6元杂芳基并5～6元杂环烷基；
    R 7选自H、卤素、CN、C 1-6烷基、C 1-6烷氧基和C 1-6烷氨基，所述C 1-6烷基、C 1-6烷氧基或C 1-6烷氨基任选被1、2或3个R取代；
    R 8、R 9分别独立地选自H、卤素、CN、C 1-6烷基、C 3-6环烷基和3～6元杂环烷基，所述C 1-6烷基、C 1-6杂烷基、C 1-6烷氨基、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
    Figure PCTCN2020106573-appb-100002
    代表
    Figure PCTCN2020106573-appb-100003
    且当
    Figure PCTCN2020106573-appb-100004
    为
    Figure PCTCN2020106573-appb-100005
    时，R 7和R 9不存在；
    L 1选自单键、CH 2、
    Figure PCTCN2020106573-appb-100006
    O、S、S(＝O)、C(＝O)、S(＝O) 2和N(R 10)；
    L 2选自CH 2、O、S和C(＝O)；
    L 3选自单键、C(R 12R 12)和C(＝O)；
    L 4选自S(＝O)、S(＝O) 2和C(＝O)；
    m选自1、2、3和4；
    n选自1、2、3和4；
    R 10选自H、C 1-6烷基、C 3-6环烷基和3～6元杂环烷基，所述C 1-6烷基、C 3-6环烷基或3～6元杂环烷基任选被1、2或3个R取代；
    R 12分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me和CF 3；
    R分别独立地选自H、卤素、OH、NH 2、CN、
    Figure PCTCN2020106573-appb-100007
    C 1-6烷基、C 1-6烷基-OC(＝O)-、C 1-6烷氧基、C 1-6烷硫基、C 1-6烷氨基和5～6元杂环烷基，其中C 1-6烷基、C 1-6烷基-OC(＝O)-、C 1-6烷氧基、C 1-6烷硫基C 1-6烷氨基或5～6元杂环烷基任选被1、2或3个R’取代；
    R’选自F、Cl、Br、I、OH、NH 2和CH 3；
    所述3～6元杂环烷基、5～6元杂环烷基、5～10元杂芳基或C 1-6杂环烷基包含1、2或3个独立选自O、NH、S、C(＝O)、C(＝O)O、S(＝O)、S(＝O) 2和N的杂原子或杂原子团。
  2. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，R分别独立地选自H、卤素、OH、NH 2、CN、
    Figure PCTCN2020106573-appb-100008
    C 1-3烷基、C 1-3烷氧基、C 1-3烷硫基、C 1-3烷氨基和5～6元杂环烷基，其中C 1-3烷基、C 1-3烷氧基、C 1-3烷硫基、C 1-3烷氨基或5～6元杂环烷基任选被1、2或3个R’取代。
  3. 根据权利要求2所述化合物、其光学异构体及其药效上可接受的盐，其中，R分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、
    Figure PCTCN2020106573-appb-100009
    其中Me、
    Figure PCTCN2020106573-appb-100010
    任选被1、2或3个R’取代。
  4. 根据权利要求3所述化合物、其光学异构体及其药效上可接受的盐，其中，R分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、
    Figure PCTCN2020106573-appb-100011
    Figure PCTCN2020106573-appb-100012
  5. 根据权利要求1～4任意一项所述化合物、其光学异构体及其药效上可接受的盐，R 1、R 2、R 11分别独立地选自H、卤素、OH、NH 2、CN、C 1-3烷基、C 1-3烷氧基和C 1-3烷氨基，所述C 1-3烷基、C 1-3烷氧基或C 1-3烷氨基任选被1、2或3个R取代。
  6. 根据权利要求5所述化合物、其光学异构体及其药效上可接受的盐，其中，R 1、R 2、R 11分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、
    Figure PCTCN2020106573-appb-100013
  7. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，R 3、R 4分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、
    Figure PCTCN2020106573-appb-100014
  8. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，R 5选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、
    Figure PCTCN2020106573-appb-100015
  9. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，R 6选自H、F、Cl、Br、I、OH、NH 2、CN、Me、CF 3、N(CH 3) 2、
    Figure PCTCN2020106573-appb-100016
  10. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，环A选自C 3-6环烷基、3～6 元杂环烷基、苯基、萘基、噻吩基、吡唑基、噻唑基、咪唑基、吡啶基、嘧啶基、吲唑基和吲哚基。
  11. 根据权利要求9或10所述化合物、其光学异构体及其药效上可接受的盐，其中，结构单元
    Figure PCTCN2020106573-appb-100017
    选自
    Figure PCTCN2020106573-appb-100018
    Figure PCTCN2020106573-appb-100019
  12. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，环B选自苯基、萘基、噻吩基、吡啶基、嘧啶基、吲唑基、吲哚基、1H-苯并[d][1,2,3]***基、1,3-二氢-2H-苯并[d]咪唑-2-酮基、苯并[d]恶唑-2(3H)-酮基、1H-吡唑并[3,4-b]吡啶基、异喹啉-1(2H)-酮基和1H-苯并[d]咪唑基。
  13. 根据权利要求8或12所述化合物、其光学异构体及其药效上可接受的盐，其中，结构单元
    Figure PCTCN2020106573-appb-100020
    选自
    Figure PCTCN2020106573-appb-100021
    Figure PCTCN2020106573-appb-100022
  14. 根据权利要求1、6或7任意一项所述化合物、其光学异构体及其药效上可接受的盐，其中，结构单元
    Figure PCTCN2020106573-appb-100023
    选自：
    Figure PCTCN2020106573-appb-100024
    Figure PCTCN2020106573-appb-100025
    Figure PCTCN2020106573-appb-100026
  15. 根据权利要求14所述化合物、其光学异构体及其药效上可接受的盐，其中，结构单元
    Figure PCTCN2020106573-appb-100027
    选自
    Figure PCTCN2020106573-appb-100028
    Figure PCTCN2020106573-appb-100029
    Figure PCTCN2020106573-appb-100030
    Figure PCTCN2020106573-appb-100031
    Figure PCTCN2020106573-appb-100032
    Figure PCTCN2020106573-appb-100033
    Figure PCTCN2020106573-appb-100034
  16. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，R 7选自H、F、Cl、Br、I、CN、Me、CF 3、
    Figure PCTCN2020106573-appb-100035
  17. 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐，其中，R 8、R 9分别独立地选自H、F、Cl、Br、I、CN、Me、CF 3、
    Figure PCTCN2020106573-appb-100036
  18. 根据权利要求1、16或17任意一项所述化合物、其光学异构体及其药效上可接受的盐，其中，结构单元
    Figure PCTCN2020106573-appb-100037
    选自
    Figure PCTCN2020106573-appb-100038
    Figure PCTCN2020106573-appb-100039
  19. 根据权利要求1～18任意一项所述化合物、其光学异构体及其药效上可接受的盐，其选自
    Figure PCTCN2020106573-appb-100040
    其中，
    R 1、R 2如权利要求1、5和6所定义；
    L 1、L 2如权利要求1所定义；
    T、T 2如权利要求1和9所定义；
    R 5如权利要求1、8和13所定义；
    R 6如权利要求1、9和11所定义；
    环A如权利要求1、10和11所定义；
    环B如权利要求1、12和13所定义；
    R 7如权利要求1、16和18所定义；
    R 8、R 9如权利要求1、17和18所定义。
  20. 根据权利要求1～18任意一项所述化合物、其光学异构体及其药效上可接受的盐，其选自
    Figure PCTCN2020106573-appb-100041
    其中，
    R 1、R 2如权利要求1、5和6所定义；
    L 1如权利要求1所定义；
    T、T 2如权利要求1和9所定义；
    R 5如权利要求1、8和13所定义；
    R 6如权利要求1、9和11所定义；
    环A如权利要求1、10和11所定义；
    环B如权利要求1、12和13所定义；
    R 7如权利要求1、16和18所定义；
    R 8、R 9如权利要求1、17和18所定义。
  21. 下式化合物、其光学异构体及其药效上可接受的盐，其选自
    Figure PCTCN2020106573-appb-100042
    Figure PCTCN2020106573-appb-100043
    Figure PCTCN2020106573-appb-100044
    Figure PCTCN2020106573-appb-100045
    Figure PCTCN2020106573-appb-100046
    Figure PCTCN2020106573-appb-100047
    Figure PCTCN2020106573-appb-100048
    Figure PCTCN2020106573-appb-100049
    Figure PCTCN2020106573-appb-100050
    Figure PCTCN2020106573-appb-100051
    Figure PCTCN2020106573-appb-100052
    Figure PCTCN2020106573-appb-100053
    Figure PCTCN2020106573-appb-100054
    Figure PCTCN2020106573-appb-100055
    Figure PCTCN2020106573-appb-100056
    Figure PCTCN2020106573-appb-100057
    Figure PCTCN2020106573-appb-100058
    Figure PCTCN2020106573-appb-100059
    Figure PCTCN2020106573-appb-100060
    Figure PCTCN2020106573-appb-100061
    Figure PCTCN2020106573-appb-100062
    Figure PCTCN2020106573-appb-100063
    Figure PCTCN2020106573-appb-100064
    Figure PCTCN2020106573-appb-100065
    Figure PCTCN2020106573-appb-100066
    Figure PCTCN2020106573-appb-100067
    Figure PCTCN2020106573-appb-100068
    Figure PCTCN2020106573-appb-100069
    Figure PCTCN2020106573-appb-100070
    Figure PCTCN2020106573-appb-100071
    Figure PCTCN2020106573-appb-100072
    Figure PCTCN2020106573-appb-100073
    Figure PCTCN2020106573-appb-100074
    Figure PCTCN2020106573-appb-100075
    Figure PCTCN2020106573-appb-100076
  22. 一种药物组合物，所述的药物组合物含有治疗有效量的如权利要求1～21任意一项所述化合物或其药学上可药用盐，以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
  23. 根据权利要求1～21任意一项所述化合物或其可药用盐或根据权利要求22所述的药物组合物在制备预防和/或治疗用作KRAS-G12C相关疾病的药物中的用途。
  24. 根据权利要求23所述的用途，其中所述的KRAS-G12C相关疾病选自非小细胞肺癌、结肠癌和胰腺癌。
PCT/CN2020/106573 2019-08-02 2020-08-03 四并环类化合物及其制备方法和应用 WO2021023154A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2022001421A MX2022001421A (es) 2019-08-02 2020-08-03 Compuesto tetracíclico, método de preparación y uso del mismo.
US17/632,167 US20220298174A1 (en) 2019-08-02 2020-08-03 Tetracyclic compound, preparation method therefor and use thereof
CA3149403A CA3149403A1 (en) 2019-08-02 2020-08-03 Tetracyclic compound, preparation method and use thereof
JP2022506075A JP2022543767A (ja) 2019-08-02 2020-08-03 四環式化合物、その調製と使用の方法
KR1020227006959A KR20220079521A (ko) 2019-08-02 2020-08-03 테트라시클릭 화합물, 그의 제조 방법 및 용도
AU2020325477A AU2020325477A1 (en) 2019-08-02 2020-08-03 Tetracyclic compound, preparation method therefor and use thereof
EP20850862.2A EP4011886A4 (en) 2019-08-02 2020-08-03 TETRACYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
IL290276A IL290276A (en) 2019-08-02 2022-02-01 Tetracyclic compounds, method for its preparation and use

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201910712388 2019-08-02
CN201910712388.0 2019-08-02
CN201910899724.7 2019-09-23
CN201910899724 2019-09-23
CN201911157922.2 2019-11-22
CN201911157922 2019-11-22
CN202010054185.X 2020-01-17
CN202010054185 2020-01-17

Publications (1)

Publication Number Publication Date
WO2021023154A1 true WO2021023154A1 (zh) 2021-02-11

Family

ID=74483410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/106573 WO2021023154A1 (zh) 2019-08-02 2020-08-03 四并环类化合物及其制备方法和应用

Country Status (10)

Country Link
US (1) US20220298174A1 (zh)
EP (1) EP4011886A4 (zh)
JP (1) JP2022543767A (zh)
KR (1) KR20220079521A (zh)
CN (1) CN112300195B (zh)
AU (1) AU2020325477A1 (zh)
CA (1) CA3149403A1 (zh)
IL (1) IL290276A (zh)
MX (1) MX2022001421A (zh)
WO (1) WO2021023154A1 (zh)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022188729A1 (en) * 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023046135A1 (en) * 2021-09-27 2023-03-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
WO2023066371A1 (zh) * 2021-10-22 2023-04-27 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11964989B2 (en) 2022-07-20 2024-04-23 Mirati Therapeutics, Inc. KRas G12D inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390818B (zh) * 2019-08-12 2023-08-22 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
AU2022314009A1 (en) * 2021-07-23 2024-01-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2023072297A1 (zh) * 2021-11-01 2023-05-04 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2024002024A1 (zh) * 2022-06-27 2024-01-04 石药集团中奇制药技术（石家庄）有限公司 三环类化合物及其用途
WO2024032703A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119183A2 (en) * 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. KRAS G12C INHIBITORS AND METHODS OF USE
WO2019099524A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015043398A1 (zh) * 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
CN113767106B (zh) * 2019-04-28 2024-02-20 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
CN112390818B (zh) * 2019-08-12 2023-08-22 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119183A2 (en) * 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. KRAS G12C INHIBITORS AND METHODS OF USE
WO2019099524A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
WO2022188729A1 (en) * 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023046135A1 (en) * 2021-09-27 2023-03-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
WO2023066371A1 (zh) * 2021-10-22 2023-04-27 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
US11964989B2 (en) 2022-07-20 2024-04-23 Mirati Therapeutics, Inc. KRas G12D inhibitors

Also Published As

Publication number Publication date
EP4011886A4 (en) 2023-07-26
CN112300195B (zh) 2021-12-24
US20220298174A1 (en) 2022-09-22
MX2022001421A (es) 2022-06-08
CA3149403A1 (en) 2021-02-11
EP4011886A1 (en) 2022-06-15
KR20220079521A (ko) 2022-06-13
JP2022543767A (ja) 2022-10-14
IL290276A (en) 2022-04-01
CN112300195A (zh) 2021-02-02
AU2020325477A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
WO2021023154A1 (zh) 四并环类化合物及其制备方法和应用
CN111484477B (zh) 一种苯并吡啶酮杂环化合物及其用途
WO2021052499A1 (zh) 稠合吡啶酮类化合物及其制备方法和应用
WO2018019297A1 (zh) 异喹啉酮类化合物及其制备抗病毒药物的应用
CN113321654B (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
WO2021043322A1 (zh) 氮杂环庚烷并嘧啶类衍生物及其医药用途
CN113024544A (zh) 一种含氰基并杂环化合物及其用途
CN112745335A (zh) 一种三并杂环化合物及其用途
CN114423758A (zh) 抗细菌化合物
WO2022063308A1 (zh) 一类1,7-萘啶类化合物及其应用
CN114685531A (zh) 四并环化合物及其药物组合物和应用
CN115667226A (zh) 作为egfr抑制剂的三环化合物
CN112457326A (zh) 一类芳香杂环并内酰胺类化合物、制备方法和用途
WO2020239107A1 (zh) 作为Cdc7抑制剂的四并环类化合物
CN110407854B (zh) 新的四环化合物
CN111971285B (zh) 咪唑并吡咯酮化合物及其应用
WO2019085996A1 (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
WO2020200284A1 (zh) 三环类化合物制备方法及其在医药领域的应用
WO2020140894A1 (zh) 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
CN111356692B (zh) Ido抑制剂
WO2022171013A1 (zh) 四氢喹唑啉类化合物
WO2024061343A1 (zh) 膜缔合酪氨酸和苏氨酸激酶抑制剂及其应用
WO2019196780A1 (zh) 一种新型吲哚胺2，3-双加氧酶抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20850862

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022506075

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3149403

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020325477

Country of ref document: AU

Date of ref document: 20200803

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020850862

Country of ref document: EP

Effective date: 20220302